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Streptococcus pneumoniae: carriage, disease and virulence factors 
The Gram-positive bacterium Streptococcus pneumoniae (the pneumococcus) is 
an important commensal resident of the human nasopharynx. Although carriage is 
usually non-symptomatic, S. pneumoniae can become invasive and spread from the 
upper respiratory tract to other organs leading to serious diseases such as pneumonia, 
otitis media, meningitis, or bacteremia (Figure 1). 
.................... t•acterem1a 
Figure 1. Schematic overview of pneumococcal diseases and sites of infection 
World Health Organization (WHO) data reported that pneumonia is the single 
largest cause of death in children worldwide and, every year, approximately 1.4 
million children younger than 5 years old die because of this disease (http://www. 
who.int/madiacentre/factsheets/fs331/en/). Pneumonia is a disease of the lungs and 
can be divided into two forms, bronchial pneumonia and lobar pneumonia. Bronchial 
pneumonia is most prevalent in infants, young children and aged adults and S. 
pnewnoniae is one of the main causative agents of the disease. Bronchial pneumonia is 
characterized by acute inflammation localized in the bronchioles. Lobar pneumonia 
occurs more frequently in younger adults. More than 80% of the cases of lobar 
pneumonia are caused by S. pneumoniae. This type of pneumonia affects one specific 
area of the lung, called "lob" and it often happens that more lobs are involved. S. 
pneumoniae is also the main cause of community-acquired pneumonia (CAP) in both 
children and adults (1). Otitis media (OM) is an infection of the middle ear that can 
be caused by bacteria and viruses. Main forms of this disease are acute OM (AOM), 
OM with effusion (OME), and recurrent otitis media (ROM). AOM is one of the 
most frequent childhood infections and the major causative agent is S. pneumoniae 
(2). Meningitis is an inflammation of the membranes, which cover and protect the 
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brain and spinal cord. The inflammation can be caused by both viruses and bacteria. 
Approximately 1.2 million cases are estimated to occur annually worldwide (3). S. 
pneumoniae and the Gram-negative bacterium Neisseria meningitidis are the main 
etiologic agents causing this disease in Europe and in the USA (3). Worldwide, many 
S. pneumoniae strains have developed resistance to penicillin, cephalosporins and 
macrolides, and some of them are resistant to multiple classes of drugs, complicating 
choices of treatment and therapy strategies (4-7). 
The pathogenicity of S. pneumoniae has been attributed to various elements, so 
called virulence factors, most of which are situated on the surface of the bacterium. 
The polysaccharide capsule provides resistance to phagocytosis and facilitates the 
escape of S. pneumoniae from host immune defenses (8, 9). The capsule is recognized 
as the major virulence factor of S. pneumoniae. In animal experiments, unencapsulated 
strains showed 50% decrease in lethal dose compared to the encapsulated ones and 
encapsulated strains were found to be at least 105 times more virulent than strains 
without capsule (10, 11 ). The capsule surrounds the bacterial cell wall, which is mainly 
composed of peptidoglycan, a compound containing amino acids ( or peptides) linked 
to polysaccharides. Cell wall polysaccharides (CWPS) have been found to induce an 
inflammatory response similar to the response to whole pneumococci. It was shown 
in fact that injection in animals of purified cell wall can mimic the clinical features 
typical of pneumococcal pneumonia, otitis media and meningitis (12, 13, 14), and anti­
CWPS have been demonstrated to protect animals against S. pneumoniae challenge 
(15-19). Other factors, including cell wall components and the toxin pneumolysin, 
are involved mainly in the inflammation caused by infection (8, 9). Pneumolysin is 
an intracellular protein that belongs to the class of thiol-activated toxins (20, 21). 
It is conserved among S. pneumoniae isolates and it has a variety of toxic effects on 
different cell types. Although the pneumococcus does not secrete pneumolysin, this 
toxin can be released upon lysis of the bacteria under the influence of autolysin (20). 
Pneumolysin stimulates the production of inflammatory cytokines, such as tumor 
necrosis factor alpha and interleukin-1 by human monocytes (22), inhibits the beating 
of cilia on human respiratory epithelial cells, disrupts monolayers of epithelial cells 
from the upper respiratory tract (23) and from the alveoli (24), and decreases the 
bactericidal activity and migration of neutrophils (25). Pneumolysin is also capable 
of activating the complement pathway (26). 
S. pneumoniae contains phosphorylcholine on the teichoic acids present both 
in the cell wall and the cytoplasmic membrane. In pneumococci, there are proteins 
bound to phosphorylcholine, the so called choline-binding proteins (CBPs). CbpA 
is the largest and most abundant representative of the CBPs (27, 28). CbpA is also 
secreted by pneumococci, and it has a number of biological functions that may 
modulate the immune system in response to pneumococcal infection (27, 28). These 
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functions include binding to the secretory component of secretory IgA (29), the 
complement protein C3 (30) and human factor H (31, 32). CbpA is hypothesized to 
act as adhesion factor in the interactions between pneumococci and the host cell, and 
it was shown to play a crucial role in S. pneumoniae adhesion to the nasopharyngeal 
tract epithelium (33) and the brain endothelium (34). 
Pneumococcal vaccines 
The development of an effective vaccine to protect from pneumococcal 
infections has been a slow process, most probably due to the poor immunogenicity 
of the polysaccharides present on the bacterial surface, which represents the 
primary target of neutralizing antibodies. In the early 1980s, a vaccine which 
consisted of purified capsular polysaccharides derived from 23 of the known S. 
pneumoniae serotypes (PPV23) was marketed in the USA and later on in Europe. The 
pneumococcal serotypes included in this vaccine were responsible for 85-90% of 
the invasive pneumococcal disease (IPD) cases among adults (35). A study on trials 
with this vaccine in the period between 1994 and 2009 raised doubts concerning the 
efficacy of PPV23, especially in developing countries where HIV infections are a 
major cause of death (36, 37, 38). Actually, there is little evidence that PPV23 protects 
against pneumococcal infections in the high-risk group of adults with HIV (36, 37, 
38). The limitations and doubts regarding PPV23 have underscored the importance 
of developing alternative vaccine strategies. A valid variant is represented by the so 
called "conjugate" vaccines. These vaccines are called "conjugated" because capsular 
polysaccharides are chemically conjugated to a highly immunogenic protein carrier, 
such as tetanus or diphtheria toxoid. The immunological advantage of this new 
class of vaccines is that they induce both B-cell-dependent and T-cell-dependent 
responses, and also induce a memory response to a booster dose of the vaccine (39). 
A conjugated vaccine containing capsular polysaccharide from seven S. pneumoniae 
serotypes (PCV7) was licensed in the USA in 2000. The entry of PCV7 in the 
pharmaceutical market tremendously decreased IPD in children (40). New conjugate 
vaccines are being tested for vaccination in young children and adults, such as a 
10-valent vaccine (PCVlO), which has been licensed in over 30 countries, and also a 
13-valent vaccine (PCV13) (41). PCV13 in particular, due to its increased coverage of 
pneumococcal serotypes, may expand the benefits of conjugate vaccines also to the 
high-risk group of adults with HIV. Lastly, new trials are currently in progress for 
the development of vaccines based on pneumococcal proteins, such as pneumolysin, 
instead of polysaccharides. Proteins are highly conserved across different serotypes 
and may thus confer more protection against most S. pneumoniae serotypes (42). 
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The Central Nervous System, the brain vasculature and the blood-brain barrier 
The experimental chapters in this thesis are focused on the interactions of S. 
pneumoniae with the endothelium of the blood-brain barrier leading to the invasion 
of pneumococci into the brain preceding meningitis. The Central Nervous System 
(CNS) consists of the brain and the spinal cord. In vertebrates, the brain is covered 
and protected by the skull, and enclosed in the meninges. The brain is the center of 
the nervous system in all vertebrate and most invertebrate animals. The physiological 
function of the brain is to exert a centralized control over all the compartments of the 
body by generating patterns of muscle activity and guiding secretion of chemicals 
called hormones. The brain is primarily composed of two classes of cells, the neurons 
and glial cells. Neurons are the basic building blocks of the nervous system (43). They 
consist of a central cell body and an axon, which is a thin protoplasmic fiber that 
extends from the cell body and projects with various branches to other areas nearby. 
Neurons send signals to specific target cells over long distances (44). The axons 
transmit signals in the form of electrochemical pulses, called action potentials (45), 
to other neurons through specialized neuron-neuron connections called synapses. 
One single axon can make thousands of synaptic connections with other neurons 
(46). When an action potential travels along the axon, it reaches the synaptic junction 
and causes the release of a chemical, called neurotransmitter, which binds to the 
membrane of the target cell ( 47). The crucial function of the brain is the cell-to-cell 
communication and synapses are the key of this communication processes in the 
brain (48). 
The blood circulatory system of the brain comprises the microvasculature, 
which includes arterioles, capillaries, and venules, and the macrovasculature, 
containing arteries and veins (Figure 2A,B) (49). 
The blood-brain barrier (BBB) is composed by a system of blood vessels which 
supply the whole brain, from the periphery to the inner parts, with nutrients and 
oxygen. The BBB separates the brain from the circulatory system of the rest of the 
body and protects the CNS from potentially harmful substances and regulates 
the transport of essential molecules for the maintenance of a stable environment 
(Figure 3) (50). The BBB has highly specialized properties to selectively control 
the permeability between blood and the CNS, a highly selective transport systems 
for example for mediating the flux of solutes and is also a metabolic barrier due 
to the presence of enzymes able to metabolize specific molecules in transit. Lastly, 
the BBB is also a physical barrier due to its tight endothelial cell to cell junctions 
(50). Endothelial cells (ECs) line all the blood vessels and they represent a crucial 
component of the BBB. Brain ECs express on their plasma membrane proteins and 
receptors which provide selective routes of entry for nutrients, glucose (GLUT-1), 
ions (Na, K-ATPase and Na, K) and macromolecules (e.g. insulin), and routes of exit 
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Dy Light 594 labeled Lycopersicon Esculentum Lectin, 
marker for blood vessels in brain of rodents 
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SA2 Subarachnoid space 
C= Cerebral cortex 
SE= Septum 
CP= Choroid plexus 
Figure 2B. Schematic 
representation of mouse brain 
section 
for potentially toxic metabolic substances (51). Astrocytes, also known as astroglia, 
are characteristic star-shaped cells in the brain. They are the most abundant cells in 
the human brain and they have several important functions, including biochemical 
support for endothelial cells of the BBB, provision of nutrients to the nervous tissue, 
and repair of the brain and spinal cord following traumatic injuries (52, 53). 
The brain can be considered an "immune privileged" organ because it is 
separated from the rest of the body by the BBB, which functions as a "road block" 
to prevent pathogens from reaching the nervous tissue. In the case that infectious 
agents or harmful substances invade the nervous tissue, the brain requires a quick 
immune response to control and decrease the inflammation and eradicate the 
infectious agent. Microglia are the macrophages of the brain and spinal cord, and 
represent the main form of active immune defense in the CNS. Microglia are able 
to phagocytose foreign materials and display these molecules for T-cell activation. 
Phagocytic microglia travel to the site of the injury and secrete pro-inflammatory 
factors to promote more microglial cells to proliferate and do the same. Microglia 
also interact with astrocytes and neurons to fight and eradicate infections as quickly 
as possible (53, 54, 55). 
The endothelium 
The endothelium is the layer of cells that line the interior surface of blood 
vessels (56). The cells forming the endothelium are called endothelial cells. Those 
endothelial cells that are in contact with the blood are called vascular endothelial 









Figure 3. Schematic representation of the blood brain barrier 
endothelium acts as a barrier between the lumen of the vessel and the surrounding 
tissue, and controls the trafficking of materials and white blood cells in and out 
of the bloodstream. TI1e endothelium provides a non-thrombogenic surface that 
contains heparan sulfate which acts as co-factor for the activation of the protease 
anti-thrombin which prevents thrombus formation (56). Endothelial activation, 
induced by pro-inflammatory cytokines, such as interleukin 1 and tumor necrosis 
factor a, allows endothelial cells to participate in the inflammatory response and 
is mostly characterized by an increase of the interactions of endothelial cells with 
leukocytes (57). Endothelial cells are also necessary for the formation of new blood 
vessels from pre-existing ones upon e.g. damage, a process known as angiogenesis, 
and furthermore these cells execute fundamental functions to assist in the control of 
the blood pressure, such as vasoconstriction and vasodilatation (56). 
Itisabsolutelyimportantthattheendotheliumremainsinanunperturbedcondition 
to optimize the expression of anticoagulant and anti thrombotic activities. However, the 
endothelium is a very dynamic organ that responds to various environmental changes 
and is subjected to events that can cause disorders. Plasma factors such as antibodies 
or lipoproteins which perturb the endothelial cell functions have been identified in 
vitro (56). A pathological state of the endothelium can contribute to several disease 
processes, such as hypertension, hypercholesterolaemia, diabetes and septic shock 
(58). Endothelial cells express on their plasma membrane PECAM-1, one of the major 
endothelial adhesion molecules (59). PECAM-1 is involved in the interactions between 
leukocytes and endothelial cells and in leukocyte transendothelial migration during 
inflammation and neuroinflammation (60). PECAM-1 is also involved in development 
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of infectious diseases. Recently, Lovelace et al. biochemically demonstrated that human 
and murine PECAM-1 bind to S. typhimurium (61). Furthermore, PECAM-1-1- mice are 
more resistant than wild-type mice to oral infection upon oral administration of S. 
hjphimurium (61 ). These novel findings indicate that PECAM-1 is not only able to bind S. 
typhimurium, but that PECAM-1 also has a functional role in the oral infection caused by 
Salmonella. Other studies showed that PECAM-1 is required for neutrophil recruitment 
during many inflammatory responses, but not during pneumococcal pneumonia (62, 
63). However, whether PECAM-1 is capable to bind S. pneumoniae is not known. The 
integrity of the endothelium is maintained by the intercellular junctions between the 
endothelial cells. VE-Cadherin for example, is an adhesion molecule mainly expressed 
on the cell-cell junctions, which is of vital importance for the maintenance and control 
of endothelial cell contacts (64, 65). 
Pathogens can invade the brain only after crossing the endothelial cell layer of 
the blood-brain barrier. It has been hypothesized that bacteria can adhere to epithelial 
and endothelial cells by a receptor-mediated adhesion process. Meningeal bacterial 
pathogens, such as S. pneumoniae and N. meningitidis, are able to interact with specific 
receptors expressed by the plasma membrane of endothelial cells and once they are 
bound to these receptors they can cross the endothelial layer through a process called 
transcytosis and transmigrate from the blood vessels of the blood-brain barrier to the 
nervous tissue of the brain (34, 66). 
Meningitis 
As mentioned above, meningitis is an inflammation of the meninges, the 
protective membranes covering the brain and the spinal cord (67). In adults, the most 
common clinical symptom of meningitis is severe headache, occurring in almost 
90% of bacterial meningitis cases. The classic clinical picture of meningitis consists 
of nuchal rigidity, sudden high fever and an altered mental status. These three 
symptoms are observed in 44-46% of the bacterial meningitis cases (68, 69). Other 
signs associated with suspected meningitis are photophobia (intolerance to bright 
light), phonophobia (intolerance to loud noise) and, especially in young children, 
leg pain, cold extremities and abnormal skin color (70, 71). Bacterial meningitis is a 
disease with high morbidity and mortality worldwide despite the implementation of 
several vaccination programs and antimicrobial agents (72). As mentioned above, the 
most common etiological agents are Streptococcus pneumoniae and Neisseria meningitis, 
known also as the meningococcus, which are responsible for 80% of all cases (72). 
In particular, S. pneumoniae is responsible for two-thirds of cases in Europe and in 
the USA (73). Meningitis must be treated with antibiotics, which can penetrate the 
blood-brain barrier (BBB), such as chloramphenicol, tetracyclines, sulphonamides, 
erythromycin, sulphadiazine (74). 
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When the immune system of the CNS tries to eradicate the pathogens, it 
starts defensive actions that eventually can lead to worsening of the infection and 
inflammation. During meningitis the BBB becomes more permeable allowing large 
numbers of leukocytes to enter the brain. This influx of leukocytes during the 
inflammatory response leads to intracerebral edema and meningeal swelling (75, 76). 
In particular during pneumococcal meningitis, microglia are stimulated to produce 
nitric oxide after interacting with streptococci, which is neurotoxic and can worsen 
the inner edema (77). Pro-inflammatory cytokines are molecules which are produced 
to enhance inflammation and they can be released by different types of cell, such 
as endothelial cells, macrophages, neutrophils. Concentrations of Interleukin (IL) 1 
and Tumor Necrosis Factor (TNF) alpha were found to be significantly higher in the 
cerebrospinal fluid of patients with bacterial meningitis in comparison with controls 
(78). The inflammatory features and clinical complications characteristic of bacterial 
meningitis in humans can be reproduced using animal models and administration of 
bacteria directly into the cistema magna of the brain (79, 80, 81). It has been reported 
that the pro-inflammatory cytokines IL-1 beta, IL-6 and TNF alpha are significantly 
higher in animals with meningitis as compared with control groups (79, 80, 82, 83, 
84). 
Bacterial translocation over the blood-brain barrier 
Bacteria reach the meninges by two main routes, namely through the bloodstream 
or through direct contact between meninges and the external environment (e. g. skull 
fractures), but in most cases meningitis follows invasion by the pathogenic bacteria 
through the bloodstream (72). Bacteria present in the bloodstream, once having 
reached the blood vessels in the brain, have to cross the BBB to enter the brain and 
cause infection. How bacterial pathogens cross the BBB is currently unclear. Several 
possible mechanisms have been implicated in this process, such as: 1) the destruction 
of the endothelial cell layers in case of, for example, N. meningitidis (85); 2) traversal 
of the BBB in between the endothelial cells by disruption of the tight junctions (86); 
and 3) traversal of the BBB by transcytosis, an intracellular transport route for the 
transport of molecules and vesicles through cells from the apical to basolateral side 
(87). 
In meningococcal meningitis, it was shown that N. meningitidis requires 
adhesion of type IV pili to brain endothelial cells to cross the blood-brain barrier 
(85). The type IV pili-mediated adhesion to brain endothelial cells provokes the 
disruption of junctions between endothelial cells (85). N. meningitidis recruits the 
Par3/Par6/PKCzeta polarity complex to the cell-cell interface of the endothelial layer 
of the blood-brain barrier and this recruitment leads to the depletion of intercellular 
junctions between brain endothelial cells. The depletion of these proteins causes the 
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disruption of the cell-cell junctions in the endothelium, thus opening the way for 
N .meningitidis to enter the brain (85). How S. pneumoniae crosses the blood-brain 
barrier is presently unclear and subject of debate. Pneumococci could pass between 
endothelial cells either via pericellular transport systems (transport between cells) 
or via mechanistic damage, by releasing pneumolysin. It was observed in vitro that 
S. pneumoniae and group A streptococci can bind to plasminogen in the blood and 
use this binding to cleave cell-cell junctions (86, 87) .  S. pneumoniae could traverse the 
cellular barriers within leukocytes during leukocyte extravasion, as it was observed 
in vivo as a possible invasion route for Listeria monocytogenes and Mycobacterium 
tuberculosis (88). Another proposed mechanism is transcystosis, a specific receptor 
mediated process of bacterial passage through epithelial and endothelial cells 
(33, 34). Endothelial and epithelial cells express certain receptors on the plasma 
membrane, and binding of bacteria to these receptors facilitates the transmigration 
of the pathogens from the apical to the basolateral side of the host cell. The platelet­
activating factor receptor (PAFR) and laminin receptor (LR) have been shown to 
mediate adhesion of S. pneumoniae to brain endothelial cells (89, 90). It was shown 
that S. pneumoniae binds to the poly immunoglobulin receptor (plgR) expressed on 
the epithelium of the upper respiratory tract (33), but whether plgR also has a role in 
pneumococcal translocation across the blood-brain barrier is unknown. 
Receptors involved in S. pneumoniae adhesion to human cells 
As mentioned above, bacterial pathogens have the capability to bind to certain 
receptors on the plasma membrane of epithelial and endothelial cells and this 
receptor-mediated binding facilitates the bacterial invasion into and translocation 
over cell layers. One receptor implicated in adhesion to, invasion of, and also 
transcytosis through endothelial cells is PAFR. PAFR is a G-protein coupled receptor 
with seven transmembrane domains and its natural ligand is the platelet-activating 
factor (PAF). PAF is a mediator in diverse pathologic processes, such as allergy, 
asthma, septic shock, arterial thrombosis, and inflammation (91, 92). Normally PAF 
binds to PAFR and activates a GTPase function, causing phospholipid turnover 
via the phospholipases C, D, and A2 pathways, and also activates protein kinase C 
and tyrosine kinases (91). PAFR has been investigated for many years and there are 
several inhibitors and antibodies which inhibit its biological activity. PAFR has been 
proposed to bind S. pneumoniae and as such facilitate adhesion to, uptake by and 
transcytosis through endothelial cells leading to invasive disease (34, 89, 93). 
The laminin receptor (LR) is an important molecule involved in adhesion of 
the plasma membrane of epithelial and endothelial cells to the basement membrane. 
LR on endothelial cells interacts with neurotropic viruses, including Sindbis virus 
(94), Dengue virus (95), adeno-associated virus (96), tick-borne encephalitis virus, 
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and Venezuelan equine encephalitis virus (97). LR was identified to be a common 
receptor for both S. pneumoniae and N. meningitidis on the surface of rodent and human 
brain microvascular endothelial cells (90). Fluorescent beads coated with CbpA, 
that were injected intravascularly into mice, adhered to the cerebral endothelium. 
Pre-treatment with anti LR antibody led to an inhibition of the adherence of CbpA­
beads to the endothelium in mice, thus suggesting that the laminin receptor initiates 
bacterial contact with the blood-brain barrier endothelium (90). 
The poly immunoglobulin receptor (pigR) transports immunoglobulins across 
mucosal epithelial barriers (98, 99, 100). S. pneumoniae can bind to pigR expressed 
by human nasopharyngeal epithelial cells and this binding facilitates pneumococcal 
translocation through the nasopharyngeal epithelium (33). Human nasopharyngeal 
epithelial (Detroit) cells were treated with an antibody against pigR prior to bacterial 
infection. The antibody treatment significantly reduced adhesion of pneumococci 
(33), indicating that pigR is functionally involved in pneumococcal adhesion to 
nasopharyngeal epithelium. Furthermore, immunoblotting analyses showed that 
pneumococcal CbpA binds to human pigR indicating that CbpA may be required to 
mediate the binding of S. pneumoniae to this receptor (101 ). 
Outline and scope of the thesis 
As summarized in the introductory Chapter 1 of this thesis, bacterial 
meningitis is thought to occur as the result of bacteria crossing the blood-brain 
barrier to invade the CNS. Yet, little is known about the steps preceding the disease 
development. In particular, where and how adhesion of S. pneumoniae to the blood­
brain barrier endothelium takes place in vivo is still unclear. The aim of the study 
described in Chapter 2 was to investigate the spatio-temporal interactions of blood­
borne S. pneumoniae to the endothelium of the blood-brain barrier during the events 
leading up to meningitis, and the protective response of the CNS towards systemic 
pneumococcal infection. The results show that S. pneumoniae adheres to blood-brain 
barrier endothelium in vivo, and likely, that the adhesion to the brain microvascular 
endothelium is the first step by which pneumococci cross the blood-brain barrier. 
Although leukocyte detection in the brain during the entire course of infection was 
minimal, microglia and astrocytes were activated early on, already after 1 hour post 
infection, indicative that the local immune system in the brain was activated directly 
upon the presence of pneumococci in the blood. 
The role PAFR in the adhesion of S. pneumoniae to human cells, especially 
endothelial cells, is hampered by a scarcity of biochemical characterization of the 
bacteria-receptor binding, and compounded by conflicting results in the literature. 
In Chapter 3, the current literature on PAFR, S. pneumoniae and other pathogens is 
discussed, including data concerning human PAFRgenetic variations related to clinical 
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aspects of invasive pneumococcal disease (IPD), to shed light on the importance of 
PAFR in IPD. The in vitro and most of the in vivo studies analyzed and discussed in 
this chapter indicate that PAFR is involved in development of IPD. However, there 
is no unequivocal evidence that a direct interaction between S. pneumoniae and PAFR 
occurs in vivo. 
Chapter4 documents investigations aimed at elucidating a possible role of PAFR 
in S. pneumoniae adhesion to the endothelium of the blood-brain barrier. Previous 
studies have shown that pigR is expressed in the epithelium of the respiratory 
tract (33, 100, 101) and neurons (102, 103, 104). Although there are no data about 
the expression of plgR on the brain vasculature in vivo, pigR expression was not 
detectable in cultured Human Brain Microvascular Endothelial Cells (HBMEC) (33). 
Importantly, at the start if this PhD research it had not been investigated yet whether 
pigR plays a role in S. pneumoniae adhesion to the brain vascular endothelium. 
Therefore, a study aimed at clarifying the potential role of pigR in S. pneumoniae 
adhesion to the endothelial cells of the blood-brain barrier was undertaken. The 
results presented in this chapter show that a direct interaction between S. pneumoniae 
and PAFR on the brain microvascular endothelium is not likely to occur in vivo. 
Furthermore, it is demonstrated that pigR is expressed on the brain microvascular 
endothelial cells and that endothelial pigR may act as receptor for S. pneumoniae 
adhesion to the blood-brain barrier endothelium 
Chapter 5 reports on a study conducted to investigate the role of PECAM-1/ 
CD31 in S. pneumoniae pathogenesis during pneumococcal meningitis. In particular, 
it was aimed at determining whether PECAM-l/CD31 could be a receptor for S 
pneumoniae adhesion to the endothelium of the blood-brain barrier. The results 
presented in this chapter show that S. pneumoniae co-localizes with PECAM-1 in the 
brain of intravenously infected mice and furthermore that S. pneumoniae can bind 
to PECAM-1 in vitro. Taken these results together it is hypothesized that PECAM-1 
may play a role as adhesion receptor for S. pneumoniae on the blood-brain barrier 
endothelium. 
In Chapter 6 a new model for pneumococcal adhesion to endothelial cells is 
presented in which a cooperative role of PAFR, pigR and PECAM-1 is proposed. 
Furthermore, it is suggested that, by defining the pathways by which S. pneumoniae 
adheres to endothelial cells, it may be possible to interfere with the respective 
mechanisms and develop strategies to prevent and cure pneumococcal meningitis. 
Summarizing, the PhD research described in this thesis has provided novel 
insights in the adhesion of S. pneumoniae to the brain vascular endothelium, a 
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Abstract 
Streptococcus pneumoniae (the pneumococcus) is a Gram-positive bacterium and the 
predominant cause of bacterial meningitis. Meningitis is thought to occur as the 
result of pneumococci crossing the blood-brain barrier to invade the Central Nervous 
System (CNS); yet little is known about the steps preceding immediate disease 
development. To study the interactions between pneumococci and the vascular 
endothelium of the blood-brain barrier prior to meningitis, we used an established 
bacteremia-derived meningitis model in combination with immunofluorescent 
imaging. Brain tissue of mice infected with S. pneumoniae strain TIGR4, a clinical 
meningitis isolate, was investigated for the location of the bacteria in relation to 
the brain vasculature in various compartments. We observed that S. pneumoniae 
adhered preferentially to the subarachnoid vessels, and subsequently, over time, 
reached the more internal cerebral areas including the cerebral cortex, septum, and 
choroid plexus. Interestingly, pneumococci were not detected in the choroid plexus 
till 8 hours-post infection. In contrast to the lungs, little to no leukocyte recruitment 
to the brain was observed over time, though Iba-1 and GFAP staining showed that 
microglia and astrocytes were activated as soon as 1 hour post-infection. Our results 
imply that i) the local immune system of the brain is activated immediately upon 
entry of bacteria into the bloodstream and that ii) adhesion to the blood brain barrier 
is spatiotemporally controlled at different sites throughout the brain. These results 




Streptococcus pneumoniae (the pneumococcus) is a Gram-positive human 
pathogen that causes life-threatening invasive diseases such as pneumonia and 
bacteremia with high morbidity and mortality throughout the world. Moreover, 
5. pneumoniae is now the most common etiological agent of bacterial meningitis in 
the United States and Europe [1 ]. Meningitis is an infection of the Central Nervous 
System (CNS), which is characterized by inflammation of the protective membranes 
covering the brain and spinal cord, collectively known as the meninges [2, 3]. One 
entry route for S. pneumoniae into the CNS is thought to be via the bloodstream 
by crossing the blood vessels of the blood-brain barrier. The blood-brain barrier is 
composed of a specialized vasculature covered by endothelial cells that protects the 
brain from harmful substances that are present in the blood stream and supplies 
the brain with the required nutrients for its proper functions, making the brain 
an immune privileged organ [2, 3]. The entry of pathogens into the CNS leads to 
inflammation, local production of pro-inflammatory cytokines and activation of the 
endothelium. The blood-brain barrier becomes more permeable allowing for the 
influx of large numbers of leukocytes into the brain. This influx of leukocytes during 
the inflammatory response leads to intracerebral edema and swelling of the meninges 
and these pathological changes lead to neurological damage and in some cases death 
of the patient [l, 3]. High levels of the pro-inflammatory cytokines, such as interleukin 
1 beta (IL-1 beta), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF alpha), 
were detected in the cerebro-spinal fluid (CSF) of patients with meningitis, which is 
typical of the severe inflammation of the brain [4]. Astrocytes, also known as astroglia, 
are characteristic star-shaped cells in the brain. They are the most abundant cells in 
the human brain and they have several important functions, including biochemical 
support for endothelial ceIIs of the blood-brain barrier, provision of nutrients to the 
nervous tissue, and repair of the brain and spinal cord foIIowing traumatic injuries 
[5, 6]. Microglia are the resident macrophages of the brain and spinal cord and they 
act as first immune defense of the CNS in response to infections [6, 7] . Microglia 
are able to phagocytose foreign molecules and present them to T cells. Phagocytic 
microglia travel to the site of injury and release pro-inflammatory factors to promote 
the proliferation of more microglial cells. Microglia also interact with astrocytes and 
neurons to fight and eradicate the infections as quickly as possible [6, 7, 8]. During 
inflammation microglia and astrocytes get activated and their cellular morphology 
undergoes dramatic changes in a process called astrogliosis for astrocytes: the soma 
becomes more round and the dentrites shorter and thicker [9, 10, 11, 12]. 
How bacterial pathogens cross the blood-brain barrier is currently unclear. 
Several studies have implicated 1) the destruction of the endothelial cell layers by N. 
meningitidis and pneumococcal pneumolysin [13, 14], 2) traversal of the blood-brain 
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barrier in between the cells by disruption of the tight junctions [15], and 3) bacterial 
traversal of the blood-brain barrier by transcytosis, an intracellular transport route 
designed to transport molecules and vesicles through cells from the apical to the 
basolateral side [16]. 
The blood circulatory system of the brain comprises the microvasculature, which 
includes arterioles, capillaries, and venules, and the macrovasculature, containing 
arteries and veins [17]. At present, it is unknown whether S. pneumoniae interacts 
with both the micro- and the macrovasculature prior to invasion into the brain, 
when it interacts with the vasculature in different areas in the brain, and whether 
all endothelial cells along the microvascular tree engage in bacterial adhesion and 
transmigration. It is thought that an important site of entry might be the choroid plexus 
[18], as shown for Streptococcus suis, which induces blood-brain barrier disruption 
in the porcine choroid plexus [19], and may also translocate intracellularly across 
the choroid plexus epithelium [20]. In human brain microvascular endothelial cells 
(HBMEC), pneumococci were able to adhere to the platelet-activating factor (PAF) 
receptor expressed by these cells, allowing transmigration through the endothelial cell 
to the basolateral site (16, 21]. Concordantly, PAF receptor-deficient mice showed a 
decreased incidence of pneumococcal meningitis after intravenous challenge due to 
less pneumococcal translocation across the blood-brain barrier (21]. In vitro and animal 
experiments showed in strain D39 that the pneumococcal surface protein C (PspC, 
also known as CbpA) is required for development of bacterial meningitis, and that 
TIGR4-derived recombinant PspC binds to the laminin receptor, which is also targeted 
by other neurotropic pathogens including prions and bacteria, such as Haemophilus 
influenzae and Neisseria meningitidis (22]. 
Summarizing, while pneumococcal translocation occurs during natural disease 
pathogenesis, it is still unclear how and where this process takes place in vivo. The aim 
of this study was to investigate the interactions between S. pneumoniae and the brain 
endothelium before the development of meningitis. Since an important route of CNS 
infection by bacterial pathogens is via the blood stream, we challenged mice with S. 
pneumoniae through intravenous injection. Herein we report that S. pneumoniae indeed 
adheres tightly to the vascular endothelium, preferentially to the subarachnoid vessels 
and over time, increasingly to the endothelium of the cerebral cortex, septum and 
choroid plexus. This adhesion results in almost immediate microglial and astroglial 
activation but does not lead to leukocyte recruitment. Thus, our studies suggest that S. 
pneumoniae CNS invasion is spatiotemporally separated 
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Material and methods 
Bacterial strains and growth conditions 
An encapsulated S. pneumoniae, serotype 4 strain, TIGR4 [22], was used in this 
study. Pneumococci were grown standing in Todd-Hewitt broth (Oxoid Thermo 
Scientific, Basingstoke, England) at 37°C, bacterial growth was monitored by 
measuring the optical density (OD) at 600nm with a spectrophotometer. Bacteria 
were harvested at 0D600= 0.25-0.30 by centrifugation of 1 ml of culture at 10000 rpm 
for 3 minutes, and the bacteria were suspended in 1ml of sterile phosphate buffered 
saline (PBS) (Lonza, Verviers, Belgium). Serial dilutions in sterile PBS were made and 
plated on blood-agar plates to calculate the dilutions for the challenge dose of 107 
colony forming units (CPU) for each mouse. 
Bacteremia-derived meningitis model 
All experiments involving animals were performed with the prior approval 
of and in accordance with guidelines of the Institutional Animal Care and Use 
Committee of the University of Groningen (DEC nr. 6152A). The bacteremia-derived 
meningitis model described by Orihuela et al. [22] was performed in the following 
way: four groups of 5 female Balb/c mice, 6 to 8 weeks old (Harlan, Horst, NL) were 
anesthetized by inhalation of 2.5% isofluorane before the challenge. Intravenous 
tail vein injection with 200µ1 of 107 CPU of the TIGR4 wild type was performed, as 
control mice were injected with PBS (mock-infected). The mice were sacrificed at 
1 ,  3, 8, and 14 hours after bacterial challenge, the mock-infected mice after 3 hours. 
After sacrifice, to remove unattached bacteria in the blood stream, perfusion was 
performed by injecting sterile PBS in the right ventricle via the vena cava until the 
blood was completely removed. Brains, lungs, and spleens were collected and stored 
with Shandon Cryomatrix (Thermo Scientific, Runcorn, ENG) at -80°C. 
Cell lines and culture conditions 
Human Brain Microvascular Endothelial Cells (HBMEC) [23] (a kind gift from 
Dr. KS. Kim) were cultivated in RPMI-1640 (Biochrom, Berlin, GER) supplemented 
with 10% Fetal Calf Serum (PCS) (Biochrom), 10% Nu-serum (BO Biosciences, Breda, 
NL), 2mM L-glutamine (Gibco, Grand Island, United States), lmM sodium pyruvate 
(Gibco ), 1 % MEM-vitamines (Gibco) and 1 % non-essential amino acids (Gibco ) .  
HBMEC were split in T25 flasks (TPP, Trasadingen, Switzerland) after reaching 
confluency and cultured till passage 36. 
Pneumococcal adherence to endothelial cells 
HBMEC were grown on glass disks (Thermo Scientific, Braunschweig, 
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Germany) placed inside wells of 12 well-plates (TPP, Trasadingen, Switzerland). 
Cells were grown to confluency at 37°C with 5% CO2• After washing the cells with 
sterile PBS, 900 µl cell culture medium was added to each well and 100 µl containing 
approximately 106 CFU of S. pneumoniae TIGR4 was added. After 1 hour incubation at 
37°C /5% CO2 cells were washed 3 times with PBS and fixed with paraformaldehyde 
(Sigma Aldrich) 4% solution in PBS. 
Antibodies, lectin and isotype controls 
The following antibody combinations and dilutions were used for 
immunofluorescent detection, all dilutions were made in sterile PBS with 5% Fetal 
Calf Serum (FCS) (Biochrom, Berlin, GER). To detect S. pneumoniae, an anti-capsule 
serotype 4 antibody (Statens Serum Institute, Copenhagen, DEN) 1 :200 diluted was 
used, followed by Alexa Fluor 488 goat anti-rabbit (Invitrogen Life Technologies, 
Carlsbad, CA) 1 :500 diluted. As control for the bacterial detection, brain sections from 
mock-treated mice were incubated with anti-capsule serotype 4 antibody, followed 
by Alexa Fluor 488 goat anti-rabbit, and no pneumococci were detected (Figure Sl ). 
For the detection of endothelial cells, DyLight 594 labeled LEL (Vector Laboratories, 
Burlingame, CA) was used in a 1 :200 dilution. LEL binds well to glycophorin 
and Tamm-Horsfall glycoprotein and has been used effectively to label vascular 
endothelium in rodents (http://www.vectorlabs.com/catalog.aspx?prodID=1715). 
For the detection of VE-Cadherin in mouse tissue, a rat anti-mouse VE-Cadherin 
antibody 1 :50 diluted (kind gift from Dr. E. Dejana, FIRC Institute of Molecular 
Oncology, Milan, Italy) was used, while for the detection of VE-Cadherin in HBMEC 
a mouse anti-human VE-Cadherin antibody (Cell Signaling, Danvers, United States) 
1 :400 diluted was used, respectively followed by incubation with Alexa Fluor 594 
goat anti-rat and Alexa Fluor 594 goat anti-mouse both 1 :500 diluted. As leukocyte 
marker, CD45 antibody 1 :50 diluted (Dako, Ely, UK) was used followed by Alexa 
Fluor 488 goat anti-rat antibody (Invitrogen Life Technologies). For the detection of 
astrocytes, an anti-Glial Fibrillary Acidic Protein (GFAP) antibody (Dako) at 1 :400 
dilution was used, followed by Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen 
Life Technologies). Microglia were detected with goat anti-mouse ionized calcium­
binding adapter molecule 1 (Tba-1) (Abeam, Cambridge, United Kingdom) followed 
by Alexa Fluor 488 donkey anti-goat antibody (Invitrogen Life Technologies). As 
isotype controls for the primary antibodies the following antibodies were used at 
the same dilution as those for specific primary antibodies: an anti avi-Tag antibody 
(GenScript, Piscataway, NJ; rabbit IgG isotype control), anti-human CD4 antibody 
(AbD Serotec, Martinsried, Germany; rat IgG isotype control), mouse IgG (Innovative 
Research, Plymouth, United States), goat IgG (Santa Cruz Biotechnology, Heidelberg, 
Germany). The avi-Tag antibody was used in combination with Alexa Fluor 488 goat 
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anti-rabbit antibody, the anti-CD4 antibody was combined with Alexa Fluor 488 goat 
anti-rat and the mouse IgG was combined with Alexa Fluor 594 goat anti-mouse. 
No fluorescence was detected in these controls (data not shown). Incubation of the 
tissue sections with only the secondary antibodies did not result in a fluorescence 
signal either. For the immunohistochemical detection of CD31, rat anti-mouse CD31 
antibody (Pharmigen BO Biosciences, San Jose, CA) at a 1 :50 dilution was used, 
conjugated with secondary antibody rabbit anti-rat IgG 1 :40 diluted. As isotype 
control a rat anti-human CD4 antibody at the same dilution of the rat anti-mouse 
CD31 antibody was used. 
lmmunofiuorescent detection 
Brain sections of 5µm thin were cut with a cryostat, placed on microscope glass 
slides (3 sections/slide) (Starfrost, Dallas, TX), and dried under a fan for at least 30 
minutes for a better attachment of the section on the glass slide. Sections were fixed 
with acetone for 10 minutes, dried and next incubated with primary antibody for 60 
minutes. Slides were washed in PBS 3 times for 5 minutes. Subsequently, each section 
was incubated with a mixture of the appropriate secondary antibodies (see Antibodies, 
lectin and isohJpe controls) and DyLight 594 labeled LEL for 45 minutes in the dark. 
After washing with PBS 3 times for 5 minutes, the slides were incubated in the dark 
with DAPI (Roche, Mannheim, Germany) 1 :5000 diluted. After washing again twice 
for 5 minutes in PBS, Citifluor solution (Science Services, Munich, Germany) was 
added to each section after which the coverslip was applied. 
For GFAP and Iba-1 staining, brain sections of 30µm thickness were fixed with 
4% paraformaldehyde in PBS for 20 minutes. The slides were washed in PBS 3 times 
for 5 minutes and preincubated using PBS with 0.3% Triton X-100 (Sigma Aldrich) 
and 2% BSA (Sigma Aldrich) for 30 minutes. Each tissue section was incubated 
overnight at 4°C with primary antibody diluted in PBS with 0.3% Triton X-100 and 
1 % BSA. The slides were washed three times with PBS for 5 minutes. Each tissue 
section was incubated with the secondary antibody diluted in PBS with 0.3% Triton 
X-100 and 1% BSA. 
For immunohistochemical staining of CD31, brain sections were cryostat-cut at 
5µm, mounted onto glass slides (Starfrost) and fixed with acetone for 10 minutes. After 
drying, sections were incubated for 45 minutes at room temperature with primary rat 
anti-mouse CD31 antibody in the presence of 5% FCS. After washing, endogenous 
peroxidase was blocked by incubation with 0.1% H207 in PBS for 20 minutes. This 
was followed by incubation for 30 minutes at room temperature with horseradish 
peroxidase (HRP) conjugated secondary antibody rabbit-anti rat IgG (Dako) 1 :40 
diluted. Conjugate was diluted 1 :50 in PBS supplemented with 2% normal mouse 
serum. Between incubation with antibodies, sections were washed extensively with 
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PBS. Peroxidase activity was detected with 3-amino-9-ethylcarbazole (AEC) (Sigma 
Aldrich, St. Louis, USA) and sections were counterstained with Mayer's hematoxylin 
(Klinipath, Duiven, NED). 
For the VE-Cadherin staining, HBMEC and HUVEC were incubated with a 
mixture of anti-VE-Cadherin antibody and anti-capsule serotype 4 antibody after 
fixation. Afterwards, cells were washed 2 times with PBS and incubated with a 
mixture of proper secondary antibodies. Cells were washed again 2 times with PBS. 
Citifluor solution (Science Services, Munich, Germany) was added to each tissue 
section/glass disk after which the coverslip was applied. The slides were analyzed 
with a Leica DM5500B microscope, using "Fluorescence" or "Contrast Phase" mode 
depending on immunofluorescent or immunohistochemical staining. Images were 
taken with a Leica DFC 360 FX camera. Additionally a Leica SP2 AOBS confocal 
microscope was used to confirm the presence of adhered pneumococci to the brain 
vascular endothelium. 
Image processing 
All the images obtained with fluorescence microscope Leica DM5500B were 
processed by Image J (http://rsb.info.nih.gov/ij/) [24]. The TIFF images obtained with 
the 350 nm (blue), 488 nm (green) and 594 nm (red) wavelength filters were merged 
using the Color-Merge Channels function. As minor manipulation, background 
correction was applied in those images where the background was relatively or even 
across the image by using the Brightness & Contrast command of Image J. In all the 
images subjected to this minor adjustment, the background subtraction was applied 
to all parts of the image. The images of the immunohistochemical staining of CD31 
were taken in grayscale by the Leica QWin Standard software. The LEI z-stacks 
obtained with the confocal microscope Leica SP2 AOBS were merged through Imaris 
(Bitplane Scientific Software). No digital adjustment was performed on these images. 
Imaris was used also to generate the XZ and YZ plane orthogonal views. 
RN A isolation 
Frozen murine brains were mixed with 0.5ml TRlzol (Invitrogen Life Technologies) 
under liquid nitrogen and then mechanically disrupted in a Mikro-Dismembrator 
(Sartorius, Gottingen, Germany) for 2 minutes at 2600 rpm. After the addition of 0.5 ml 
TRlzol and incubation for 10 minutes at room temperature, total RNA was isolated by 
acid-phenol extraction and precipitated with isopropanol, washed with 70% ethanol 
and dissolved in 100 µl of RNase-free water. Subsequently, RNA was DNase-treated 
using the RNase-Free DNase Set (Qiagen, Venlo, The Netherlands) and purified using 
the RNA Clean-Up and Concentration Micro Kit (Norgen, Thorold, Canada). The RNA 
concentration was measured using a NanoDrop spectrophotometer and the RNA 
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quality was assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, United States), and consistently found to be intact. 
Quantitative Reverse Transcriptase PCR 
One µg of total RNA was transcribed into first strand cDNA using M-MLV 
reverse transcriptase (Invitrogen) and (dT) 12-18 (Invitrogen) oligo's. Transcript 
levels were determined on the !cycler (Bio-Rad, Hercules, CA) using SYBR 
green supermix (Bio-Rad). Calculations were done using the comparative 
Ct method according to User Bulletin 2 (Applied Biosystems, Foster City, 
CA). Each reaction was performed in triplicate. Primers used in this study 
were synthesized by Biolegio (Nijmegen, Netherlands) and the sequences 
were as follows: GAPDH-for CATCAAGAAGGTGGTGAAGC, GAPDH-rev 
ACCACCCTGTTGCTGTAG, HPRTl-for GACTTGCTCGAGATGTCA, HPRTl-rev 
TGTAATCCAGCAGGTCAG, TNF alpha-for TCTTCTGTCTACTGAACTTCGG, 
TNFalpha-rev AAGATGATCTGAGTGTGAGGG, IL-1 beta-for 
GGCAGGCAGTATCACTCATT, IL-1 beta-rev AAGGTGCTCATGTCCTCAT, IL-6-for 
CCTCTCTGCAAGAGACTTCCATCCA, IL-6-rev GGCCGTGGTTGTCACCAGCA. 
Bacterial quantification 
The surface covered by bacteria was measured using the Threshold function of 
Image J, by determining the area occupied by the 488 nm (bacteria) signal. With the 
same function the total surface of the tissue for each image was also calculated using 
the 350 nm (nuclei) signal. The bacteria to tissue ratio was calculated by dividing the 
surface of the 488 nm signal by the total area of the tissue detected in each image. 
For each time point of infection, tissue sections from 3 mice were analyzed; for 
each mouse, 4 images of each anatomical site (subarachnoid space, cerebral cortex, 
septum, choroid plexus) were taken using the 350, 488 and 594 nm excitation lines. 
The averages of each mouse were calculated for the final quantification and statistical 
analysis. Quantification of the amount of bacterial signal in the brain was performed 
at the lowest magnification (SOX) images in the same manner. For each time point of 
infection, 6 tissue sections from 3 mice were analyzed. The averages of each mouse 
were calculated and this value for 3 mice per group used for the statistical analysis. 
Scoring for co-localization 
The overlap between the S. pneumoniae signal (488 nm green signal in SOX total 
magnification images) and the vascular endothelium signal (594 nm red signal in SOX 
total magnification images) was generated using Image J Co-localization threshold. In 
this analysis, bacteria that co-localize with the vascular endothelium appear white, 




The independent student t-test of SPSS Statistics 20 (IBM) was used for all 
statistical analyses. The increase in mRNA levels of inflammatory cytokines between 
14 hours post infection and mock was analyzed using student t-test. For the cerebral 
cortex and septum, the differences between 1 hour and each of the other time points 
(3, 8 and 14 hours) were statistically analyzed, and for the choroid plexus only 
between 8 and 14 hours time points. The differences in the amounts of bacteria in 
the SOX images between the 1 hour time point and each of the other time points (3, 
8 and 14 hours) were tested in the same manner as described above. The 3 averages 
and standard deviations corresponding to the 3 mice of each time point, including 
the standard deviations, were used for the analysis. 
Results 
Progression of pneumococcal infection: from bacteremia to a disease stage leading to meningitis 
Mice were infected intravenously with 107 CFU of S. pneumoniae and sacrificed 
at fixed time points. No serious symptoms of disease were present at 1 and 3 hours, 
while the CFU in the blood was 106 CFU/ml after 1 hour. As disease progressed, 
recoverable CFU in the blood increased to 107 CFU/ml at 3 hours and to 108 CFU/ml 
after 8 hours, and did not further increase at 14 hours after infection. At eight hours 
and even more at fourteen hours post-infection, all mice showed clear evidence of 
severe pneumococcal disease, which could progress towards meningitis based on 
previous experience [25]. Thus, our model allowed for the uniform disease progression 
necessary for our spatiotemporal studies. Of note, the development of the high-grade 
bacteremia is required for pneumococcal translocation from the bloodstream into the 
CNS of mice [26] . 
Overview of the endothelium of the brain vasculature in the absence of infection 
The brain receives blood from two main sources, the internal carotid arteries 
and the vertebral arteries, which branch and narrow into the arterioles, and then 
branch further still into the capillaries in the inner part of the brain [27]. To visualize 
the brain vasculature, we used an anti CD31 antibody [28], and DyLight 594 labeled 
Lycopersicon Esculentum Lectin (LEL) [29, 30]. Double staining with an anti CD31 
antibody and the tomato lectin showed that the latter provides a more comprehensive 
detection of the brain vasculature (Figure 1) .  Brain tissue from mock-infected mice 
was next used to study the vascular structures of the blood-brain barrier under 
uninfected conditions, as represented in Figure 1. The fluorescently labeled lectin 
thus enabled us to comprehensively detect the vasculature in the different mouse 
brain compartments and was used throughout this study. 
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Cerebral cortex Choroid plOX111 
Figure 1. Vasculature in the different compartments of the mouse brain 
Immunofluorescent detection of CD31 (488 nm green signal}, tomato lectin (594 nm red 
signal) and nuclei (350 nm blue signal) in the brain of mock-infected mice; total magnification 
630X. Double staining with anti-CD31 antibodies and the lectin showed that the tomato lectin 
provides a more comprehensive detection of the brain vasculature. 
Spatiotemporal distribution of S. pneumoniae in the brain 
To measure the amount of bacteria remaining in the brain after perfusion at all 
time points, we applied a semi-quantitative method using the immunofluorescent 
signal of the specific secondary antibodies used, as described in Material and 
Methods. The amount of pneumococci in the brain steadily increased from 1 
hour up to 14 hours after infection and differences between each time point were 
statistically significant (Figure 2AB). Next, we determined the amount of bacteria in 
the various areas of the brain using the same semi-quantification approach. As soon 
as 1 hour post-infection, bacteria were found in the subarachnoid vessels and, over 
the time course of infection, the amount of bacteria detected in this site of the brain 
remained stable despite the 100-fold increase in bacterial titers (Figures 2C). In fact, 
no statistically significant differences were observed between time points in this area 
(Figure 2C). Bacteria were also found in the cerebral cortex and septum as soon as 1 
hour after infection, and increased constantly over time in these two compartments 
(Figure 2C); already between 1 and 3 hours the difference was statistically significant 
(p value = 0.01) (Figure 2C). Remarkably, only 8 hours after infection bacteria could 
be detected in the choroid plexus, after which also an increase in bacterial load was 
observed (Figures 2A and 2C) with a statistically significant difference in the bacterial 
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Figure 2. 
S p a t i o t e m p o r a l  
distribution of S. 
pneumoniae in the 
brain 
(A) Quantification of the 
amount of pneumococci 
in the brain over the 
time course of infection 
using the fluorescent 
signal of the secondary 
antibody with which the 
bacteria were detected. 
For each time point, the 
average signal in 9 brain 
sections per mouse was 
calculated and with the 
3 averages from 3 mice, 
the overall average was 
calculated, represented 
as a bold bar. In the 
graph, each black dot 
is the average value 
of 1 slide/mouse and 
each number (#1, 2, 3) 
represents one mouse . 
The ratio of bacteria 
in mock tissue was 0. 
* indicates p < 0.05, ** 
indicates p < O.Dl. (B) 
Brain slides of mice challenged with S. pneumoniae were stained for vasculature using tomato 
lectin (red) and bacteria (green) as described in Materials and Methods. Total magnification SOX. 
These images are representative of the situation in i) each brain compartment during all the time 
points of infection, and ii) each mouse that was analyzed. (C) Quantification of pneumococci 
using the fluorescent signal of the bacteria measured in the brain over the time course of infection. 
For each time point, the average signal in 4 brain sections per mouse was calculated and with 
the 3 averages from 3 mice, the overall average was calculated, represented as a black line. In the 
graphs, each gray dot is the value of 1 section/mouse and each number (#1, 2, 3) represents one 
mouse. The ratio of bacteria in mock tissue was 0. * indicates p < 0.05, ** indicates p < 0.01. 
S. pneumoniae adheres to the brain endothelium 
Using the Co-localization Threshold function of hnageJ [24 ], we next determined 
the fraction of pneumococci, which co-localized with the vascular endothelium 
(Figure 3A). At the earliest time points most pneumococci were associated with the 
blood-brain barrier endothelium. However, at the later stages of infection (8 and 
14 hours time points) the amount of pneumococci whose signal did not co-localize 
38 
Chapter 2 
with the brain vasculature increased (Figure 3A). Most bacteria, which were not co­
localized with the blood vessels, seemed to be present in the brain tissue instead of in 
the lumen of the vasculature (Figure S2) .  
To gain further insight in pneumococcal interaction with the endothelium, 
detailed immune fluorescence analysis was performed on the brain slides. 
Pneumococci were associated with subarachnoid vessels at all time points (Figures 
2B, 3A and 3B). Interestingly, in this area at the latest stage of infection (14 hours) the 
bacteria seemed to form clusters associated with the endothelium (Figure 3B). There 
were no quantitative differences between the various time points in the subarachnoid 
space (Figure 2C). In the cerebral cortex, only a few pneumococci were associated 
with the microvasculature at 1 and 3 hours post infection (Figure 3B). At the later 
stages of the infection, groups of S. pneumoniae were detected in close proximity to 
endothelium of the blood vessels in this area of the brain (Figure 3B). In the septum, a 
few bacteria were present at 1 hour time point post infection and up to 8 hours there 
were little changes in the amounts of bacteria which co-localized with the vasculature 
(Figures 2C and 3B). The main difference was observed at the latest stage of infection 
at 14 hours, when large numbers of bacteria were observed on the endothelium of 
the blood vessels of this area (Figures 2C and 3B). In the choroid plexus a completely 
different picture emerged, in fact no S. pneumoniae was detected in this area of the 
brain during the early stages of pneumococcal infection. Only at 8 and 14 hours after 
infection bacteria were associated with the blood vessels (Figures 2B, 3A and 3B). 
To confirm that S. pneumoniae adhered to, or at least was in close proximity of the 
endothelium of the brain vessels, confocal microscopy was used. The same brain 
tissue slides used for the immunofluorescence analysis were studied. At all time points 
post-infection, brain slides were analyzed and three-dimensional reconstruction 
of pneumococci interacting with the brain vasculature endothelium was obtained 
by assembling a series of thin slices (z-stacks) taken along the vertical axis. These 
imaging results showed that the staining of the bacteria and the LEL signal were 
completely co-localized demonstrating that S. pneumoniae is indeed adhered tightly 
to the brain endothelium (Figure 4 and S2; movies in the Supplementary Material). In 
general our tissue section analysis agreed with our results from the semi-quantitative 








Figure 3. Spatiotemporal distribution of S. pneumoniae in the different 
compartments of the brain 
(A} Visualization of S. pneumoniae co-localized with the vasculature in the brain during 
the entire course of infection, same images as shown in Figure 2B; total magnification SOX. 
Pneumococci that co-localized with the vascular endothelium appear as white, pneumococci 
not co-localized appear as green. (B) Brain slides of mice challenged with S. pneumoniae were 
stained for vasculature using tomato lectin (red}, bacteria (green}, and nuclei (blue) as described 
in Materials and Methods. Total magnification of subarachnoid space, septum, choroid plexus 
630X; total magnification of cerebral cortex lOOOX. At 14 hours post infection the white arrow 
indicates the pneumococci forming clusters in the subarachnoid vessels. For each time point of 
infection, brains from 3 mice were analyzed, and of each mouse 4 brain sections were used for 
the immunofluorescent detection. These images are representative of the situation in i) each 
brain compartment during all the time course of infection and ii) each mouse that was analyzed. 
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Figure 4. S. pneumoniae adheres to the brain vascular endothelium 
Visualization of S. pneumoniae (green) adhering to the brain vascular endothelium (red) using 
confocal microscopy. The scale of each image is shown by the white scale bar. White arrows 
points to completely overlapping staining of the bacteria and the lectin resulting in a yellow 
color, strongly suggesting a co-localization of S. pneumoniae with endothelial cells. For each 
time point of infection, brains from 3 mice were analyzed, and of each mouse 3 brain sections 
were used for the confocal detection. The images at the later stages of infection were used, 
because more bacteria were detected at those time points and thus these provide a clear 
picture of the bacteria anchored to the vasculature. Images of all time points after infection 
are shown in Figure S2. 
Interaction of S. pneumoniae with the blood-brain barrier does not cause major disruption of 
the intercellular junctions of brain endothelial cells 
The integrity of endothelium is maintained by the intercellular junctions 
between the endothelial cells. VE-Cadherin is an adhesion molecule expressed by 
the vascular endothelium and it is mainly present on the cell-cell junctions [31, 
32] . For this reason this molecule was used as indicator for the loss of integrity of 
the endothelium [13]. VE-Cadherin staining in HBMEC after a 1-hour incubation with 
106 CFU of S. pneumoniae TIGR4 did not differ from that observed in HBMEC under 
normal conditions. VE-Cadherin expression was homogeneous in the intercellular 
junctions also in proximity of adhered bacteria, indicating no major disruptions of 
endothelial integrity (Figures SA and SB). Especially the :XZ and YZ planes show that 
the VE-Cadherin signal is continuous without interruptions after incubation with 
pneumococci (Figures SC and SD). Furthermore, the VE-Cadherin staining pattern in 
the subarachnoid space and choroid plexus in brain tissue of infected mice was similar 
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Figure 5. Interaction of S. pneumoniae with endothelial cells does not cause serious 
disruption of the intercellular junctions in vitro 
Immunofluorescent detection of VE-Cadherin (red) and S. pneumoniae (green) in H BMEC in 
normal conditions and after 1 hour incubation with 106 CFU pneumococci. Cells were stained 
as described in Material and Methods. Panel A shows a fluorescence microscopic image 630X 
total magnification; panel B shows a confocal microscopy image; panels C and D show the YZ 
and XZ orthogonal view planes. 
Leukocyte recruitment during pneumococcal infection 
Inflammation is a crucial process in the defense mechanism against 
various infectious diseases, and leukocytes are the principal cellular mediators of 
inflammation. To evaluate the degree of inflammation in the brain and compare it 
to other tissue compartments, such as the lungs, during the course of S. pneumoniae 
infection we studied tissue influx of leukocytes using the leukocyte common antigen 
marker CD45 [33, 34, 35] .  As expected, in brain and lungs of mock treated mice no 
leukocytes were detected (Figure S4). The CD45 staining showed almost no influx of 
leukocytes in any compartment of the brain at the early stages of infection (Figure 
S4), and even at the later stages, the presence of leukocytes was minimal (Figure 
6A). In contrast, in the lungs a different picture was observed. At all time points of 
pneumococcal infection, large numbers of leukocytes were present in the lungs, even 
as soon as after 1 hour (Figure 6B). These results reveal that intravenous injection of S. 
pneumoniae causes distinct tissue-specific responses. Furthermore, in contrast to the 
presence of large numbers of leukocytes in the lungs, no such infiltration was observed 
in the brain during the time course of our pneumococcal infection. Presumably, this 
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Figure 6. Leukocyte presence in the brain and lungs of mock-treated and S. 
pneumoniae-infected mice at different time points after infection 
(A) Immunofluorescent staining of the leukocyte common antigen CD45 (green) and nuclei 
(blue) in the subarachnoid space/cerebral cortex, septum and choroid plexus at 14 hours-post 
infection; total magnification 400X. The CD45 staining showed no influx of leukocytes in all 
the compartments of the brain in the early stages of infection (data not shown), and even 14 
hours after infection the presence of leukocytes was minimal. For each time point of infection, 
brain sections from 3 mice were analyzed, and of each mouse 3 brain sections were used for 
the imrnunofluorescent detection. The images are representative of the situation observed in 
each mouse that was analyzed.(B) Imrnunofluorescent staining of leukocyte common antigen 
CD45 (green) and nuclei (blue) in lungs of mock-treated and S. pneurnoniae-infected mice; total 
magnification 630X. For each time point of infection, lungs from 3 mice were analyzed, and of 
each mouse 3 lung sections were used for the imrnunofluorescent detection. The images are 
representative of the situation observed in each mouse that was analyzed. 
The local immune system in the brain is activated early on 
To evaluate the local status of inflammation in the CNS during pneumococcal 
infection, Iba-1 [36] and GFAP [37, 38] staining was performed on mouse brain sections 
representative of various areas in the brain. In the mock-treated tissue, microglia 
and astrocytes had a normal cellular morphology (Figures 7, SSA and SSB). In the 
infected animals activated microglia and astrocytes were detected as soon as 1 hour 
after pneumococcal infection (Figures 7, SSA and SSB). From then on there was a 
gradual increase in the amount of astrogliosis and activated microglia especially at the 
latest time points at 8 and 14 hours, where some microglia and astrocytes displayed 
an abnormal increase in the dimensions of the soma and the dendrites were almost 
completely retracted (Figures 7, SSA and SSB). Thus, this analysis revealed that the local 
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Figure 7. Activation of the local immune system in the brain upon pneumococcal 
infection 
Immunofluorescent staining of Iba-1 as marker for microglia (A) and GFAP as marker for 
astrocytes (B) in brain of a mock-treated mouse and during all the time points of pneumococcal 
infection. Total magnification 630X. The white rectangles delineate the activated microglia 
and astrocytes. Brains from 3 mice for each time point were analyzed, and for each mouse 3 
brain sections were used for the confocal imaging analysis. Each time point is representative 
for the situation observed in each mouse that was analyzed. 
Inflammatory cytokine profile reveals that the infection is progressing to meningitis 
To confirm that inflammation was indeed occurring in the brain, RNA from 
brains of the mock-treated and infected mice of the 14 hours time point was used 
to measure changes in inflammatory cytokine production. We selected IL-1 beta, 
IL-6 and TNF alpha for the quantitative reverse transcriptase PCR, since they are 
known to be the major inflammatory cytokines detected in the CSF during bacterial 
meningitis [39]. As controls, the house-keeping genes GAPDH and HPRT1 were 
used. We observed at 14 hours post infection a statistically significant 40-fold increase 
in levels of IL-6 and TNF alpha, and a 4-fold increase in IL-1 beta compared to the 
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Figure 8. Inflammatory cytokine levels in the brain during pneumococcal infection 
mRNA levels (AU= arbitrary units) of the pro-inflammatory cytokines TNF alpha, lL-1 beta, 
IL-6 and the housekeeping genes G APDH and HTR1 in the brains of mock-treated mice and 
mice sacrificed at 1 4  hours after infection, as quantified by Real Time PCR. * indicates p < 0.05 . 
Discussion 
Translocation of bacteria from the blood stream across the blood-brain barrier 
is hypothesized to be the principal mechanism by which the pneumococcus and 
other meningeal pathogens invade the CNS. A crucial moment in this translocation 
mechanism is the adhesion of the bacteria to the vasculature endothelium composing 
the blood-brain barrier. It is still unclear how and where this process takes place in 
vivo. The purpose of this study was to dissect the manner by which S. pneumoniae in 
the blood stream adheres to 
the endothelium of the blood-brain barrier during the events leading up to meningitis 
and not meningitis itself. For this reason the mice were intravenously challenged 
with S. pneumoniae and, after the sacrifice at different time points after infection, they 
were perfused in order to remove all bacteria not attached to the blood vessels. A 
second goal was to determine whether S. pneumoniac in the bloodstream elicits an 
inflammatory response from the brain before the development of meningitis. 
There were several indications that pneumococcal infection in the mice was 
progressing towards meningitis. There was a significant, steady increase in the 
amount of bacteria in the brain from the first stage of infection up to 14 hours post 
challenge, which did not have a linear relation with the CFU's in the blood. Our 
scoring method to determine which bacteria co-localized with the brain vasculature 
showed that at the start of infection most pneumococci were associated with the 
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vasculature. At the later stages the amount of pneumococci not co-localized with 
blood vessels increased and these bacteria seemed to be present in the brain tissue. 
We think that these signals represent bacteria that have already crossed the blood 
brain barrier. This idea was strengthened by the confocal microscopy analysis, which 
showed that at 14 hours post infection, in the subarachnoid space, septum and 
choroid plexus, some pneumococci did not co-localize with the brain vasculature 
and seemed already in the brain (Figure S3). Additionally, at 14 hours the expression 
of pro-inflammatory cytokines was increased significantly. On the other hand, the 
absence of leukocyte influx, even at 14 hours, indicates that we studied the processes 
leading to meningitis, but not the pathogenesis of the actual disease. 
The fact that we did not observe bacteria in the choroid plexus until after 8 
hours of infection in combination with the finding that the number of bacteria 
attached to subarachnoid vessels remained constant despite an increase in bacterial 
load in the blood confirmed that we did indeed remove all non-attached bacteria. 
The immune fluorescent analysis combined with the confocal images clearly showed 
that the pneumococci are indeed adhering to the brain vascular endothelium. It 
was hypothesized that within the subarachnoid space, bacteria grow and release 
proinflammatory compounds [40]. In this study we observed that at 1 hour post­
infection a higher number of bacteria was observed in the subarachnoid vessels than 
in the other anatomical sites, implying that S. pneumoniae adheres preferentially to 
blood vessels at this site. Over time conditions seemed to change, which allowed 
bacterial attachment at blood vessels in distinct anatomical sites in the inner brain, 
such as the cerebral cortex, septum and choroid plexus. What factors are responsible 
for this preferential adhesion are currently unknown, but may include increased 
basal levels of PAF or laminin receptors. Levels of these NFkB-regulated ligands may 
also change during infection, explaining the increased adhesion to other sites at later 
time points. Future studies are warranted to determine if this is indeed the case. No 
increase of bacteria in the subarachnoid vessels was observed over time, which might 
indicate that there is no change in receptor expression at this location. 
In the literature it is postulated that the choroid plexus, where the cerebrospinal 
fluid is produced, is the location where bacterial CNS invasion is most likely to occur 
[18]. Along such lines, it was shown that S. suis is able to pass through the blood­
brain barrier at this site [19, 20]. In contrast, in our study the adherent pneumococci 
appeared in this area only at the later stages of infection, when levels of bacteremia 
were high, indicating that it is most likely not the site of initial CNS invasion. To our 
knowledge, this is the first study to specifically examine the spatiotemporal events 
of CNS invasion in the brain. Unfortunately, the level of CPUs in blood in humans 
that are developing pneumococcal meningitis is unknown, which makes it hard 
to extrapolate this data from mice with acute bacteremia to the human situation. 
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Although events in humans with a more prolonged infection might have a distinct 
pathogenesis, it seems l ikely that the interaction of the pneumococci with the 
endothelium is similar. 
In meningococcal meningitis N. 111cningitidis is able to form microcolonies 
during the passage through the blood-brain barrier [41 ],  and we also observed S. 
pneumoniae clusters in our study. In a neonatal rat meningitis mode, breakdown of 
the blood-brain barrier was observed [42] and pneumolysin was thought to be the 
main inducer of damage to brain microvascular endothelial cells [43]. In patients with 
meningitis caused by N. meningitidis, disruption of the blood-brain barrier has been 
shown to be a crucial event for the development of the disease [44]. In fact, during 
meningococcal meningitis metalloproteinases of the extracellular matrix contribute 
to blood-brain barrier disruption [45] .  Using VE-Cadherin staining, Coureuil  ct al. 
showed that N. meningitidis recruits the polarity complex, which also plays a role 
in formation of tight junctions. This leads to a depletion of tight junction proteins at 
other places in the cell, which leads to a disruption and opening of the intercellular 
junctions of brain endothelial cells. After incubation of brain endothelial cells with N. 
meningitidis, openings and breaks in the intercellular junctions between endothelial 
cells were observed using amongst others immune fluorescent staining of VE­
cadherin [13]. In our study, VE-Cadherin staining in HBMEC showed no disruption 
after 1 hour incubation with S. pnewnoniae TIGR4. Furthermore, we observed a 
continuous and homogeneous staining of VE-Cadherin in the brains of infected mice. 
These findings indicate that blood-borne S. pneumoniae might not cause endothelium 
disruption during the translocation across the blood-brain barrier and support the 
idea of pneumococcal translocation through a pericellular or transcytosis routes 
[46). Additionally, these data might indicate that toxicity of pneumolysin towards 
endothelial cells is limited under these conditions. 
Both in vitro and in vivo, S. pneumoniae has been shown to lose its polysaccharide 
capsule during invasion into the host cell [47]. In our study, we primarily used 
antibodies that recognized the capsular polysaccharide of the bacteria. To investigate 
this issue in more detail, we also detected the pneumococci in the brain using a 
total anti-pneumococcal antiserum, recognizing capsulated and unencapsulated 
pneumococci, generated in a similar way as the antiserum described in Elm C. et 
al., 2004 [48]. Brains from 3 mice were analyzed for each time point and from each 
brain one brain section was used for the immunofluorescent detection with this 
serum. Interestingly, a preliminary quantification analysis indicated no differences 
in the amount of bacteria associated with the brain vascular endothelium compared 
to the data obtained with the anti-capsule antibody (data not shown).  Therefore, S. 
pneumoniae might maintain i ts capsule during translocation over the blood-brain 
barrier or translocation events via an intracellular route are rare. 
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The inflammatory features and clinical complications following bacterial 
meningitis normally observed in humans can be reproduced using mouse models. 
Most in vivo models that examine the pathophysiology of bacterial meningitis 
consist of the direct injection of pneumococci into the brain of mice or rats [25, 49, 
50] .  Administration of bacteria directly into the brain bypasses the need for blood­
brain barrier translocation. Our aim was to study the interaction of blood-borne 
S. pneumoniae with the brain vascular endothelium in vivo preceding meningitis 
development, hence we used a bacteremia model. We observed clear evidence of 
activated microglia and astrocytes already 1 hour post challenge, which implies that 
the local immune system in the brain is activated early on. Pneumococcal bacteremia 
caused a severe systemic inflammatory response, characterized by the infiltration of 
leukocytes in the lungs, however very little leukocyte influx in the brain was observed. 
Low influx of leukocytes could mean that the vascular endothelial cells are not yet 
activated enough over this time frame to recruit leukocytes to transmigrate over the 
endothelium and reach the site of infection. Mook-Kanamori et al. showed neutrophil 
infiltration at 30 hours after infection, when meningitis is already established [25]. The 
inflammatory cytokine profile revealed that IL-1 beta, IL-6 and TNF alpha expression 
was increased at 14 hours post-injection compared to the control group. This increase 
was comparable to the increase observed in other studies in which the meningitis 
condition of the mice and rats was established by direct injection of bacteria into 
the cistema magna of the brain [25, 49, 51, 52, 53] . Moreover, this increase in mRNA 
levels of pro-inflammatory cytokines reflects the cytokine levels measured in the 
CSF of hospitalized patients with bacterial meningitis that all recovered [4]. This 
data indicates that during bacteremia the brains displays signs of inflammation and 
indicates that the mice were likely progressing towards meningitis development. 
The brain is able to develop an inflammatory reaction in response to 
lipopolysaccharides (LPS}, a major component of the outer membrane of Gram­
negative bacteria [54]. Previous studies by Orihuela et al. have shown that purified 
pneumococcal bacterial cell wall is alone sufficient to induce apoptosis of neurons in 
the dentate gyrus of the hypocampus of infected mice [55] . Thus, we can at present 
not determine whether the adhesion of the bacteria to the endothelial cells provokes 
a response from the CNS or whether solely the presence of bacterial molecules in 
blood is the cause of the early immune activation that we observe. 
In conclusion, in this study we have shown that S. pneumoniae preferentially adheres 
to the subarachnoid vessels, and over time reaches other anatomical sites in the inner 
brain, such as the cerebral cortex and septum. Only at the later stages of infection S. 
pneumoniae interacts with the endothelium of the choroid plexus. Furthermore, the 
local immune system of the brain seems to sense bacterial adhesion to the endothelial 
cells and is activated immediately, even before meningitis develops. Our findings 
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suggest that S. pneumoniae preferentially crosses the blood brain barrier as a result of 
adhesion, invasion and translocation through or between endothel ial cells without 
causing overt disruption of the vascular endothelium. This implies that S. pneumoniae 
might indeed use an intracellular or paracel lular route for translocation of the blood­
brain barrier. One implication of this result is that use of bacterial adhesins as vaccine 
candidates and/or that adhesion inhibited via a pharmacological route could prevent 
the development of meningitis. 
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Abstract 
Streptococcus pneumoniae (the pneumococcus) is an opportunistic human pathogen, 
which causes serious invasive disease, such as pneumonia, bacteremia and meningitis. 
The interaction of the bacteria with host receptors precedes the development of invasive 
disease. One host receptor implicated in pneumococcal adhesion to, invasion of and 
ultimately translocation of cell layers is the platelet activating factor receptor (PAFR). 
PAFR is a G-protein coupled receptor, which binds PAF, a potent phospholipid activator 
involved in many leukocyte functions, platelet aggregation and inflammation. PAFR has 
been proposed to bind S. pneumoniae and as such facilitate adhesion to, uptake by and 
transcytosis of endothelial cells leading to invasive disease. However, there is a shortage 
of biochemical data supporting direct interaction between PAFR and the bacteria, in 
addition to conflicting data on its role in development of invasive pneumococcal disease 
(IPD). In this review, we will discuss current literature on PAFR and S. pneumoniae and 
other pathogens, including data concerning human PAFR genetic variation related to 
IPD clinical aspects, to shed light on the importance of PAFR in invasive pneumococcal 
disease (IPD). Clarification of the role of this receptor in IPD development has the 
potential to enable the development of novel therapeutic strategies for treating 
pneumococcal disease by interfering with the PAFR. 
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Introduction 
Streptococcus pneumoniae is an opportunistic human pathogen that causes life­
threatening invasive diseases, such as pneumonia, bacteremia and meningitis, resulting 
in high morbidity and mortality throughout the world. Every year, over a million people 
succumb to infections by S. pneumoniae worldwide (Bogaert et al., 2004). S. pneumoniae 
colonizes the human nasopharynx, which is asymptomatic in most cases. However, 
especially in infants, the elderly and immune-compromised individuals, the bacterium 
can switch to an invasive lifestyle, translocate over cell layers and cause disease. As for 
other pathogens, specific interactions between bacterial proteins and host receptors are 
thought to play an important role in this switch. 
One receptor implicated in adhesion to, invasion of and also transcytosis in 
endothelial cells is the Platelet Activating Factor Receptor (PAFR) (see Figure lA). 
Transcytosis is a mechanism by which various macromolecules are transported across 
the interior of a cell (Fishman et al., 1987) and has been proposed as mechanism for 
pneumococcal translocation over epithelial and endothelial cell layers (Zhang et al., 
2000; Ring et al., 1998). The ligand of PAFR is the platelet-activating factor (PAP), a 
phospholipid (1-0-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) that functions as a 
mediator in diverse pathologic processes, such as allergy, asthma, septic shock, arterial 
thrombosis, and inflammation (Shukla, 1992; Honda et al., 2002). PAFR is a G-protein 
coupled receptor with seven transmembrane domains and binding to its natural ligand, 
PAF, activates several signaling mechanisms. PAP bound to PAFR activates GTPase, 
causes phospholipid turnover via the phospholipases C, D, and A2 pathways and 
also activates protein kinase C and tyrosine kinases (Shukla, 1992). The role of PAFR 
in inflammation is based on PAP-induced pathological responses and prevention of 
the pathological conditions by PAFR antagonists (Honda et al., 2002). PAFR has been 
identified in lungs, brain, platelets and leukocytes, and was found to participate in 
trafficking of leukocytes and the generation of bronchospasms and inflammation in 
asthma (Snyder, 1990; Chao and Olson, 1993; Shirasaki et al., 1994; Stoll et al., 1994). 
Endothelial activation, induced by pro inflammatory cytokines such as interleukin (IL) 
1 and tumor necrosis factor (TNF) cc, which allows endothelial cells to participate in the 
inflammatory response (Pober, 2002), causes an increase in the expression of specific 
molecules important for leukocyte trafficking, including PAP and the PAFR (Shukla, 
1992; Chao and Olson, 1993). The PAFR has been investigated for many years and 
several inhibitors and antibodies that block its biological activity exist (see Table 1). To 
what extent these antibodies and chemical components interfere with the signaling 
cascade of PAFR is currently not known. 
Interpretation of the importance of the PAFR in the development of invasive 
pneumococcal disease is hampered by a scarcity of biochemical characterization of 
the bacteria-receptor binding, and compounded by conflicting results in the literature. 
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In this review, we summarize the current literature on S. pneumoniae and PAFR 
interactions and provide an overview of PAFR involvement in disease caused by other 
pathogens. A better understanding of the role of PAFR in IPD development will enable 
the development of new therapeutic strategies. 
PAFR-mediated interaction of S. pneumoniae with human cells 
Thefirststudytoshow aroleforPAFRintheinteractionofS. pneumoniaewithhuman 
cells demonstrated thatpre-trea tmentofcellswi th a PAFRantagonistreduced the adhesion 
and internalization of S. pneumoniae into activated endothelial cells and A549 human lung 
epithelialcells(Cundelletal., 1995)approximatelybyhalf (seeTable1).Subsequentanalysis 
of S. pneumoniae infecting the non-activated rat brain capillary endothelial cell line rBCEC6 
using confocal microscopy indicated that the bacteria and PAFR are in close 
physical proximity, as co-localization was observed in 82% of the eukaryotic cell 
population studied (Radin et al., 2005). PAFR expression was markedly increased in 
cells infected with bacteria compared to non-infected ones, suggesting that endothelial 
activation and subsequent induction of receptor expression can be invoked by S. 
pneumoniae (Radin et al., 2005). S. pneumoniae has been shown in vitro to traverse 
eukaryotic cell layers via transcytosis (Ring et al., 1998; Zhang et al., 2000), which has 
been proposed to be a crucial event in the development of invasive disease. Transcytosis 
is a process by which macromolecules are transported through cells in vesicles and is 
mediated by a specific signaling cascade (Fishman et al., 1987). The exact mechanisms 
that control this process are still poorly understood, but host membrane receptors shown 
to be involved are plgR for epithelial and PAFR for endothelial cells (Ring et al., 1998; 
Zhang et al., 2000). Pretreatment of both rat and human brain microvascular endothelial 
cells (BMEC) with a PAFR antagonist decreased the amount of intracellular bacteria by 
35% and the relative amount of transcytosed pneumococci by 25% (when using human 
BMEC) and 30% (rat BMEC), suggesting that pneumococcal transcytosis is reduced in 
the absence of PAFR (Ring et al., 1998). 
Acid exposure of human tracheal epithelial cells increased both PAFR mRNA and 
protein levels as well as adhesion of S. pneumoniae to tracheal epithelial cells (Ishizuka 
et al., 2001). Treatment with a specific competitor of PAF for the binding to the PAFR, 
decreased the number of S. pneumoniae adhered to human tracheal epithelial cells 
exposed to acid and not under normal conditions (Ishizuka et al., 2001). A study that 
looked at pneumococcal adherence to human airway epithelial cells exposed to urban 
particulate matter also indicated a role for PAFR (Mushtaq et al., 2011). In both A549 
airway epithelial cells and human primary bronchial epithelial cells, exposure to urban 
particulate matter increased the mRNA transcript level, PAFR protein expression and 
pneumococcal adhesion. In addition, the PM-stimulated bacterial adhesion to A549 
cells was attenuated by addition of a PAFR antagonist (Mushtaq et al., 201 1). 
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PAF contains a phosphorylcholine (ChoP) moiety, which is also a component 
of teichoic and lipotechoic acids in the cell wall of S. pneumoniae (Briles and Tomasz, 
1973). 111erefore, it was hypothesized that the pneumococcal ChoP moiety is the initial 
pneumococcal component responsible for binding to the PAFR through molecular 
mimicry. In line with this, growing S. pneumoniae in medium with ethanolamine and no 
choline, which removes the phosphorylcholine from the cell wall, with the consequence 
that the choline binding proteins would also no longer be anchored to the bacterial 
surface (Thomas et al., 1978), reduced bacterial adhesion to human endothelial cells to 
levels observed with quiescent, non-stimulated cells (Cundell et al., 1995). S. pneumoniae 
occurs in various phase variants such as opaque and transparent forms. Opaque 
variants contain more capsular polysaccharide relative to the ChoP containing cell wall 
teichoic acids, an increase in the amount of pneurnococcal surface protein A (PspA), the 
pneurnococcal autolysin LytA and a decrease in choline-binding protein (Cbp) A (also 
known as PspC), compared to transparent variants (Briles and Tornasz, 1973; Weiser et 
al., 1994; Kim and Weiser, 1998; Gosink etal., 2000). The opaque form has a reduced ability 
to colonize the nasopharynx, but an increased virulence in the blood stream, as was 
shown in mouse models of systemic disease (Briles and Tornasz, 1973; Weiser et al., 1994; 
Kirn and Weiser, 1998; Gosink et al., 2000) .  Transparent variants invaded both human 
and rat BMEC more readily than opaque variants, and activation of BMEC with TNFa 
resulted in increased invasion of both transparent and opaque pneurnococci (Ring et al., 
1998). The increase in pneumococcal invasion was more marked in transparent variants 
and growth of these variants in medium with ethanolarnine reduced levels of adherence 
and invasion to the basal level observed with opaque variants and non-activated cells. 
Pretreatment of TNFa-activated and resting HBMEC with a PAF receptor antagonist 
resulted in a 35% and 15% decrease in invasion of transparent phase variants, but had 
a smaller effect on the invasion of opaque variants, which was expected because they 
contain less phosphorylcholine than transparent variants (Ring et al., 1998). Transparent 
pneurnococci harbor significantly larger amounts of CbpA, which is non-covalently 
bound to ChoP in the cell wall and shown to be important for adhesion to host cells and 
virulence (Rosenow et al., 1997; Jedrzejas, 2001). Deletion of CbpA had no impact on 
colonization of the nasopharynx, but impaired transition to the lungs, resulting in less 
fulminate pneumonia compared to wild-type (WT) bacteria and prevented entry into 
the cerebral spinal fluid (CSF) (Orihuela et al., 2006). In a bacterernia model, deletion of 
CpbA led to a significant increase in survival rates, as the 50% lethal dose was 250-fold 
higher than for the WT bacteria (Iannelli et al., 2004). It was proposed that CbpA may act 
as a bridge between pneurnococcal ChoP and PAFR, which could explain the observed 
virulence defects of CbpA mutants and the increased invasiveness of transparent 
variants. Thus, these studies indicate that the amount of ChoP in the cell wall of S. 
pneumoniae can modulate the interaction with the PAFR receptor (Thornton et al., 2010). 
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A study by Garcia Rodriguez (Garcia Rodriguez et al., 1995) indicated that 
N-glycosylation facilitates expression of the PAFR on the cell membrane, as the amount 
of PAFR lacking the N-linked glycosylation site on the second extracellular loop on the 
surface was only 30 % of the WT. In line with this, adhesion of pneumococci to COS 
cells transfected with the mutant fonn of human PAFR was also reduced to 30%. This 
suggests that pneumococci may recognize a protein component of the PAFR and also 
support a role for the receptor in pneumococcal binding. 
Although all these in vitro studies point to a direct role of PAFR in the pneumococcal 
adhesion to invasion of and transcytosis of human cells, treatment with antagonists 
or antibodies against PAFR never inhibits pneumococcal interaction completely, most 
studies reach an approximately 50% reduction at most. This indicates the existence of 
PAFR-independent pathways for adhesion and invasion. In fact, inflammation also 
leads to an increase in protein level of keratin 10, laminin receptor and pigR, all of 
which are known to be mediators of pneumococcal adhesion to human cells (Hinojosa 
et al., 2009; Orihuela et al., 2009; Sanchez et al., 2010; Shivshankar et al., 201 1). Therefore, 
inflammation and subsequent endothelial activation can induce the expression of several 
receptors, including the P AFR that may be responsible for the increased adhesion and 
uptake of pneumococci. 
Role of PAFR in pneumococcal disease in animal models 
The involvement of PAFR in IPD was also investigated using in vivo animal 
models representing various aspects of pneumococcal disease in combination with 
absence of the PAFR gene (Ptafr I mice) or treatment with PAFR antagonists (see Table 
2). Ptafr+ mice had more bacterial growth locally in the lungs at 24 h after inoculation 
as determined using bioluminescent S. pneumoniae variants, but after 48 h, the incidence 
and degree of bacteremia was much higher in WT mice than in Ptafr+mice (Radin et al., 
2005). Imaging of the infection showed that in Ptafr+ mice the infection was restricted 
to the pulmonary area 48 h after challenge. In contrast, in WT mice the bacteria were 
dispersed throughout the body including the central nervous system (CNS), probably 
due to the higher level of bacteremia in the WT mice. Thus, in this model trafficking of 
S. pneumoniae from the lungs to the blood and from the blood to the brain depends on 
the presence of PAFR (Radin et al., 2005). 
Another study looking at the role of PAFR in pneumococcal pneumonia, found 
that all WT mice died within 85 h after infection, while mortality was delayed and 
reduced in Ptafr 1- mice (Rijneveld et al., 2004). The bacterial loads in the lungs of 187 
Ptajr+ mice were significantly lower than in WT mice and, in line with the previous 
study, the amount of bacteria in blood was also lower in Ptafr+ mice. Moreover, at 42 h 
after challenge, heavy inflammatory infiltrates were detected in the lungs of WT mice, 
while lung inflammation was less pronounced in Ptafr+ mice, showing that PAFR 
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influences disease severity in pneumococcal pneumonia (Rijneveld et al., 2004). 
A role for PAFR in IPD was also shown in an experimental sickle cell disease 
mouse model. Sickle cell disease causes a 600-fold increased risk of IPD. After intranasal 
administration of S. pncu111011iac, 57% of mice transplanted with sickle cell bone marrow 
died, compared to 16'¼> of mice transplanted with normal bone marrow (Miller et al., 
2007). Histopathological analysis showedthat "sickle cell mice" expressed significantly 
more PAFR on the endothelium and epithelium than their healthy controls. Complete 
absence of PAFR led to a continuous protection from pneumococcal-induced mortality, 
whereas pharmacological intervention with PAFR antagonist was only transiently 
protective, in fact at 48 h the antagonist effect was lost (Miller et al., 2007). 
Additional evidence of PAFR involvement in IPD is provided by studies on the 
uptake of pneumococcal cell wall into host cells by innate immunity receptors. Upon 
injection, choline-containing bacterial cell walls bound to endothelial cells and caused 
rapid lethality in WT, Tlr2 ' , and Nod2 ' mice but not in Ptafr mice (Filion ct al., 2006). 
Additionally, pneumococcal cell wall-mediated toxicity in WT mice was abrogated in 
the presence of a PAFR antagonist and partially in the presence of cytidine diphosphate 
(CDP)-choline, an intermediate in the generation of phosphatidykholine from choline 
(Filion et al., 2006). This also supports the idea that PAFR recognizes and facilitates 
uptake of pneumococcal choline-containing cell wall in vivo and that this might mediate 
binding and uptake of S. pneumoniae to non-phagocytic cells. 
In the absence of infection, aged mice have increased basal levels of lung 
inflammation, shown by cytokine analysis and histopathology of lung sections. Keratin 
10 (KlO), laminin receptor (LR) and PAFR, host proteins known to be mediators of 
pneumococcal adhesion to human cells, were increased in the lungs (Shivshankar et 
al., 2011) .  Exposure of normal A549 cells to conditioned media from senescent cells 
doubled the amount of PAFR protein and S. pneumoniae adhesion (Shivshankar et al., 
201 1). Similarly, aged mice and young ones pre-treated with TNFa to mimic increased 
basal inflammation, had increased levels of plgR and PAFR in their lungs and were 
more susceptible to pneumococcal infection. Whether aged mice also had lower levels 
of TNF-alpha during infection was not mentioned. However, during pneumonia, aged 
mice had reduced levels of both plgR and PAFR in comparison to the young ones, which 
was unexpected because the aged mice had 10,000-fold more bacteria in their lungs at 
the time of the tissue collection (Hinojosa et al., 2009). 
Other studies established an indirect role for PAFR in pneumococcal disease. 
The involvement of the PAFR in pneumolysin-induced acute lung injury was studied 
in mice, in which the pulmonary arterial pressure (Ppa) was continuously monitored, 
as pulmonary hypertension is often associated with lung damage (Witzenrath et al., 
2007; Jyothula and Safdar, 2009). Pneumolysin (PLY), a cholesterol-dependent toxin, is 
one of the major virulence factors of S. pneumoniae and facilitates bacterial adherence 
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to host cells and subsequently damages them during bacterial invasion (Marriott et al., 
2008). Ex vivo analysis performed on lungs revealed that the PLY-induced Ppa increase 
was significantly lower in Ptafr-l- mice compared to WT mice. Moreover, treatment 
with PAFR antagonist reduced the PLY-induced hypertension in the lungs of WT mice 
(Jyothula and Safdar, 2009). 
The CCAAT/enhancer-binding protein b (C/EBPb) was recently discovered as an 
essential mediator of the inflammatory response to bacterial infections (Duitman et al., 
2012). C/EBPb is a member of the C/EBP family of transcription factors (Lekstrom-Himes 
and Xanthopoulos, 1998). Expression of C/EBPb is typically low in most cell types, but is 
rapidly induced upon various extracellular stimuli, such as IL-1, IL-6, LPS, and TNF-a 
(Alam, 1992; Juan, 1993) and several in vitro studies have suggested that C/EBPb has an 
important role in inflammation (Alam et al., 1992; Hu et al., 2000). Expression of P AFR was 
significantly reduced during pneumococcal infection in Cebpd·1· mice compared with WT 
controls. Of particular interest, in mice intranasally infected with S. pneumoniae it was 
found that PAFR expression was low than uninfected mice and increased significantly 
over time in epithelial cells of WT mice and, only marginally, in Cebpd+ mice (Duitman 
et al., 2012). Thus, these results suggest that C/EBPb-mediated PAFR expression is an 
important factor for S. pneumoniae dissemination into the bloodstream. 
Taken together, these mouse model studies clearly show that P AFR plays a 
distinctive role in pneumococcal pathogenesis. However, there are also studies that 
argue against a role for P AFR in pneumococcal pathogenesis. Sepsis-associated neuronal 
damage (SAND) was induced in mice using an intravascular challenge with purified 
pneumococcal cell wall. This study showed that neuronal damage can occur without 
direct invasion of the brain by bacteria (Orihuela et al., 2006). Interestingly, SAND was 
still present in mice lacking the PAFR, but was less severe in mice without cell wall 
recognition proteins TLR2 and NOD2, and in mice overexpressing interleukin-10 (IL-
10) in macrophages (Orihuela et al., 2006). These findings showed that PAFR and/or 
binding of pneumococcal cell wall to PAFR does not have a crucial role in inflammation 
caused by pneumococcal components and that inflammation outside the PAFR axis can 
be damaging. Recently, it has been described that the laminin receptor (LR), a 67kDa 
protein present on eukaryotic cell basolateral membranes, promotes contact of S. 
pneumoniae and other meningeal pathogens with the blood-brain barrier in a bacteremia­
derived meningitis model (Orihuela et al., 2009). Furthermore, CbpA was identified 
as interaction partner for LR using CbpA coated beads. However, binding of CbpA­
coated beads was independent of PAFR-mediated bacterial uptake, as adherence of 
pneumococci to CbpA-coated beads was equally high in Ptajr+ and WT mice (Orihuela 
et al., 2009). These studies argue against a role of PAFR in binding CbpA and/or choline­
containing cell wall, and thus IPD development. 
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Involvement of the PAFR in the development of secondary pneumonia due to S. 
pneumoniae and influenza virus synergism 
HistoricaIIy, bacterial infections following influenza are an important cause 
of morbidity and mortality worldwide. S. pneumoniae is commonly associated with 
secondary pneumonia in humans infected with influenza virus (McCullers, 2006). 
However, the mechanisms that cause this lethal synergism are still not clear. In an 
attempt to elucidate what causes the susceptibility to pneumococcal pneumonia 
after an influenza infection several studies have scrutinized the role of PAFR in trus 
process. One study did not find any indications that the PAFR plays a role in secondary 
infection development (McCullers, 2006). In post-influenza pneumonia induced by S. 
pneumoniae, groups of mice treated with PAFR antagonist had survival rates similar 
to those of control mice. Moreover, bacterial titers in lung and blood were even rugher 
when PAFR was blocked by PAFR antagonist (McCullers and Rehg, 2002). Furthermore, 
PtaJr1- mice infected with influenza and challenged 7 days later with S. pneumoniae had 
survival rates 20-40% lower than those of WT mice (McCullers et al., 2008). Interestingly, 
the same study showed that neither antibody-mediated nor chemical inhibition of the 
PAFR affected adherence of pneumococci to A549 cells, nor did it interfere with the 
increased adhesion induced by pre-incubation with the virus (McCullers et al., 2008). 
Thus, these studies indicate that PAFR plays no role in the development of secondary 
pneumonia and the increased adhesion of pneumococci to respiratory epithelial cells 
pre-treated with influenza virus. 
In contrast, Van der Sluijs et al demonstrated a role for the PAFRin the S.pneumoniae­
influenza virus synergism. An increase in PAFR expression was observed in lungs of 
mice infected with influenza virus. Furthermore, PtaJr1-mice had a significantly reduced 
bacterial infection in the lungs and an increased survival rate of the secondary infection 
(van der Sluijs et al., 2006). The models to study the role of PAFR in S. pneumoniae 
influenza virus synergism were not identical and different pneumococcal strains were 
used, which prevents a direct comparison of the results. Thus, whether or not the PAFR 
is involved in secondary pneumococcal infections still remains unclear. 
Clinical significance of genetic variation in PAFR in human IPD 
Adoption and twin studies have shown that genetics are major determinants 
of susceptibility to infectious diseases (Sorensen et al., 1988; Haralambous et al., 2003). 
Defects in innate immunity have been described to be associated with susceptibility 
to IPD within families (Johnson et al., 1992; Fijen et al., 1994). These studies support 
the idea that genetics are important in susceptibility to IPD. Single base-pair alterations 
(single nucleotide polymorphisms [SNPs]) occur regularly in genes controlling the host 
response to microbes, and may explain inter-individual differences in susceptibility 
(Kwiatkowski, 2000; Brouwer et al., 2009). A meta-analysis on genetic association studies 
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in IPD showed that genetic variation in the complement (mannose-binding-lectin), and 
the Toll-like receptor activation pathway (NFKBIA, NFKBIE, TIR.AP) influence the risk 
of infection (Brouwer et al., 2009). Recently, genetic variation in the G-coupled protein 
receptor p2-adrenoceptor (ADRB2) was described as a risk factor for susceptibility in IPD 
as well (Adriani et al., 2012). Functional diversity of the PTAFR gene may as well play a 
role in host-pathogen interaction. A functional miss-sense mutation from Ala to Asp on 
position 224 of the PTAFR gene has been described in the Japanese population and was 
shown to influence coupling of the receptor to G-proteins, and impair the PAF-PTAFR 
signaling cascade (Fukunaga et al., 2001). The impaired coupling resulted in a 66% less 
effective chemotaxis in cells homozygous for the variant allele (Fukunaga et al., 2009). A 
population-based study assessed the influence of this SNP on the risk of pneumococcal 
infections in 182 European Americans and 53 African Americans with IPD (Lingappa et 
al., 2011 ) .  African American patients with IPD were more likely to have the variant allele 
compared to African American controls (odds ratio 2.38, 95% confidence interval 1 .29-
4.39; P= 0.005). In European Americans the genotype frequencies were similar between 
patients and controls, with a low minor allele frequency in both groups (3%). Because no 
correction for multiple testing was performed in this study and 28 different SNPs were 
tested, the results could however be false positive (Lingappa et al., 2011). Therefore, 
validation of this result should be performed before any firm conclusions can be drawn 
on the role of genetic variation in PTAFR as a risk factor for IPD. 
PAFR and disease development by other pathogenic microorganisms 
The PAFR has also been implicated in disease development by other pathogenic 
bacteria, and some viruses also exploit the PAFR for interaction with human cells. Non­
typeable H. infiuenzae (Nllii) is a common cause of human invasive disease and initiates 
infection by colonizing the upper respiratory tract. Pretreatment of bronchial epithelial 
cell monolayers with a PAFR antagonist significantly inhibited the invasion of the NTHi 
2019 strain (Swords et al., 2001 ). Confocal microscopy of bronchial cell layers, showed 
only partial co-localization of NTHi and PAFR, suggesting that H. influenzae binding to 
PAFR may not be essential for the observed effects (Swords et al., 2000). Additionally, 
histopathologic analysis of lungs of WT and Ptajr1- mice 24 h after challenge with NTHi, 
showed no difference in the degree of inflammation (Branger et al., 2004), which argues 
against a major role of PAFR in the development of NTHi pneumonia. In addition, it has 
been suggested that ChoP contributes to adherence of the pneumococcus to host cells 
by binding to PAFR, whose natural ligand, the PAF, also contains ChoP, suggesting that 
ChoP might function as an adhesin also in H. infiuenzae (Weiser et al., 1998) . The role of 
ChoP in host-pathogen interactions has been discussed in detail by two recent reviews 
(Thornton et al., 2010; Clark and Weiser, 2012). 
Staphylococcus aureus is a Gram-positive coccus that can cause diseases ranging 
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from minor skin infections to life-threatening conditions, such as pneumonia, meningitis 
and bacteremia. It was observed that stapyholoccal LTA stimulates an immediate 
intracellular Ca2+ flux in human epidermoid (KB) cells, which depended on the presence 
of PAFR and mimicked the effect seen with PAFR agonist treatment. In line with this, 
intradermal injections of LTA and the PAFR agonist induced cutaneous inflammation 
in WT but not in Ptajr+ mice (Zhang et al., 2005). The role of PAFR was also investigated 
in a rabbit sinusitis model induced by heat-killed S. aureus. Histopathological analysis 
of the sinus mucosa clearly showed decreased inflammation in the group treated with 
a PAFR antagonist compared to the controls (Karasen et al., 2004). Similar results were 
obtained using a guinea pig model of otitis media, in which inflammation was induced 
by middle ear inoculation of killed S. aureus. Histopathology of the temporal bones 
showed decreased inflammation in the PAFR antagonist-treated group compared to the 
controls (Karasen et al., 2000). These results suggest that the PAFR might be involved in 
S. aureus pathogenesis; however, S. aureus does not contain PspC or ChoP, suggesting 
that this is probably due to its role in inflammation. 
Pseudomonas aeruginosa is a major cause of nosocomial pneumonia, a serious 
disease associated with high morbidity and mortality worldwide, especially in cystic 
fibrosis patients. Upon intranasal challenge with P. aeruginosa to induce pneumonia, 
the host defense was compromised in Ptajr+ mice, which was reflected by increased 
bacterial outgrowth at the primary site of infection in compared to the WT background 
and increased inflammation and damage in the lungs. In addition, the ability of Ptafr-1 
neutrophils to phagocytose P. aeruginosa in vitro was reduced compared to WT-derived 
cells. These finc)ings suggest that PAFR is an essential component for an effective host 
response to P. aeruginosa pneumonia (van de Zoelen et al., 2008). 
Acinetobacter baumannii is a Gram-negative bacterium, which can cause severe 
nosocomial disease and also contains ChoP on the outer membrane protein PorinD. 
Removal of ChoP from the A. baumannii cells reduced adherence to and invasion of A549 
by 95%. Immunofluorescent analysis of A549 cells infected with A. baumannii Chop+ 
showed that ChoP co-localized with A549 cells. In addition, in a mouse pneumonia 
model for lung infection, A. baumannii Chop+ was attenuated by the PAFR antagonist. 
In fact, treatment with the PAFR antagonist significantly reduced bacterial loads in 
infected lungs by approximately 1 log cfu/ml. Therefore, these data strongly suggest 
that A. baumannii interacts with PAFR to invade the host cell (Smani et al., 2012). 
The role of PAFR in influenza virus infection by subtypes A/WSN/33 HlNl or A H3Nl, 
was studied using both the administration of a PAFR antagonist after the occurrence of 
the influenza symptoms in WT mice and infection of Ptafr1 mice. Absence or blockade 
of PAFR caused significant protection against influenza-associated lethality and lung 
injury, which was correlated with decreased levels of neutrophil recruitment, lung 
edema, vascular permeability and injury (Garcia et al., 2010). 
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Bacterial microbiota examinations have revealed the presence of S. pneumoniae in 
the upper respiratory tract of patients infected with different types of virus, including 
rhinovirus (RV). Interestingly, a specific inhibitor of PAFR, PAF and the pyrrolidine 
derivative of dithiocarbamate, an inhibitor of the transcription factor nuclear factor­
kappaB, decreased the number of pneumococci adhering to human tracheal epithelial 
cells after RV-14 infection (Ishizuka et al., 2003). Thus, it seems that RV-14 infection 
facilitates adhesion of S. pneumoniae in human tracheal epithelial cells by inducing PAFR 
expression. Neural apoptosis is a clear sign of Human immunodeficiency virus type 1 
(HIV-1) infection of the CNS. Activated H IV-1-infected rnonocytes produce high levels 
of lNFa and PAF that cause neuronal apoptosis, which can be blocked by incubation 
with PAFR antagonist (Perry et al., 1998). This suggests that the blockade of PAFR may 
be a treatment option for HN-1- associated neurodegeneration, for example Alzheimer 
Disease. In summary, all studies above indicate that PAFR is an important factor in 
the development of invasive infections, but provide little to no evidence for the direct 
binding of the pathogens to the receptor. 
Concluding remarks 
Currently, knowledge of the mechanisms by which various host receptors 
contribute to development of IPD is far from complete. For some receptors, such as plgR 
and LR, pneumococcal proteins have been clearly established as ligands, but for PAFR 
the mechanisms involved are still unclear. The in vitro and most of the in vivo experiments 
discussed in this review clearly indicate that PAFR contributes to the development of 
IPD. However, none of them provides unequivocal evidence that S. pneumoniae anchors 
to the PAFR in vivo and that this is crucial for IPD development due to invasion and 
translocation of host cells. In fact when PAFR is genetically deleted or chemically 
inhibited significant adhesion and invasion of human cells by S. pneumoniae still occurs, 
indicating the presence of alternative receptors that are engaged by the bacteria. Only 
a few indications exist for direct binding of S. pneumoniae to the PAFR, including the 
confocal microscopy imaging study by Radin (Radin, 2006), which however provides 
no biochemical evidence for a direct interaction, and the study by Garcia Rodriguez et 
al. (Garcia Rodriguez et al., 1995), which indicates that N-linked glycosylation in the 
second extracellular loop may not be a putative binding site for S. pneumoniae on the 
PAFR. This is in contrast to studies performed on the interaction of PspC with plgR 
and the LR, or between S. pneumoniae and extracellular matrix proteins (Zhang et al., 
2000; Hammerschmidt et al., 2007; Quin et al., 2007; Bergmann et al., 2009; Orihuela 
et al., 2009; Agarwal et al., 2010). The direct interaction between human plgR and S. 
pneumoniae was clearly demonstrated through a biochemical approach and CbpA was 
identified as ligand for the receptor by immunoblot analysis in combination with affinity 
purification (Zhang et al., 2000). Additionally, the complement regulator Factor H also 
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binds to PspC, which was clearly shown using deletion constructs and surface plasmon 
resonance experiments (Agarwal et al., 2010). Upon contact of S. pneumoniae with host­
cell-bound vitronectin, pneumococci are confined to peculiar forms such as microspike­
like structures. Specific interactions of S. pneumoniae with the heparin-binding sites of 
purified multimeric and not monomeric vitronectin have been demonstrated using 
flow cytometry, immunoblotting, and peptides inhibiting the interaction (Bergmann et 
al., 2009). Both the interaction with vitronectin and with Factor H also facilitates uptake 
of the bacteria by the host cells (Hammerschmidt et al., 2007; Quin et al., 2007; Agarwal et 
al., 2010). In vitro and animal experiments showed that pneumococcal PspC is required 
for development of bacterial meningitis, and that PspC binds to laminin receptor 
(Orihuela et al., 2009). Thus, in comparison with other pneumococcal interactions with 
host proteins, the interaction of S. pneumoniae with PAFR is not well characterized. The 
effects observed in the papers discussed in this review, might well be exerted through 
the binding of PAF or pneumococcal cell wall components to the receptor and the 
subsequent inflammatory consequences of its activation (see Figure lB). 
Additional studies using approaches similar to those employed to demonstrate 
the pneumococcal interaction with plgR, factor H, LR and vitronectin are needed to 
determine whether or not S. pneumoniae binds to the PAFR. Thus studies together 
with investigation of the role of PTAFR genetic variation in human populations would 
determine the nature of the PAFR involvement in IPD development. Most studies 
clearly show a role for PAFR in IPD and that treatment of mice with PAFR-antagonists 
exerts a beneficial pharmacological effect as it prevents or ameliorates disease. This 
suggests that modification of PAFR activity could be a promising therapeutic option 
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Figure 1. Schematic representation of the S. pneumoniae - PAFR interactions 
discussed in this review. 
(A) PAFR is proposed to directly bind S. pneumoniae via the ChoP moieties in the TA and LTA of the 
cell wall and/or CbpA. Binding of pneumoocci to the PAFR would lead to uptake of the bacteria 
followed by transcytosis and bacterial translocation of the cell layer. (B) Proposed model based on the 
literature reviewed of the involvement of PAFR in invasive pneumococcal disease via indirect effects. 
Upon infection with S. pneumoniae, inflammation develops due to the presence of the bacteria and or 
pneumococcal components. Subsequently, PAF and or pneumococcal components bind and activate 
PAFR leading to inflammation and neutrophil infiltration. This would then facilitate pneumococcal 
transmigration over human cell layers. 
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Table 1. Overview of the in vitro studies and results discussed in the review. 
Reference Cell type Experimental PAFR Results approach antagonist 
L659989 Approximately 50% reduction of Cundell, HUVEC, Treatment with adherence and internalization of S. 
1995 A549 PAFR antagonist WEB2086 pneu111011ine in cells activated by TNFa 
or IL-1 . 
Confocal 
microscopy 
82% co-localization of PAFR and S. Radin, 2005 Rat BMEC analysis of PAFR none p11eu111011inc. expression and 
pneumococci 
Invasion decreased to 35 % 
Human, Treatment with a (transparent) and 20 % (opaque) in Ring, 1998 
rat BMEC PAFR antagonist L659989 activated and 25 % (transparent) in resting cells (no inhibition of opaque 
variants in resting cells). 
Human 
Approximately 30-40% reduction in lshizuka, Tracheal 
2001 Epithelial 
PAFR antagonist Y24180 adherence of S. p11cu111011inc only after 
Cells acid exposure. 
Musthaq, PM increased PAFR expression and led 
2011 A549 PAFR antagonist WEB2086 to a 3-fold increase of pneumococcal 
adhesion. 
Anti PAFR 3,4,5-trime- Neither antibody-mediated nor McCullers, A549 antibody, PAFR thoxyphe- chemical inhibition of the PAFR 2008 antagonist nyl-1,3-diox- affected adherence of pneumococci to 
olane A549 cells. 
HUVEC = Human Umbilical Vein Endothelial Cells, A549 = Human Nasopharyngeal Epithelial 
Cells, PAFR = Platelet-Activating Factor Receptor, TNF = Tumor Necrosis Factor, IL = Interleukin, 
BMEC = Brain Microvascular Endothelial Cells, PM = Particulate Matter 
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At 48 h afler challenge, incidence and degree 
Comparison of Balb/e mice of bactcremia was much higher in WT than in 
Radin, 2005 Pta/r· vs WT lntratracheal chal- none Ptafr 1·• 





Mortal i ty delayed and reduced in PAFR-1• . 
PAFR'· vs WT none At 42 h heavy inflammatory infiltrates 
2004 mice 
Intranasal challenge 
were detected in the lungs of WT. 
Comparison of Sickle cell mice expressed significantly more 
PtaJi-1• vs WT 
C57BL/6 mice PAFR on the endothelium and epithelium. 
Miller, 2007 mice and PAFR 
Intranasal challenge 
BN5202 1 
Ptafr 1- resulted in protection of sickle cell mice 
antagonist from mortality by S. pneumoniae. 
Comparison of 
C57BL/6 mice 
Choline-containing cell walls caused lethality in 
Filion, 2006 
PtaJi-1• vs WT 
lntravascular admin- CV6209 
WT but not in Ptaji· 1 
mice and PAFR 
istration 




Balb/c mice Aged mice had increased lung inflammation and 
kar, 20 1 1 Intranasal chal lenge 
none 
more PAFR expression. 
Balb/c mice 
TN Fa increased levels of PAFR in the lungs and 
Hinojosa, Aged mice Intranasal chal lenge none 
increased susceptibility to pneumococcal infection. 
2009 During pneumonia, aged mice had reduced levels 
of PAFR. 
Comparison of PLY-induced Ppa increase significantly lower in 
Witzenrath, 
Ptaji-'· vs WT Balb/c mice BN50730 the PtaJi-1•• 
mice and PAFR Direct infusion into 
2007 
antagonist the pulmonary artery 
BM l 3505 PAF R  antagonist reduced PLY-induced 
hypertension in the lungs of WT mice 
Orihuela, 
Comparison of Balb/c mice 
2006 
Ptafr'· vs WT Intranasal and intra- none SAND still present in Ptaji· mice 
mice venous challenge 
Orihuela, 
Comparison of C57BL/6 mice Pneumocoecal adherence was equal in WT and 
2009 
Ptafr1• vs WT I ntravascular cha I- none Ptafr 
mice lengc 
McCullcrs, Balb/c mice 
PAFR antagonist did not change survival rates. 
2002 
PAFR antagonist 
Intranasal chal lenge 




C57BL/6 mice Pta[,-'· lower rates of survival. 
2008 
Pta/i-'· vs WT Intranasal challenge 
none 
No bacteria in the blood observed in PAFR·1· . 
mice 
Van der 
Comparison of C57BL/6 mice Ptaji·-1- reduced bacterial infection in the lungs and 
Sluijs, 2006 
Ptaji-'· vs WT 
Intranasal challenge 
none 
increased survival rate of the secondary infection 
mice 
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Novel _insights in the roles of the platelet-activating factor and poly 
immunoglobulin receptors in Streptococcus pneumoniae adhesion to 
the brain microvascular endothelium 




Streptococcus pneumoniae (the pneumococcus), the main causative agent of 
bacterial meningitis in Europe and in the USA, is thought to invade the 
Central Nervous System via the bloodstream by crossing the endothelium 
of the blood-brain barrier. Receptor-mediated adhesion of the bacteria to the 
brain endothelium is considered a key event leading to the development of 
meningitis. The platelet-activating factor receptor (PAFR) is implicated in 
pneumococcal adhesion to brain endothelial cells. However, absence or blocking 
of PAFR reduces pneumococcal adhesion at most 50% and it is unclear whether 
pneumococci directly bind to PAFR in vivo. S. pneumoniae was shown to bind to 
the poly immunoglobulin receptor (plgR) on human nasopharyngeal epithelial 
cells. Whether pigR mediates pneumococcal adhesion to the blood-brain barrier 
endothelium in vivo has not yet been fully investigated. Therefore, we studied 
the role of PAFR and pigR in S. pneumoniae adhesion to brain endothelial 
cells in a blood-home model of meningitis. Mice were intravenously infected 
with pneumococci and sacrificed at various time points prior to the onset of 
meningitis. Immunofluorescent analysis of brain tissue showed almost no co­
localization of endothelial PAFR with S. pneumoniae. Brain endothelium cells 
produced plgR and pneumococci frequently co-localized with the receptor 
both in the brains and in vitro. Blocking of pigR with antibodies in vitro reduced 
pneumococcal adhesion to brain endothelial cells and incubation of the bacteria 
with cell lysates showed that they bind pigR. In conclusion, we showed in 
vivo and in vitro that S. pneumoniae does not co-localize with endothelial PAFR 
implying that pneumococci may not bind to PAFR. On the other hand, we 
demonstrated that plgR is expressed by brain endothelial cells. Additionally, 
S. pneumoniae co-localizes with this receptor in vivo and the bacteria physically 
interact with plgR in vitro. These findings indicate that plgR on the blood-brain 
barrier endothelium represents a novel adhesion receptor for S. pneumoniae. 
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Introduction 
Bacterial meningitis is a life-threatening infectious disease leading to cerebral 
dysfunctions and, in the most serious cases, death (1, 2). The Gram-positive bacterium 
Streptococcus pncumoniac (the pneumococcus) is a main causative agent of this disease 
(3, 4). S. pncumoniae is thought to invade the Central Nervous System (CNS) via the 
bloodstream by crossing the blood vessels of the blood-brain barrier, a specialized 
system of endothelial cells that protects the brain from harmful substances present 
in the bloodstream and supplies the brain with the required nutrients for its proper 
functions (1, 2, 3). How S. pneumoniae adheres to the blood brain barrier is unclear 
and subject of debate. The platelet-activating factor receptor (PAFR) is implicated 
in pneumococcal adhesion to endothelial cells (5, 7, 8). PAFR is a G-protein coupled 
receptor and the binding of its natural ligand, p la telet-acti va ting factor (PAF), activates 
several signaling mechanisms which mediate diverse pathological processes, such 
as allergy, asthma, septic shock, arterial thrombosis, and inflammation (9-14). In 
vitro blocking and transfection studies and most in vivo experiments using mice that 
genetically lack the receptor clearly indicate that PAFR contributes to the development 
of invasive pneumococcal disease (IPD) (5, 7, 8, 15). The question that still remains is 
whether S. pneumoniae binds directly to the PAFR. 
When PAFR is genetically deleted or chemically inhibited, pneumococci still 
adhere to and invade human cells and cause disease in mice (5, 7, 8) indicating that S. 
pneumoniae can engage alternative receptors besides PAFR (15). One candidate might 
be the poly immunoglobulin receptor (plgR), which is known to bind to pneumococci 
in human nasopharyngeal epithelial cells (6). Within the host, plgR mediates the 
transport of immunoglobulins across mucosa] epithelial barriers (16-19). Treatment 
of human nasopharyngeal epithelial cells (Detroit) with anti-plgR antibody 
significantly blocked pneurnococcal adherence and translocation over epithelial 
cells (6) . Furthermore, irnrnunoblotting analysis showed that pneumococcal choline­
binding protein (Cbp) A binds to human plgR (20). PigR was previously shown to be 
expressed in neurons (21, 22, 23), but was not detected in Human Brain Microvascular 
Endothelial Cells (HBMEC) (6). However, there are no data on expression of plgR on 
the brain vasculature in vivo. 
In this study, we investigated whether pneumococci co-localize with PAFR 
expressed by the brain vascular endothelium during events preceding meningitis. 
Immunofluorescent analysis performed on brain tissue from infected mice failed 
to show co-localization between PAFR and S. pneumoniae suggesting that a direct 
interaction between PAFR and pneumococci is unlikely to occur in vivo. However, 
we showed that plgR is present on HBMEC and on the vascular endothelium of 
mouse brain tissue. The majority of pneumococci co-localized with endothelial plgR 
and inhibition of the receptor reduced pneumococcal adherence. Furthermore we 
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biochemically demonstrated that S. pneumoniae binds to pigR from endothelial cell 
lysates. Taken together, we have indications that direct interaction of S. pneumoniae 
with PAFR is unlikely to occur in vivo and that pigR, which is expressed on brain 
vascular endothelium, may act as adhesion receptor for S. pneumoniae on the blood­
brain barrier. 
Results 
PAFR is heterogeneously expressed by the endothelium of the blood-brain barrier and S. 
pneumoniae does not co-localize with this receptor 
In agreement with previous studies (5, 8), treatment of HBMEC with anti­
PAFR antibodies significantly reduced pneumococcal adherence by approximately 
50 % compared to treatment with IgG from non-immunized rabbit or the absence 
of added antibodies (Figure lA). When PAFR was blocked in Human Umbilical 
Vein Endothelial Cells (HUVEC) S. pneumoniae adhesion was approximately 30% 
less compared to treatment with rabbit IgG or in absence of blocking antibody, 
although this was statistically not significant (data not shown). This result confirms 
that PAFR plays a role in pneumococcal adherence to brain endothelial cells. 
Subsequently, we investigated whether S. pneumoniae co-localized with PAFR in vitro. 
Immunofluorescent detection of PAFR in HBMEC showed heterogeneous expression 
by certain clusters of cells, whereas other areas of the monolayer did not express 
PAFR (Figure 1B). Interestingly, co-localization analysis using imageJ showed that 
most pneumococci adherent to HBMEC did not co-localize with PAFR (Figure lC). 
In brain tissue of mock-infected mice PAFR was detected mainly on the endothelium 
although expression was not homogenous in the various compartments of the brain 
(Figure 2). This distribution of PAFR expression was not influenced by S. pneumoniae 
infection (Figure 3). Throughout the time course of infection, most bacteria did not 
co-localize with the PAF receptor in the various brain compartments (Figure 3). 
Specifically, analysis of the brain slides using ImageJ indicated that only about 0.8% 
of the pneumococci were co-localized with PAFR at all time points of infection in all 
brain compartments. These findings suggest that, although the PAFR is involved in 
pneumococcal adhesion to brain endothelial cells, direct association of S. pneumoniae 
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Figure 1. PAFR is 
indirectly involved 
in S. pneumoniae 
adhesion to human 
endothelial cells 
(A) Blocking of PAFR 
(white column) in HBMEC 
cells leads to a reduction 
of pneumococcal adhesion 
in comparison with 
HBMEC treated with 
isotype control (hatched 
column) and with 
HBMEC treated without 
blocking antibody (black 
column). * P value < 0.05. 
(B) Immunofluorescent 
staining of PAFR (red), 
adherent S. pneumoniae 
(green) and cellular nuclei (blue) in HBMEC. After 1 hour incubation with pneumococci, 
HBMEC cells were washed with PBS in order to remove the non-adherent bacteria, Total 
magnification 400X. (C) Co-localization of pneumococci and PAFR detected in panel B. 
White pixels represent the areas of bacterial signal co-localized with PAFR while green pixels 
represent the area of bacterial signal not co-localized with PAFR. White arrows indicate the 




Figure 2. Heterogeneous expression of PAFR by brain endothelium in absence of 
infection 
Irnmunofluorescent detection of PAFR (blue) and endothelial cells (red) in the different brain 
compartments of mice in the absence of bacterial infection. Total magnification 630X 
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Figure 3. S. pneumoniae does not co-localize with PAFR on brain endothelium 
during the course of infection 
Brain slides of mice intravenously challenged with S. pneumoniae were stained for vasculature 
endothelium (red), pneumococci (green), and PAFR (blue). Total magnification 630X. For each time 
point, the panel "Co-localization analysis S. pneumoniae-PAFR" shows bacteria co-localizing with PAFR 
in white, and bacteria not co-localizing with PAFR in green; white arrows indicate the only pneumococci 
co-localized with PAFR. For each time point of infection, brains from three mice were analyzed, and 
of each mouse three brain sections were used for the immunofluorescent detection. The images are 
representative of the situation in each brain compartment during the entire time course of infection and 
in each mouse that was analyzed. 
S. pneumoniae co-localizes with plgR in HBMEC and blockade of this receptor reduces 
pneumococcal adherence 
To assess whether the anti-mouse plgR antibodies could be used for 
immunohistochemistry/ immunofluorescence detection of plgR in mouse 
tissue, we applied it to lung sections and showed that epithelial cells do express 
plgR, as was previously reported (6, 18) (Figure S1). Immunofluorescent 
analysis with anti-human plgR antibodies showed that plgR was also present 
on HBMEC (Figure 4A). As it was previously reported that endothelial KC 
cells do not express plgR (6), a Western blot with the anti-human plgR antibody 
was performed. This analysis showed that plgR was produced by Detroit cells, 
and that a band of the same molecular weight was detectable in HBMEC cells. 
As expected no plgR expression was observed in A549 cells (6) (Figure S2), 
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confirming that the immune fluorescent analysis indeed detected plgR on HBMEC. 
Furthermore, co-localization analysis showed that most pneumococci adherent to 
HBMEC co-localized with pigR (Figure 4B). HUVEC also expressed pigR (Figure 4C) 
and, S. pneumoniae adherent to these cells also mostly co-localized with this receptor 
(Figure 4D). To exclude the possibility that the antibody non-specifically bound S. 
pneumoniae, we stained the pneumococci with the anti-human pigR antibody only 
and consistently found that the bacteria were not detectable with this antibody ( data 
not shown). Importantly, blocking of pigR in HBMEC and HUVEC cells with the 
anti-human plgR antibody led to a significant reduction of pneumococcal adhesion 
compared to cells incubated without this antibody and cells treated with isotype 
control antibodies. Together, these findings show that plgR is functionally involved 
in S. pneumoniae adhesion to endothelial cells (Figures 4E and 4F). 
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Figure 4. PlgR is involved in S. pneumoniae adhesion to human endothelial cells 
and pneumococci co-localize with plgR 
(A) Immunofluorescent detection of plgR (green), adherent S. pneumoniae (red) and cellular nuclei (blue) 
in HBMEC cells after 1 hour incubation with pneumococci. After 1 hour incubation with pneumococci, 
HBMEC cells were washed with PBS to remove the non-adherent bacteria. Total magnification 400X. (B) 
Co-localization between pneumococci and plgR detected in panel A. White pixels represent the areas 
of bacterial signal co-localized with plgR, while red pixels indicate the area of bacterial signal not co­
localized with plgR. (C) Immunofluorescent detection of plgR (green), adherent S. pneumoniae (red) and 
cellular nuclei (blue) in HUVEC cells after 1 hour incubation with pneumococci. After 1 hour incubation 
with pneumococci, HUVEC cells were washed with PBS to remove the non-adherent bacteria. Total 
magnification 400X. (D) Co-localization between pneumococci and plgR detected in panel C. White 
pixels represent the areas of bacterial signal co-localized with plgR, while red pixels indicate the area 
of bacterial signal not co-localized with plgR. E-G. Blocking of plgR (white column) in Detroit cells (E), 
HBMEC (E) and HUVEC (F) leads to a significant reduction of pneumococcal adhesion in comparison 
with HBMEC/HUVEC treated with isotype control IgG (hatched column) or with HBMEC/HUVEC 
cells incubated without a blocking antibody (black column). * P value < 0.05. 
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S. pneumoniae co-localizes with plgR expressed on the brain vascular endothelium 
Based on the finding that HBMEC and HUVEC express plgR, we analyzed plgR 
expression in brain tissue of healthy mice that had been 'mock-treated' with PBS as 
a control for the infection experiments described below. PigR was indeed detected 
in the healthy brain and, amongst others, associated with endothelial cells (Figure 
SA). To confirm that plgR was indeed expressed by the vascular endothelium, we 
analyzed brain sections of healthy mice, 1 and 14 hours after mock-treatment using 
a three-dimensional reconstruction after confocal microscopy. This analysis showed 
that plgR expression is indeed associated with endothelial cells (Figure SB). 
To investigate whether pneumococci co-localized with plgR in the brain of 
infected mice, it was necessary to label the anti-capsule antibodies with Alexa Fluor 
350. When S. pneumoniae was detected with Alexa Fluor 350 (Figure 6A) the coccoid 
shape and chain structure typical of the pneumococcus were not always as well 
distinguishable as when pneumococci were detected with Alexa Fluor 488 (Figure 
3). To confirm that the Alexa Fluor 350 signal indeed represented pneumococci, we 
stained S. pneumoniae in brain tissue using first the anti-capsule serotype 4 antibody 
labeled with Alexa Fluor 350, followed by the same antibody labeled with Alexa Fluor 
488. This showed that the bacteria signal detected with Alexa Fluor 350 always co­
localized with the signal obtained with Alexa Fluor 488 (Figure S3). In brain sections 
of intravenously-infected mice, the expression pattern of plgR was similar to that in 
mock-infected mice. Notably, most pneumococci co-localized with plgR expressed on 
the vascular endothelium in all brain compartments at all time points after infection 
(Figure 6A) .  An estimation of the signals in the brain slides with ImageJ indicated 
that > 95% of pneumococci present in the brain were co-localized with plgR at all time 
points of infection in all brain compartments. Confocal microscopy confirmed that 
S. pneumoniae indeed co-localized with plgR on the endothelial cells (Figure 6B and 
movies in the Supporting Information). This implies that systemically administered 
S. pneumoniae anchors to plgR expressed on brain vascular endothelium prior to 
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Figures 5. Heterogeneous expression of plgR by brain endothelium in the absence 
of infection 
(A) lmmunofluorescent detection of plgR (green) and endothelial cells (red) in the brain in 
absence of bacterial infection shows heterogeneous expression of plgR on brain endothelium 
in vivo. Total magnification 630X. (B) Confocal microscopy images visualizing plgR (green) 
on the brain vascular endothelium (red). Overlaps in the plgR signal and endothelial cell 
staining resulted in a yellow color, suggestive of plgR expression by endothelial cells. The 
white scale bar in each image represents 20 µm. The images are representative of the situation 
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Figure 6. S. pneumoniae co-localizes with plgR on brain endothelium during the 
entire course of infection 
(A) Brain slides of mice challenged with S. pneumoniae were stained for vasculature endothelium 
using tomato lectin (red), pneumococci (blue), and plgR (green). Total magnification 630X. For 
each time point of infection, brains from 3 mice were analyzed, and of each mouse 3 brain sections 
were used for the immunofluorescent detection. The images are representative of the situation 
in each brain compartment during the entire time course of infection and in each mouse that was 
analyzed. For each time point, the panel "Co-localization analysis S. pneumoniae-plgR" shows 
bacteria co-localizing with plgR in white, and bacteria not co-localizing with plgR in blue. 
(B) Confocal visualization of S. pneumoniae (red) and plgR (green) in the different brain 
compartments during the whole time course of pneumococcal infection detected by confocal 
microscopy. The white scale bar in each image represents 5 µm. The yellow color of the 
bacteria is the result of co-localization of the red-colored S. pneumoniae and green-colored 
plgR. For each time point of infection, brains from 3 mice were analyzed, and of each mouse 
3 brain sections were used for the confocal detection. The images are representative of the 
situation in each brain compartment during the entire time course of infection and in each 
mouse that was analyzed. 
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S. pneumoniae binds to plgR expressed by human endothelial cells 
Since S. pneumoniae co-localized with plgR expressed by the brain vascular 
endothelium in vivo, we wondered whether pneumococci can physically interact with 
plgR expressed by endothelial cells. Thus, we set up a ligand-receptor interaction 
assay as detailed in the Materials and Methods section (Figure S4). Since binding of 
pneumococci to plgR expressed by Detroit cells was previously described (5), we first 
tested our method using Detroit cell lysates as a positive control. After incubation of 
the pneumococci with Detroit cell lysate, plgR was indeed detected on the bacteria 
(Figure 7 A). As a negative control, we used an anti-human tubulin antibody. Tubulin 
was not detected on the pneumococci, indicating that the interaction was specific 
for plgR and that endothelial proteins did not become associated with the bacteria 
through non-specific interactions for instance through precipitation or centrifugation 
(Figure 7B). Subsequently, S. pneumoniae cells incubated with either HBMEC or 
HUVEC lysates were stained with anti-pneumococcal antiserum and the anti-human 
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(A) lmrnunofluorescent detection of S. pneumoniae (red) and plgR (green) after pneumococci 
were incubated with Detroit, HBMEC or HUVEC cell lysates. Total magnification 400X. 
The overlay indicates plgR signal on the pneumococci. (B) Immunofluorescent detection of 
S. pneumoniae (red) and a tubulin (green) after pneumococci were incubated with Detroit, 
HBMEC or HUVEC cell lysates. Total magnification 400X. 
Discussion 
The aim of this research was to clarify whether pneumococci adhering to the 
brain endothelium co-localize with either P AFR or plgR during the events preceding 
meningitis. In line with previous data (5, 8), we demonstrated that the blocking 
of PAFR significantly reduces S. pneumoniae adhesion to HBMEC. Yet, we did not 
observe a co-localization between endothelial PAFR and pneumococci, neither in 
vitro nor in vivo. In contrast, we observed plgR on brain endothelial cells, which 
co-localized with S. pneumoniae in vitro and in vivo. Blocking of plgR by antibodies 
reduced pneumococcal adherence to endothelial cells and pneumococci bound 
plgR present in endothelial cell lysates. These data suggest that a direct interaction 
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between PAFR and S. pneumoniae is not likely to occur at the blood-brain barrier 
endothelium. Instead, plgR seems to represent a crucial and so far overlooked 
receptor for pneumococcal adhesion to the blood-brain barrier endothelium. 
Data from previous studies clearly indicate that PAFR is involved in invasive 
pneumococcal disease. In vitro, blocking of the receptor reduced adherence to and 
invasion of endothelial cells. In addition, disease severity was reduced in PAFR·1 
mice, in particular the translocation from blood to the brain was impaired (7). These 
findings were interpreted as a role for PAFR in pneumococcal adherence to the blood 
brain barrier. However, no biochemical evidence for a direct interaction between 
pneumococci and PAFR has thus far been published (15). In our present study, the 
possible co-localization of pneumococci with PAFR was not detectable, neither in vitro 
not in vivo, which lead us to conclude that S. pneumoniae is unlikely to bind to PAFR 
directly at least at the blood-brain barrier. This is in contrast with a study that reported 
considerable co-localization of PAFR and S. pneumoniae in rat brain endothelial cells 
in vitro (7). Unfortunately, no overview images from the latter study are available that 
show the level of PAFR expression in rBCEC6 cells. However, it is conceivable that 
these cells might express PAFR at higher levels than the cells we used in our present 
studies, which would increase the chance of co-localization. In any case, our finding 
that the pattern and levels of PAFR expression by the HBMEC cells was similar to that 
observed in the brains of infected and uninfected mice (heterogeneous and patchy), 
indicates to us that the PAFR expression that we observed in vitro likely represents the 
physiological situation in mice and man. Another difference is that whereas we used 
anti-capsule antibodies to detect the bacteria, Radin et al. used an anti-ChoP antibody 
(7). Although ChoP is a part of the cell wall of the bacteria, this antibody could in 
principle also detect ChoP not associated with bacteria. The amino acid sequence of 
rat PAFR has 79% identity with human PAFR (25) and 91 % identity with mouse PAFR 
rat. Non-conserved amino acid residues are present also in the extracellular portion 
of the protein, in particular in the second extracellular loop (26). These differences in 
the PAFR amino acid sequences may also account for the apparent S. pneumoniae co­
localizing to PAFR on the rat endothelium and the absence of this co-localization with 
human or murine PAFR. 
Although PAFR has been implicated in the adhesion of several pathogens to 
human cells there is a scarcity of data that demonstrates direct interaction of the 
bacteria with this receptor (15). Recently, it was shown that Neisseria meningitidis is 
capable of binding to PAFR on human airway cells through the ChoP and glycan 
modification of its pili. As in our study, PAFR was also shown to be heterogeneously 
expressed in bronchial epithelial cells, but in case of N. meningitidis there was a 
100% co-localization between the bacteria and the receptor. Furthermore, immune 
precipitation and ELISA using purified components confirmed that PAFR is an 
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adhesion receptor for N. meningitidis (27). As we do not observe any co-localization 
between PAFR and pneumococci in HBMEC and in the brain of mice, and co­
localization is a prerequisite for a direct interaction, we consider it highly unlikely 
that S. pneumoniae binds to PAFR. Thus, it seems that PAFR is an important receptor 
for respiratory pathogens, either as a direct receptor for meningococci or indirectly 
for S. pneumoniae. The inflammation induced by the presence of pneumococci leads 
to the release of proteins and cytokines by the endothelium, including inflammation 
mediators such as PAF, which binds to and activates its receptor, PAFR. Alternatively, 
ChoP-containing fragments of the pneumococcal cell wall, released during growth 
and or destruction of the bacteria, could bind to PAFR and activate the receptor (28, 
29). The signaling cascade of PAFR then leads to a pro-inflammatory state and events, 
such as neutrophil infiltration. This activation of the brain endothelial cells might 
subsequently facilitate transmigration of S. pneumoniae over cell layers and lead to 
invasive disease. 
PlgR is expressed by the respiratory epithelium (6, 18, 19, 20) and on neurons 
(21, 22, 23), and it is a well-known receptor for S. pneumoniae (6). It has been 
implicated in the translocation of pneumococci over the epithelium through an 
intracellular pathway known as transcytosis (6). Furthermore, through interaction 
with the bacterial ligand CbpA, also known as PspC, plgR is necessary and sufficient 
for pneumococcal adherence to epithelial cells (30). Binding of the bacteria to plgR 
leads to the activation of signaling cascades that drive pneumococcal invasion 
of epithelial cells (6, 30, 31). An absence of plgR was reported in human alveolar 
epithelial cells (A549) and the human brain microvascular endothelial cell line KC 
(6), which led to the suggestion that plgR would be an exclusively epithelial receptor 
for S. pneumoniae. In addition, the interactions between plgR and S. pneumoniae have 
been studied using Madin-Darby Canine Kidney (MOCK) or Calu-3 cells which are 
epithelial cells, but also did not investigate the presence of plgR on endothelial cells 
(31, 32). On the other hand, we detected plgR both on Detroit cells and in HBMEC 
cells, but not A549 cells as reported before (Figure S4). This discrepancy might be due 
to the use of different endothelial cell lines, but is more likely to be due to the use of 
different antibodies by Zhang et al. and us. Zhang et al. prepared a rabbit antiserum 
against human plgR and a sheep antiserum against mouse plgR (6), while we used 
commercial antibodies specific for human or mouse plgR (see Antibodies and lectin in 
Material and Methods) . 
PlgR acts as receptor for transport of immunoglobulins across the mucosa} 
epithelium (16-19). It is presently unclear what the function of plgR might be on the 
brain endothelium. As well as epithelial cells, also endothelial cells employ specific 
mechanisms for the transport of immunoglobulins. It is known that endothelial 
cells express the MHC class I-related receptor, FcRn, which plays an essential role 
86 
Chapter 4 
in the transcytosis of IgG (33, 34, 35). It is thus conceivable that pigR may have a 
physiological function in endothelial cells that is analogous to the one exercised by 
FcRn. 
To the best of our knowledge, our immunofluorescence and confocal analyses 
of the co-localization of S. pneumoniae with pigR in brains of infected mice represent 
the first demonstration of pneumococcal adhesion to a receptor in vivo. Furthermore, 
our data reflects the findings obtained with pigR on epithelial cells, suggesting that 
S. pneumoniae wi11 also have a 100 % co-localization with pigR on lung epithelium 
after a nasopharyngeal challenge. It also implies that adhesion to pigR may 
induce invasion of endothelial cells possibly also through interaction with PspC. 
Pneumococci lacking PspC (also known as CbpA) were shown to be less adhesive to 
rat BMEC than wild-type, and PspC was shown to be involved in the transition from 
the lungs to the blood and from the blood into the cerebra-spinal fluid (CSP) (5, 36, 
37). This indicates that, at least in the rat model, the binding of PspC to pigR might be 
important for the development of both sepsis and meningitis. Thus inclusion of PspC 
in experimental protein vaccines could perhaps induce a broad protection against 
IPD. After intranasal chaIIenge, mice lacking pigR showed less nasal colonization and 
decreased levels of bacteremia compared to wild-type mice (6) but, unfortunately, no 
data was provided on the presence of the bacteria in the brain and or CSF. To finally 
assess whether the absence of pigR significantly reduces bacterial translocation 
into the brain in vivo, intravenous administration of pneumococci in pigR1· and WT 
mice should be performed. Based on our present findings and previously published 
observations from others, we hypothesize that pigR is involved in pneumococcal 
adhesion, not only to the mucosal epithelial barrier of the respiratory tract (6), but 
also to the blood-brain barrier endothelium. 
In conclusion, in this study we have shown that PAFR, which facilitates 
pneumococcal adhesion to brain endothelial cells, does not co-localize with S. 
pneumoniae in vivo and likely has no physical interaction with the bacteria in vivo. 
On the other hand, S. pneumoniae does co-localize to pigR, which is expressed by the 
brain vascular endothelium, and can physically interact with this receptor in vitro. 
We thus conclude that pigR may act as a novel receptor for S. pneumoniae adhesion to 
the blood-brain barrier endothelium. 
Material and Methods 
Cell lines, primary cells and culture conditions 
The HBMEC line (kind gift from Dr. K.S. Kim) (38) was cultivated in RPMI-
1640 (Biochrom, Berlin, Germany) supplemented with 10% Fetal Calf Serum 
(PCS) (Biochrom), 10% Nu-serum (BD Biosciences, Breda, The Netherlands), 2mM 
L-glutamine (Gibco, Grand Island, United States), lmM sodium pyruvate (Gibco), 
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1 % MEM-vitamins (Gibco) and 1 % non-essential amino acids (Gibco ). HUVEC 
(obtained from Endothelial Cell Facility, University Medical Center Groningen) were 
cultivated in DMEM (Cellgro, Huissen, The Netherlands) supplemented with 1 % 
L-glu ta mine (Gibco ), 1 % non-essential amino acids (Cellgro ), 1 % heparin (Sigma) and 
20% FCS (Sigma). Detroit cells (obtained from Department of Molecular Virology, 
University Medical Center Groningen) (39) were cultivated in RPMI-1640 (Biochrom) 
supplemented with 10% FCS (Biochrom), 2mM L-glutamine (Gibco), lmM sodium 
pyruvate (Gibco) and 1% non-essential amino acids (Gibco). A549 (obtained from 
Department of Molecular Virology, University Medical Center Groningen) (40) 
were cultivated in RPMI-1640 (Biochrom) supplemented with 10% FCS (Biochrom), 
2mM L-glutamine (Gibco) and 1% non-essential amino acids (Gibco). All cells were 
cultured at 5% CO2 at 37°C. 
Bacterial strains and growth conditions 
For the in vivo experiments, an encapsulated S. pneumoniae serotype 4 strain, 
TIGR4 (36) was used, while for the adhesion assays and the in vitro physical interaction 
between bacteria and receptors an unencapsulated S. pneumoniae, serotype 4 strain, 
TIGR4 was used. Encapsulated TIGR4 was grown in Todd-Hewitt broth (Oxoid 
Thermo Scientific, Basingstoke, United Kingdom), un-encapsulated TIGR4 in M17 
medium supplemented with 0,5% glucose. Both strains were grown at 37°C, bacterial 
growth was monitored by measuring the optical density (OD) at 600 nm with a 
spectrophotometer. Bacteria were harvested at OD600= 0.25-0.30 by centrifugation 
of 1 ml of culture at 10,000 rpm for 3 minutes. Subsequently, encapsulated TIGR4 
was resuspended in 1ml of sterile phosphate-buffered saline (PBS) (Lonza, Verviers, 
Belgium) till reaching a challenge dose of 107 colony-forming units (CFU) for each 
mouse, while un-encapsulated TIGR4 was re-suspended in HBMEC cell culture 
medium till reaching a bacterial concentration of approximately 106 CFU. 
Bacteremia-derived meningitis model 
All experiments involving animals were performed with the prior approval 
of and in accordance with guidelines of the Institutional Animal Care and Use 
Committee of the University of Groningen (DEC nr. 6152A). The bacteremia-derived 
meningitis model described by Orihuela et al. (36) was adapted in the following way: 
four groups of 5 female Balb/c mice, 6 to 8 weeks old (Harlan, Horst, The Netherlands) 
were anesthetized by inhalation of 2.5% isoflurane before the challenge. Intravenous 
tail vein injection with 200µ1 of 107 CFU of the TIGR4 wild-type was performed, and 
as a control 2 mice were injected with PBS (mock-infected). The mice were sacrificed 
at 1, 3, 8, or 14 hours after the bacterial challenge. After sacrifice, to remove unattached 
bacteria in the blood stream, perfusion was performed by injecting sterile PBS in the 
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right ventricle via the vena cava until the blood was completely removed. Brains, 
lungs, and spleens were collected and stored in Shandon Cryomatrix (Thermo 
Scientific, Runcorn, The Netherlands) at -80°C. 
Antibodies and lectin 
The following antibody combinations and dilutions in sterile PBS with 5% Fetal 
Calf Serum (FCS) (Biochrom, Berlin, Germany) were used for immunofluorescent 
detection. To detect S. pneumoniae, an anti-capsule serotype 4 antibody (Statens 
Serum Institute, Copenhagen, Denmark) 1 :200 diluted was used in combination with 
an Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen Life Technologies, Carlsbad, 
United States) 1 :500 diluted. For the detection of endothelial cells, Dy Light 594-labeled 
Lycopersicon Esculentum Lectin (tomato lectin) (Vector Laboratories, Burlingame, 
United States) was used in a 1 :200 dilution. LEL binds well to glycophorin and Tamm­
Horsfall glycoprotein and has been used effectively to label vascular endothelium in 
rodents (http://www.vectorlabs.com/catalog.aspx?prodID=17l5). For the detection 
of nuclei DAPI (Roche, Mannheim, Germany) 1 :5,000 diluted was used. For the 
detection of PAFR in human cells and mouse tissue, a polyclonal rabbit anti-PAFR 
antibody (Cayman Chemicals, Ann Arbor, United States) was used in a 1 :50 dilution. 
For the detection of pigR in human cells and mouse tissue, respectively, a goat 
anti-human pigR antibody and a goat anti-mouse pigR antibody (R & D Systems, 
Abingdon, United Kingdom) were used in a 1 :50 dilution. As isotype controls for the 
primary antibodies, rabbit IgG (Innovative Research, Plymouth, United States) and 
a goat IgG (Sa_nta Cruz Biotechnology, Dallas, United States) were used at the same 
dilution as those for specific primary antibodies. For the detection of PAFR and S. 
pneumoniae (both on HBMEC and brain tissue), both primary polyclonal antibodies 
were labeled using the Zenon Rabbit IgG Labeling Kit (Invitrogen Life Technologies, 
Carlsbad, United States), and the anti-PAFR antibody was labeled with Alexa Fluor 
350 (blue fluorescence), while the anti-capsule serotype 4 antibody was labeled with 
Alexa Fluor 488 (green fluorescence). Subsequently, the labeled antibodies were 
diluted 1 :50. Also isotype controls were labeled with the Zenon Rabbit IgG Labeling 
Kit and used at the same dilution as were used for specific primary antibodies; 
no fluorescence was detected in all controls (data not shown). For the detection of 
pigR and S. pneumoniae (both on HBMEC and brain tissue) through fluorescence 
microscopy, a goat anti-mouse plgR antibody was used in combination with an 
Alexa Fluor 488 donkey anti-goat antibody (Invitrogen Life Technologies), while the 
anti-capsule serotype 4 antibody was labeled with Alexa Fluor 350 with the Zenon 
Rabbit IgG Labeling Kit. The goat IgG isotype control was used at the same dilution 
as used for the anti-plgR antibody in combination with an Alexa-fluor 488 donkey 
anti-goat antibody (Invitrogen Life Technologies); no fluorescence was detected in 
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all controls (data not shown). To detect plgR and S. pneumoniae on brain tissue by 
confocal microscopy, the goat anti-mouse plgR antibody was used in combination 
with an Alexa Fluor 488 donkey anti-goat antibody (Invitrogen Life Technologies), 
and the anti-capsule serotype 4 antibody was labeled with Alexa Fluor 488 using the 
Zenon Rabbit IgG Labeling Kit. 
For studies on the in vitro physical interaction between S. pneumoniae and 
particular receptors, bacteria were detected with a rabbit anti-pneumococcal 
antiserum (Eurogentec, Maastricht, the Netherlands), and for the detection of the 
receptors the same antibodies as mentioned above were used. As negative control 
for the physical interaction between S. pneumoniae and particular receptors, a mouse 
anti-human a tubulin antibody (Sigma Aldrich) in combination with Alexa Fluor 488 
Goat anti-Mouse were used. 
For Western blotting analyses, goat anti-human plgR (R & D Systems) and an a 
tubulin antibody (Sigma Aldrich) were used for the detection of respectively human 
plgR and a tubulin. 
Immunofluorescent detection 
For immunofluorescent staining of brain and lung cells, sections of 5µm thin 
were cut with a cryostat, placed on microscope glass slides and dried under a fan 
for at least 30 minutes. Sections were fixed with acetone for 10 minutes and dried 
for 5 minutes. For immunofluorescent staining of HBMEC, after 1 hour incubation 
with S. pneumoniae, cells were fixed with 4% paraformaldehyde (Sigma Aldrich) 
and washed 2 times with PBS prior starting the staining procedure. 
For the detection of PAFR and S. pneumoniae in brain tissue (Table 1 ), the slides 
were first incubated with an anti-PAFR antibody labeled with Alexa Fluor 350 for 1 
hour in the dark at room temperature (RT). Slides were then washed in PBS 3 times 
for 5 minutes. Subsequently, the slides were incubated with anti-capsule serotype 4 
antibody labeled with Alexa Fluor 488 for 1 hour in the dark at room temperature 
(RT). After washing with PBS 3 times for 5 minutes, the slides were incubated at RT 
in the dark with DyLight 594 labeled LEL. Slides were washed 3 times with PBS for 
5 minutes and incubated with DAPI (Roche, Mannheim, Germany) for 10 minutes at 
RT in the dark. Lastly, the slides were washed twice for 5 minutes in PBS. 
For the detection of plgR and S. pneumoniae in brain tissue (Table 1 ), the slides 
were first incubated with anti-capsule serotype 4 antibody labeled with Alexa Fluor 
350 for 1 hour in the dark at RT. Slides were then washed in PBS 3 times for 5 minutes. 
Subsequently, the slides were incubated with anti-plgR antibody for 1 hour in the 
dark at RT. After washing with PBS 3 times for 5 minutes, the slides were incubated 
at RT in the dark with a mixture of DyLight 594 labeled LEL and Alexa Fluor 488 
donkey anti-goat. Slides were washed 3 times with PBS for 5 minutes, incubated with 
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DAPI for 10 minutes at RT in the dark, and washed again twice for 5 minutes in PBS 
at RT in the dark. 
For detection of pigR in lung (Table 1), slides were first incubated with anti­
plgR antibody for 1 hour at RT. Slides were then washed 3 times in PBS for 5 minutes. 
Slides were incubated with Alexa Fluor 488 donkey anti-goat for 1 hour at RT in 
the dark, and then washed 3 times in PBS for 5 minutes. At the end, slides were 
incubated with DAPI for 10 minutes at RT in the dark and washed again with PBS 2 
times for 5 minutes. 
For the detection of PAFR and S. pneumoniae in HBMEC and HUVEC (Table 
1), cells were first incubated with anti-PAFR antibody labeled with Alexa Fluor 594 
following incubation with anti-capsule serotype 4 antibody labeled with Alexa Fluor 
488. For the detection of plgR and S. pneumoniae in HBMEC and HUVEC (Table 1), 
cells were first incubated with a mixture of the anti-plgR and anti-capsule serotype 4 
antibodies, following incubation with a mixture of Alexa Fluor 488 donkey anti-goat 
and Alexa Fluor 594 goat anti-rabbit antibodies. For the immune fluorescent staining 
of human cells, the same procedure applied for the tissue sections was used, the only 
difference being that the PBS used to wash the cells was immediately removed. 
For immunostaining on mouse tissue, the slides were washed 3 times with 
PBS for 5 minutes in between each incubation step and 2 times with PBS for 5 
minutes after DAPI incubation. For immunostaining on HBMEC and HUVEC, cells 
were washed once with PBS for a few seconds after each incubation step. Citifluor 
solution (Science Services, Munich, Germany) was added to each tissue section/glass 
disk after which the coverslip was applied. The slides were analyzed with a Leica 
DM5500B microscope and images were recorded with a Leica DFC 360 FX camera. 
Additionally a Leica SP2 AOBS confocal microscope was used to confirm the presence 
of pneumococci adhering to the brain vascular endothelium. 
Image processing 
All images recorded with the Leica DM5500B fluorescence microscope were 
processed with ImageJ (41). The TIFF images obtained with the 350nm (blue), 488nm 
(green) and 594nm (red) wavelength filters were merged using the Color-Merge 
Channels function. As minor manipulation, background correction was applied in 
those images where the background was across the image by using the Brightness & 
Contrast command of ImageJ. In all the images subjected to this minor adjustment, 
the background subtraction was applied to all parts of the image. The LEI z-stacks 
obtained with the confocal microscope Leica SP2 AOBS were merged through Imaris 




Co-localization of S. pneumoniae with plgR and PAFR was analyzed with ImageJ 
(41). The images with the bacterial signal and plgR/PAFR were opened separately 
and analyzed with the ImageJ plugin Analyze/Co-localization analysis. White pixels 
were automatically generated on the areas of the bacterial signals co-localizing with 
the receptor signals. Bacteria that did not co-localize with the plgR signal remained 
blue and bacteria not co-localized with the PAFR remained green. 
Bacterial quantification 
The surface covered by bacteria was measured using the Threshold function 
of ImageJ, by determining the area occupied by the 488 nm bacterial signal and the 
white pixels of the bacteria co-localized with receptors. The percentage of the bacteria 
co-localized with receptors compared to the total bacterial signal was calculated by 
dividing the surface area of white bacteria by the surface area of the green bacteria in 
each image and multiplication with 100. 
In vitro interaction of S. pneumoniae with receptors 
Lysis buffer was prepared with 50 mM tris-HCl (Promega, Mannheim, GER) pH 
7.4, 150 mM NaCl, 1 % triton 100X, 1 % sodium deoxycholate, 0.1 % SDS (all from Sigma 
Aldrich), 1 mM EDTA (Merck Millipore, Billerica, United States), protease inhibitors 
1 X (Roche, Mannheim, Germany). 250 µl of lysis buffer was added to confluent 
monolayers of HBMEC or HUVEC cells grown in small T25 flasks (TPP, Trasadingen, 
Switzerland). After 1 minute incubation at room temperature, monolayers were 
scraped with a cell scraper (Nalge Nunc International, Rochester, United States) and 
the lysate harvested. After centrifugation at 14,000 rpm for 15 minutes at 4°C, the cell 
lysate in the supernatant was harvested and the pellet discarded. coomassie brilliant 
blue staining was used as quality control to visualize the proteins of the cell lysates 
separated by SDS-page. A solution of approximately 106 CFU of un-encapsulated 
TIGR4 was prepared in sterile phosphate buffered saline (PBS) (Lonza, Verviers, 
Belgium). 50 µl of HBMEC or HUVEC lysate was added to 50 µl of the bacterial 
solution and the mixture was incubated at 4°C with gentle agitation for 1 hour. The 
mixture of cell lysate and bacteria was then centrifuged at 14,000 rpm for 20 minutes 
at 4°C. All the supernatant was removed and the bacterial pellet was washed 2 times 
with 100 µl PBS. After washing, the pellet was re-suspended with 100 µl of an anti­
pneumococcal antiserum (1:100 dilution) (Eurogentec, Maastricht, The Netherlands) 
directly labeled with Alexa Fluor 594 (Zenon Rabbit IgG Labeling Kit), following an 
incubation at 4 °C for 1 hour. After washing, the bacterial pellet was stained for plgR 
using an anti-human pigR antibody, followed by incubation with an Alexa Fluor 
Donkey anti-Goat 488 antibody. The same procedure has been adopted to check the 
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physical interaction between S. pneumoniae and the PAFR, the only difference being 
that the anti-PAFR antibody was labeled with 594 Alexa Fluor (Zenon Rabbit IgG 
Labeling Kit) instead of using a secondary antibody for the detection. As a negative 
control for the physical interaction between S. pneumoniac and receptors, an anti­
human a-tubulin antibody was used. Incubation with the anti-a-tubulin antibody 
was followed by incubation with an Alexa Fluor 488 Goat anti-Mouse antibody. 
Finally, the bacterial pellet was re-suspended in 100 µl of distilled water. A 5 µl drop 
was pipetted on a microscope glass slide, covered with a coverslip and analyzed 
by fluorescence microscopy. The slides were inspected with a Leica DM5500B 
microscope and the images were recorded with a Leica DFC 360 FX camera. 
Pneumococcal adherence to endothelial cells 
HBMEC and HUVEC cells were grown in 12-well plates (TPP) .  When 
immunofluorescent staining was performed after the adherence assay, cells were 
grown on glass disks placed inside each well. For adherence of HUVEC on glass, 
disks were coated with gelatin for 45 minutes. After removal of the gelatin, disks 
were incubated with 0.5% glutaraldehyde (Sigma Aldrich) for 45 minutes. Disks 
were then washed 2 times with PBS and 2 times with HUV EC culture medium. 
Cells were grown to confluency at 37°C under 5% CO2• To block the PAFR or pigR 
receptors, cells were incubated with the respective receptor-specific antibody at a 
final antibody concentration of 50 µg/ml. As controls, cells were incubated with 
a rabbit IgG (Innovative Research, Plymouth, United States) or a goat IgG (Santa 
Cruz biotechnology, Heidelberg, Germany) at the same concentration as the anti­
PAFR or anti-pigR antibodies. As a further control, we also used cells that had not 
been incubated with antibody/IgG. Cells were grown to confluency in an incubator 
at 37°C with 5% CO2 overnight. After washing the cells with sterile PBS, 900 µl cell 
culture medium was added to each well and 100 µl of approximately 106 CFU of 
unencapsulated S. pneumoniae TIGR4 was added. After 1 hour incubation at 37°C at 
5% CO2, cells were treated with a 50/50 mix of 1 % saponin and trypsin-EDTA (0.05%-
0.02%) and Iysed. CPUs were determined by plating serial dilutions of lysed cells 
on blood agar plates. The ratio of adherent bacteria was calculated by dividing the 
adhered bacteria by the total amount of bacteria (adherent + non-adherent bacteria). 
Western blotting procedure 
Lysates of Detroit, A549 or HBMEC cells were prepared as described above 
for in vitro studies on the interactions between S. pneumoniae and particular 
receptors. Proteins of the cell lysates were separated by SDS-PAGE using NuPAGE 
gels (Invitrogen), and then blotted (75 min, 100 mA per gel) onto a nitrocellulose 
membrane (Protran®, Schleicher & Schuell, Bath, United Kingdom). Subsequently, 
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human plgR was detected using a specific antibody and a- tubulin was used as 
loading control (see the above section on antibodies and lectin). Antibody detection 
was performed with fluorescent IgG secondary antibodies IRDye 800 CW donkey 
anti-goat (LiCor Biosciences, Bad Homburg, Germany) for human plgR detection or 
700 CW goat anti-mouse antibodies for a-tubulin detection, in combination with the 
Odyssey Infrared Imaging System (LiCor Biosciences). Fluorescence was recorded at 
700 and 800 nm. 
Statistical analyses 
The independent student t-test of SPSS Statistics 20 (IBM) was used for the 
statistical analysis of the adherence assay results. The comparison between ratio of 
adherent bacteria in HBMEC/HUVEC cells treated with receptor antibodies and 
HBMEC/HUVEC cells treated with isotype IgG or no antibody was statistically 
tested. 
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Table 1 . Immunofluorescent detection scheme 
Detection of 1st 2nd 3rd 4th 
PAFR and S. 
p11eu11ro11iae in Anti PAFR antibody Anti capsule serotype tomato lectin DAPI 
brain tissue labeled with Alexa Fluor 4 antibody labeled 
350 (Zenon Kit) with Alexa Fluor 488 Dilution 1 :200 1 :5000 
(Zenon Kit) 
Dilution 1 :50 
Dilution 1 :500 
Detection of 1st 2nd 3rd 4th 
plgR and S. 
p11e111no11iae in Anti capsule serotype 4 Anti pigR antibody Mixture tomato DAPI 
brain tissue labeled with Alexa Fluor lectin and 
350 (Zenon Kit) Dilution 1 :50 Alexa Fluor 488 1 :5000 
Donkey anti 
Dilution 1 :50 Goat 
Dilution 1 :500 
Detection of 1st 2nd 3rd 
plgR in lung 
tissue Anti pigR antibody Alexa Fluor 488 DAPI 
Donkey anti Goat 
Dilu tion 1 :50 Dilution 1 :5000 
Dilution 1 :500 
Detection of 1st 2nd 3rd 
PAFR and S. 
p11e11mo11iae in Anti PAFR antibody Anti capsule serotype DAPI 
HBMEC and labeled with Alexa Fluor 4 antibody labeled 
HUVEC 594 (Zenon Kit) with Alexa Fluor 488 1 :5000 
(Zenon Kit) 
Dilution 1 :50 
Dilution 1 :50 
Detection of 1st 2nd 3rd 
plgR and S. 
p11e11111011iae in Mixture of anti pigR Mixture of Alexa Fluor DAPI 
HBMEC and antibody (dilution 1 :50) 488 Donkey anti Goat 
HUVEC and anti capsule serotype and Alexa Fluor 594 Dilution 1 :5000 
4 antibody (dilution 1:200) Goat anti Rabbit 
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Abstract 
Bacterial meningitis is a life threatening infectious disease leading to cerebral 
dysfunction and consequently death. The Gram-positive bacterium Streptococcus 
pneumoniae is the main causative agent of this disease. S. pneumoniae is thought to 
invade the Central Nervous System via the bloodstream by crossing the vascular 
endothelium of the blood-brain barrier, a specialized system of endothelial cells 
that protects the brain from harmful substances that are present in the bloodstream 
and supplies the brain with the required nutrients for its proper function. The exact 
mechanism by which pneumococci cross endothelial cell barriers before meningitis 
develops is unknown. Here we investigated the role of PECAM-l/CD31, one of the 
major endothelial cell adhesion molecules, in S. pneumoniae adhesion to vascular 
endothelium of the blood-brain barrier. Mice were intravenously infected with 
pneumococci and sacrificed at various time points to mimic the stages preceding 
meningitis. Immunofluorescent analysis of brain tissue of infected mice showed 
that pneumococci co-localized with PECAM-1. Also in Human Brain Microvascular 
Endothelial Cells (HBMEC) incubated with S. pneumoniae we observed a clear co­
localization between PECAM-1 and pneumococci. Blocking of PECAM-1 reduced 
the adhesion of S. pneumoniae to endothelial cells in vitro, implying that PECAM-1 
is involved in pneumococcal adhesion to endothelial cells. Furthermore, we 
demonstrate using endothelial protein lysates that S. pneumoniae physically binds 
to PECAM-1 in vitro. In vitro we also show that PECAM-1 co-localizes with the S. 
pneumoniae adhesion receptor plgR, which we previously demonstrated to be present 
on endothelial cells. In brain tissue of infected mice S. pneumoniae was associated with 
both receptors. Lastly, immunoprecipitation experiments revealed that PECAM-1 
can physically interact with plgR. In summary, we show for the first time that blood­
borne S. pneumoniae can bind to PECAM-1 expressed on the brain microvascular 
endothelium and that PECAM-1 can interact with plgR. We hypothesize that this 
interaction may play a major role in pneumococcal binding to the blood-brain barrier 
vasculature prior to invasion into the brain. 
Chapter 5 
Introduction 
Streptococcus pneumoniae (the pneumococcus) is a Gram-positive bacterial 
pathogen that causes life-threatening invasive diseases in humans, such as pneumonia 
and bacteremia. Every year, over a million people worldwide succumb to diseases 
caused by S. pneumoniae (1). Moreover, this bacterium is the most common causative 
agent of bacterial meningitis, an inflammation of the protective membranes covering 
the brain and spinal cord, collectively known as the meninges (2, 3). S. pneumoniae 
is thought to invade the brain mainly via the bloodstream by crossing the vascular 
endothelium of the blood-brain barrier, a specialized system of endothelial cells that 
protects the brain from harmful substances that are present in the bloodstream and 
supplies the brain with the required nutrients for its proper function (2, 3) . 
Meningeal pathogens, such as S. pneumoniae and Neisseria meningitidis, bind to 
receptors expressed on the plasma membrane of epithelial and endothelial cells and, 
through this binding, they can invade and translocate over human cell layers (4- 6). 
The platelet-activating factor receptor (PAFR) has been described as one of the major 
receptors involved in the interaction between S. pneumoniae and endothelial cells (7-
9). Blocking of PAFR leads to a significant reduction of pneumococcal adhesion to 
endothelial cells in vitro, and the complete absence of PAFR leads to less invasive 
pneumococcal disease in mouse models ( 4, 7). However, in Chapter 4 of this thesis, we 
showed data suggesting that physical interaction between S. pneumoniae and PAFR 
is not likely to occur as we did not observe co-localization between the receptor and 
the bacteria in the brain tissue of intravenously infected mice. Orihuela et al. showed 
that the laminin receptor initiates the contact of S. pneumoniae to the brain vascular 
endothelium in vivo (10). The poly immunoglobulin receptor (plgR) was furthermore 
shown to mediate binding of pneumococci to the epithelium of the upper respiratory 
tract (5) and in Chapter 4 we showed that plgR expressed by brain endothelial cells is 
capable of binding S. pneumoniae. It is unclear at the moment whether more receptors 
are involved in pneumococcal adherence to the blood brain endothelium. 
The platelet endothelial cell adhesion molecule-1 (PECAM-1; also known as 
CD31}, is a pan-endothelial protein that is present in the intercellular junctions of the 
endothelial cells (11, 12). PECAM-1 is involved in leukocyte migration, angiogenesis, 
and integrin activation (11, 12). In particular, the involvement of PECAM-1 in leukocyte­
endothelium interaction and leukocyte trans-endothelial migration in the vascular 
system makes PECAM-1 a key molecule in inflammation and neuroinflammation (13, 
14). Recently PECAM-1 was implicated in Salmonella typhimurium infections (15). This 
raised the question whether PECAM-1 might also play a role in host-pneumococcal 
interactions. Accordingly, the specific aim of the present study was to investigate 
whether PECAM-1 plays a role in S. pneumoniae adhesion to the vascular endothelium 
of the blood-brain barrier. To study this, Balb/c mice were intravenously infected 
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with S. pneumoniae strain TIGR4 and sacrificed at different time-points to mimic 
the stages preceding meningitis (16). In brief, the present immunofluorescent and 
confocal microscopic analyses of brain sections in combination with in vitro blocking 
experiments and immunoprecipitation show that PECAM-1 may well be a novel 
adhesion receptor for pneumococci that possibly exerts this action in conjunction with 
plgR. Thus, novel insights in the receptors that S. pneumoniae can employ to adhere to 
the vascular endothelium of the blood-brain barrier are presented. 
Results 
S. pneumoniae co-localizes with PECAM-1 expressed by the vascular endothelium of the 
blood-brain barrier in vivo and by HBMEC in vitro 
Previously we have shown that, as soon as 1 hour after infection, pneumococci 
adhere to the blood-brain endothelium. However, there are significant spatiotemporal 
differences in the invasion of the brain. Most noticeable, the bacteria occurred in the 
choroid plexus only after 8 hours post infection (16) .  It was therefore of interest to 
investigate the possible co-localization of S. pneumoniae with PECAM-1 at all time 
points during infection. Unexpectedly, our present immunofluorescent analyses of 
brain tissue from the infected mice revealed that, at all time points of infection, most 
adherent bacteria co-localized with PECAM-1 (Figures lA,B and SlA,B). In fact, the 
assessment of the bacterial and PECAM-1 signals with ImageJ showed that > 95% of 
the pneumococci were co-localized with PECAM-1 in all brain compartments at all 
time-points of infection (Figures lA,B and SlA,B). This observation was subsequently 
verified by confocal microscopy, which confirmed that S. pneumoniae was indeed 
co-localized with PECAM-1 (Figure S2 and movies in Supporting Information). In 
vitro, co-localization analyses also showed that most pneumococci co-localized with 
PECAM-1 in HBMEC cells (Figure 2). Our immunofluorescent analyses furthermore 
showed that in brain tissue of mock-treated healthy mice the PECAM-1 signal was 
weak and patchy (Figure 3A). Interestingly, the PECAM-1 signal increased over 
the time course of infection and, in particular, it seemed that this increase of the 
PECAM-1 signal was detectable in association with pneumococci or nearby areas 
where the bacteria were present (Figure 3B). 
To confirm that the PECAM-1 protein levels increased upon the presence of 
pneumococci and not because of inflammation caused by bacterial infection, we 
immunofluorescently stained PECAM-1 in lung tissue. We previously showed that 
intravenous injection of S. pneumoniae TIGR4 causes a high influx of leukocytes in the 
lungs right from 1 to 14 hours post challenge, which is a clear sign of inflammation 
(16). No differences were, however, observed in PECAM-1 signal between lungs of 
mock-treated mice and lungs of infected mice up to 8 hours post challenge (Figure 
4A). Bacteria were occasionally detected in the lungs only at 14 hours post challenge 
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(Figure 4B), and this was paralleled by a more intense PECAM-1 fluorescent signal 
nearby the areas where bacteria were visible than in areas where no bacteria were 
detected (Figure 4B). Together, these results suggest that the presence of pneumococci 
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Figure 1. In vivo co-localization of S. pneumoniae and PECAM-1 on brain 
endothelium 
Brain slides of mice systemically infected with S. pneumoniae were immunofluorescently stained 
for PECAM-1 (red), pneumococci (green), and cellular nuclei (blue). The images are representative 
for the situation in each brain compartment at 1 hour (A) and 14 hours (B) post bacterial challenge. 
At 1 hour no pneumococci were detected in the choroid plexus. For each time point of infection, 
6 brain sections from 3 mice in each group were analysed. Total magnification of subarachnoid 
space, septum and choroid plexus 630X; total magnification of cerebral cortex lOOOX. 
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Figure 2. Co-localization of S. pneumoniae and PECAM-1 in HBMEC 
Immunofluorescent detection of S. pneumoniae (green}, PECAM-1 (red) and cellular nuclei 



















Figure 3. Increased PECAM-1 signal in the presence of pneumococci in the brain 
hnmunofluorescent detection of tomato lectin (red}, PECAM-1 (green} in the brain of mock-treated 
mice (A) and S. pneumonia-infected mice at different time points post infection (8). Total magnification 
SOX Brains from 2 mock-treated and 3 S. pneumoniae-infected mice were analyzed, and of each mouse 
3 brain sections were analyzed. The images are representative of the situation in the brains of healthy 
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Figure 4. Specific induction of PECAM-1 in the presence of pneumococci in the 
lungs 
Immunofluorescent detection of PECAM-1 (red) and cellular nuclei (blue) in lungs of (A) 
mock-treated mice, (B) during systemic infection with S. pneumoniae up to 8 hours post 
challenge, and (C) in lungs of infected mice at 14 hours post challenge. As expected, no 
pneumococci were detected in lungs of mock-treated mice up to 8 hours post infection (data 
not shown). Bacteria were occasionally detected in the lungs at 14 hours post challenge Total 
magnification 400X. Lungs from 3 infected mice were analyzed, and of each mouse 3 lung 
sections were stained, the images showing representative outcomes of the situation in the 
lungs at each time point and condition. 
Blocking of PECAM-1 reduces adhesion of S. pneumoniae to endothelial cells 
The immunofluorescent analysis showed co-localization between pneumococci 
and PECAM-1 on brain endothelium in vivo and on brain endothelial cells in vitro. 
Therefore, the next step was to investigate whether PECAM-1 is functionally 
involved in pneumococcal adhesion to human endothelial cells. Indeed, in HBMEC 
and Human Umbilical Vein Endothelial Cells (HUVEC) treated with anti-PECAM-1 
antibody prior to incubation with pneumococci, the bacterial adhesion was - 45-50% 
reduced compared to control conditions (Figures SA,B). This shows that PECAM-1 is 
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Figure 5. Blocking of PECAM-1 significantly reduces pneumococcal adhesion to 
human endothelial cells 
Blocking of PECAM-1 with anti-PECAM-1 antibody (white bars) led to a significant 
reduction of pneumococcal adhesion to HBMEC (A) and HUVEC (B) compared to isotype 
IgG treahnent (hatched bars) and untreated HBMEC/HUVEC (black bars). Data represent 
averages of triplicate repeats per condition plus standard deviations. The Y- axis shows 
the ratio of adherent bacteria. The ratio of adherent bacteria was calculated by dividing 
the adherent bacteria by the total amount of bacteria in the well (adherent + not adherent 
bacteria). * P value < 0.05 as determined by the students t-test. Assays have been repeated 
three times in each endothelial cell type. 
Physical interaction between S. pneumoniae and PECAM-1 from human endothelial cell 
lysates 
After the observation that blocking of PECAM-1 with a specific antibody 
leads to a significant reduction of pneumococcal adhesion to endothelial cells, we 
investigated whether S. pneumoniae can physically interact with PECAM-1 present in 
lysates of endothelial cells. To this end, the bacteria were incubated with the HBMEC 
or HUVEC lysates as described in chapter 4 of this thesis. Briefly, the bacteria 
were incubated with a lysate of cultured cells and collected by centrifugation. The 
supernatant was discarded from the bacterial pellet and, after extensive washing steps, 
the bacteria were probed for the presence of bound eukaryotic proteins from the cell 
lysate using immuno-fluorecence. Indeed, a specific PECAM-1 signal was detected 
on the surface of pneumococci incubated with HBMEC or HUVEC cells (Figure 
6A), which indicates that the PECAM-1 protein binds to pneumococci. In contrast, 
the control protein a-tubulin was not detected on the pneumococcal cells (Figure 
6B), indicating that the interaction was specific for PECAM-1 and that endothelial 
proteins like tubulin did not generally become associated with the bacteria through 
non-specific interactions. Importantly, these results unequivocally demonstrate that 
S. pneumoniae can physically interact with the PECAM-1 protein as present in lysates 
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Figure 6. S. pneumoniae bound to PECAM-1 present in HBMEC and HUVEC 
lysates 
(A) Immunofluorescent detection of S. pneumoniae (green) and PECAM-1 (red) after 
pneumococci were incubated with HBMEC and HUVEC lysates. Total magnification 400X. 
The co-localization of the fluorescence in the overlay (yellow) indicates that PECAM-1 signal 
is associated with the pneumococci. Parts of the overlay images (within white rectangles) are 
enlarged and shown on the right. (B) Immunofluorescent detection of S. pneumoniae (green) 
and a-tubulin (red) after pneumococci were incubated with HBMEC and HUVEC lysates. 
Total magnification 400X. The overlay indicates that the a-tubulin signal is not detectable 
on the pneumococci. Parts of the overlay images (within white rectangles) are enlarged and 
shown on the right. 
PECAM-1 interacts with plgR, which may lead to the formation of a double receptor for the 
adhesion of S. pneumoniae 
Our previous studies have shown that S. pneumoniae binds the plgR receptor on 
brain endothelial cells and that this binding is important for pneumococcal adherence 
to such cells (chapter 4 of this thesis). In the light of our present results, this would 
suggest that plgR and PECAM-1 could be co-localized. We therefore investigated 
the possible co-localization of these two receptors. Indeed, confocal imaging showed 
that PECAM-1 and plgR are frequently co-localized in HBMEC and HUVEC in the 
absence of infecting bacteria (Figures 7 A,B). Furthermore, after incubation with S. 
pneumoniae for 1 hour, pneumococci adherent to endothelial cells co-localized with 
both PECAM-1 and plgR at the same time (Figures 7C,D). Immunofluorescent 
analysis of brain tissues from healthy mice showed that PECAM-1 and plgR were 
frequently co-localized in all brain compartments. Analysis of brains from infected 
mice also showed that these two receptors were frequently co-localized (Figures SA-C 
and S3A,B) and, on top of this, most S. pneumoniae co-localized with both PECAM-1 
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and plgR (Figures 8B,C and S3A,B). These observations strongly support the view 
that PECAM-1 and plgR are co-localized and may both have a role of pneumococcal 
adherence to endothelial cells. 
To determine whether PECAM-1 and plgR interact with each other, we 
performed immunoprecipitation experiments in which we pulled down one protein 
from HBMEC or HUVEC lysates and detected the other one by Western blotting, 
or vice versa, As a positive control f-actin was used, which is known to interact with 
PECAM-1 (17). As a negative control p53 was used, since there is no evidence in the 
literature for a direct interaction between p53 and PECAM-1 (Figure 9A). Indeed, 
PECAM-1 and plgR were co-immunoprecipitated with either antibody, which 
demonstrated that PECAM-1 and plgR can physically interact in HBMEC and 
HlNEC lysates (Figures 9A,B). Lastly, preliminary data indicate that the adhesion 
of S. pneumoniae to HBMEC and HUVEC cells was more strongly impaired when 
PECAM-1 and plgR were simultaneously blocked with specific antibodies than when 
either PECAM-1 or plgR were blocked individually (Figures lOA,B). This suggests 
that PECAM-1 and plgR could cooperatively facilitate the pneumococcal adhesion to 
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Figure 7. Endothelial 
PECAM-1 and plgR 
are co-localized in vitro 
and S. pneumoniae 
is co-localized with 
PECAM-1 close to plgR 
Confocal imaging of 
PECAM-1 and plgR in 
HBMEC (A) and HUVEC 
(B) in the absence of 
bacteria, and in HBMEC 
(C) and HUVEC (D) after 
a 1 hour incubation with 
pneumococci. The overlay 
shows PECAM-1 co­
localized with plgR. For 
each cell type, 10 cells have 
been randomly selected 
for imaging. The images 
are representative of the 
situation in the monolayer, 
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Figure 8. In vivo PECAM-1 and plgR co-localization on brain microvascular 
endothelium and preferential co-localization of S. pneumoniae with plgR and 
PECAM-1 at the same time 
Immunofluorescent detection of PECAM-1 and plgR in brain tissue of mock-treated mice (A) 
and of PECAM-1, plgR and S. pneumoniae in brain tissue of infected mice at 1 hour (B) and 
14 hours (C) post challenge. Total magnification of subarachnoid space, septum and choroid 
plexus was 630X; total magnification of cerebral cortex was lO00X. Brains from 2 mock-treated 
and 3 intravenously infected mice were analyzed, and of each mouse 3 brain sections were 
used for fluorescence staining. The images are representative of the situation in the brains of 
healthy mock-treated mice, and at 1 and 14 hours post challenge with S. pneumoniae. 
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Figure 9. PECAM-1 interacts with plgR in HBMEC and HUVEC cell lysates 
Immunoprecipitation of either PECAM-1 or plgR followed by Western blot analysis of various 
proteins showed that PECAM-1 interacts with plgR present in HBMEC and HUVEC lysates 
(A) as well as with f-actin, while no interaction with p53 is detectable (B). Immunoprecipitation 
of plgR in HBMEC and HUVEC lysates followed by detection of PECAM-1. Control 
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Figure 10. Blocking of PECAM-1 and plgR reduces the pneumococcal adhesion to 
human endothelial cells to lower levels than blocking of the individual receptors 
Simultaneous blockong of PECAM-1 and plgR reduces the pneumococcal adherence to H BMEC 
(A) and HUVEC (B) to a greater extent than blocking of the individual receptors. White bars 
represent the percentage of adhesion in the presence of anti-receptor antibodies, hatched bars 
in the presence of antibody isotype controls, and black bars in the absence of added antibodies 
(medium incubation). The y-axis shows the percentage of the adhesion ratio where the antibody 
isotype control adhesion ratio was set at 100%. Data sets obtained for adhesion in the presence 
of individual or a mix of both receptor antibodies were obtained independently; each set of 
experiments was repeated three times for each endothelial cell type. 
Discussion 
The aim of this study was to investigate whether S. pneumoniae has the capacity 
to bind to the PECAM-1 protein expressed by the vascular endothelium of the 
blood-brain barrier. To study this, we mimicked the events preceding meningitis by 
intravenously infecting mice with pneumococci and sacrificing them at various time 
points after challenge (16). In addition, we performed in vitro bacteria-endothelial 
adhesion assays. In the course of these analyses, we have demonstrated that S. 
pneumoniae co-localizes with PECAM-1 in vivo and in vitro, and that PECAM-1 
blocking with a specific antibody significantly reduces adhesion of S. pneumoniae to 
endothelial cells in vitro. The idea that PECAM-1 has a role in pneumococcal adhesion 
to endothelial cells is strongly supported by immunoprecipitation experiments, 
which show that S. pneumoniae binds the PECAM-1 present in HBMEC and HUVEC 
cell lysates. Importantly, PECAM-1 and a second receptor on brain endothelial 
cells, the poly immunoglobulin receptor plgR, both interact with S. pneumoniae in 
vitro, and are co-localized at the sites of bacterial adhesion in vivo and in vitro. Co­
immunoprecipitation studies show that PECAM-1 and plgR are non-covalently 
bound to each other in endothelial cell extracts. Altogether, these observations 
imply that the interacting PECAM-1 and plgR proteins mediate the adhesion of S. 
pneumoniae to the blood-brain barrier endothelium. 
PECAM-1 is involved in leukocyte migration during neuroinflammation by 
mediating the interaction of leukocytes with the vascular endothelium. HIV infection 
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leads to enhanced transmigration of HIV-infected leukocytes into the central nervous 
system (CNS) and changes in the blood-brain barrier permeability through alterations 
in PECAM-1 interactions between endothelial cells and between leukocytes and 
endothelial cells (18). Recently, we showed that pneumococcal interaction with the 
blood-brain barrier endothelium did not cause a major disruption of endothelial 
integrity (16). Furthermore, we also showed that influx of leukocytes in the brain was 
low up to 14 hours post intravenous challenge (16). Thus, while PECAM-1 alterations 
in HIV infection lead to leukocyte recruitment into the CNS and consequent alterations 
in blood-brain permeability, interaction of blood-borne S. pneumoniae with PECAM-1 
on the brain microvascular endothelium does neither seem to cause a serious influx 
of leukocytes nor a major disruption in blood-brain barrier integrity. 
Relatively little is known about PECAM-1 as a putative a receptor for pathogens. 
PECAM-J-1- mice were more resistant to gastrointestinal infection with Salmonella 
typhimurium than wild-type mice, resulting in lower bacterial loads in systemic organs, 
such as the liver and spleen (15). Whole bacterial cell ELISA experiments revealed 
that human and murine PECAM-1 can bind to S. typhimurium, which indicates that 
PECAM-1 can bind to bacteria and that this may have pathogenic consequences (15). 
In our study, S. pneumoniae is clearly shown to co-localize with PECAM-1 both in 
vitro and in vivo, and incubation of S. pneumoniae with endothelial cell lysates leads 
to PECAM-1 association with the bacteria. This implies that PECAM-1 may also 
serve as a receptor for S. pneumoniae which, in tum, may have consequences for the 
development of invasive pneumococcal disease (IPD). 
As shown by our immunofluorescence detection method the PECAM-1 signal in 
the healthy mouse brain is relatively weak (Figure 3A). However, upon pneumococcal 
infection, more cells display a fluorescent PECAM-1 signal, in particular when S. 
pneumoniae is attached to the cells (Figure 3B). Using lung tissues of the same mice, 
we showed that inflammation per se may not be enough to induce a PECAM-1 signal, 
but that the presence of the bacteria is needed. This implies that the induction of this 
receptor may be a direct consequence of bacterial binding to the receptor. Additional 
experiments will be needed to further establish whether such a causal role between 
bacterial binding and (transcriptional or post-transcriptional) control of PECAM-1 
expression exists. 
After intravenous injection of 107 colony forming units (CFU) S. pneumoniae 
TIGR4, the systemic numbers of bacteria were reduced by 10 fold 1 hour after the 
challenge (16), but as the disease progressed, the recoverable CFU in the blood 
increased. A significant drop in CFU in the blood after intravenous administration 
of pneumococci was previously observed also in a rabbit model (19). PECAM-1 is 
present in the endothelial cells of the entire vascular system, so it may be possible 
that this apparent 10-fold drop in CFU in the blood within 1 hour is the result of 
an immediate attachment of bacteria to PECAM-1 in the blood vessels in specific 
111 
Chapter 5 
compartments of the body, such as the heart and kidney vasculature where 
PECAM-1 is  highly expressed (20), which would sequester the bacteria. In principle, 
the immediate attachment of bacteria to the vasculatures of organs expressing high 
levels of PECAM-1 may lead to bacterial invasion into these organs. However, S. 
pneumoniae is known to mainly cause pneumonia, bacteremia, otitis media and 
meningitis. It would, therefore, be interesting to investigate whether blood-borne 
pneumococci are also able to translocate over the endothelium of organs with a high 
PECAM-1 expression, such as the heart and kidney. 
Receptor-mediated adhesion to human cells is a mechanism described also 
in the meningeal invasion by N. meningitidis. It was reported that Type IV-pili of 
meningococci adhere first to a receptor, possibly PAFR (21), and afterwards to the 
/3-adrenoceptor as expressed on the cell membrane of HBMEC. These two receptors 
together allow meningococci to adhere to and traverse the endothelial cells leading to 
invasion of the brain ( 6, 21 ). A similar receptor cooperation concept may also apply to 
S. pneumoniae adhesion to and invasion of endothelial cells of the blood-brain barrier. 
The results presented in Chapter 4 of this thesis show that S. pneumoniae co-localizes 
with endothelial plgR in all brain compartments at all time-points of infection. Here 
we show that plgR and PECAM-1 co-localize in the healthy murine brain and in 
the presence of infecting bacteria. Furthermore, preliminary data indicate that the 
blocking of both receptors with specific antibodies reduces pneumococcal adhesion 
approximately 20% more than blocking each receptor separately. Moreover, the 
present immunoprecipitation analyses show that PECAM-1 and plgR can interact 
with each other. Thus, it may well be that these two proteins form a double receptor on 
the plasma membrane of endothelial cells, which may have a functional consequence 
for bacterial adhesion to the endothelium. 
The hypothetical double receptor PECAM-1-plgR might provide two 
independent binding sites for the bacteria. Thus, when only PECAM-1 is blocked, S. 
pneumoniae can still bind to plgR and vice versa. This could explain why blocking both 
receptors reduced pneumococcal adherence more than blocking only one receptor. 
To unequivocally demonstrate a role for these receptors per se in S. pneumoniae 
pathology, intravenous challenges with S. pneumoniae in PECAM-1 + mice and plgR-1-
mice should be performed. In case of a direct role, fewer bacteria would be expected 
to translocate the blood-brain barrier, and accordingly meningitis symptoms should 
be reduced. Lastly, systemic challenges in mice lacking both PECAM-1 and plgR 
should be performed to determine whether pneumococcal adhesion to the brain 
endothelium and disease symptoms are diminished to a greater extent in the double 
mutant mice than in mice lacking only one receptor. This would establish whether 
and, if so, to what extent the two receptors cooperate, and whether this has functional 
and pathological consequences. 
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In conclusion, based on the data presented, we propose that S. pneumoniae in 
the blood stream can bind to PECAM-1 expressed by brain microvascular endothelial 
cells, and that PECAM-1 may form a double receptor with pigR on the plasma 
membrane of endothelial cells for S. pneumoniae adhesion. Additional experiments 
need to be executed to shed light on the functional role of both receptors in facilitating 
S. pneumoniae invasion into the brain in vivo, and to answer the question whether 
their blockade may have any therapeutic advantage for patients with bacteremia and 
meningitis. 
Materials and Methods 
Cell lines, primary cells and culture conditions 
The HBMEC cell line (kindly provided by Dr. K.S. Kim) (22) was cultivated in 
RPMI-1640 (Biochrom, Berlin, Germany) supplemented with 10% Fetal Calf Serum 
(FCS) (Biochrom), 10% Nu-serum (BD Biosciences, Breda, The Netherlands), 2mM 
L-glutamine (Gibco, Grand Island, United States), lmM sodium pyruvate (Gibco), 
1% MEM-vitamines (Gibco) and 1% non-essential amino acids (Gibco). HUVEC 
(obtained from the Endothelial Cell Facility, University Medical Center Groningen) 
were cultivated in DMEM (Cellgro, Huissen, The Netherlands) supplemented with 
1 % L-glutamine (Gibco), 1 % non-essential amino acids (Cellgro), 1 % heparin (Sigma) 
and 20% FCS (Sigma). Detroit cells (obtained from the Department of Molecular 
Virology, University Medical Center Groningen) (23) were cultivated in RPMI-1640 
(Biochrom) supplemented with 10% FCS (Biochrom), 2mM L-glutamine (Gibco), 
lmM sodium pyruvate (Gibco) and 1% non-essential amino acids (Gibco). All cells 
were cultured at 5% CO2 at 37°C 
Bacterial strains and growth conditions 
For the in vivo experiments an encapsulated S. pneumoniae, serotype 4 strain, 
TIGR4 (24, and Chapter 4) was used. For the adhesion assays and the in vitro studies 
on physical interactions between bacteria and receptors, an unencapsulated S. 
pneumoniae, serotype 4 strain, TIGR4 was used. Encapsulated TIGR4 was grown in 
Todd-Hewitt broth (Oxoid Thermo Scientific, Basingstoke, United Kingdom), and 
unencapsulated TIGR4 in M17 medium supplemented with 0.5% glucose. Both 
strains were grown at 37°C, bacterial growth was monitored by measuring the 
optical density at 600 nm (OD600) with a spectrophotometer. Bacteria were harvested 
at OD600 = 0.25-0.30 by centrifugation of 1 ml of culture at 10,000 rpm for 3 minutes. 
Subsequently, encapsulated TIGR4 was resuspended in 1ml of sterile phosphate 
buffered saline (PBS) (Lonza, Verviers, Belgium) till reaching a challenge dose of 107 
CFU for each mouse, while unencapsulated TIGR4 was resuspended in HBMEC cell 
culture medium till reaching a bacterial concentration of approximately 106 CFU. 
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Bacteremia-derived meningitis model 
All experiments involving animals were performed with the prior approval of, 
and in accordance with guidelines of the Institutional Animal Care and Use Committee 
of the University of Groningen (DEC nr. 6152A). The bacteremia-derived meningitis 
model described by Orihuela et al. (24) was adapted as described before (16). 
Antibodies and lectin 
The following antibody combinations and dilutions in sterile PBS with 5% Fetal 
Calf Serum (FCS) (Biochrom, Berlin, Germany) were used for immunofluorescent 
detection. To detect S. pneumoniae, either a rabbit anti-capsule serotype 4 antibody 
(Statens Serum Institute, Copenhagen, Denmark) 1 :200 diluted or a rabbit anti­
pneumococcal antiserum (Eurogentec, Maastricht, The Netherlands) 1 :50 diluted 
were used, either combined with an Alexa Fluor 488 goat anti-rabbit antibody 
(Invitrogen Life Technologies, Carlsbad, United States) 1 :500 diluted or labeled with 
Alexa Fluor 350 (Zenon Rabbit IgG Labeling Kit, Invitrogen Life Technologies). For 
the detection of endothelial cells, DyLight 594 labeled Lycopersicon Esculentum 
Lectin (tomato lectin) (Vector Laboratories, Burlingame, United States) was used 
in a 1 :200 dilution. LEL binds to glycophorin and Tamm-Horsfall glycoprotein and 
has been used effectively to label vascular endothelium in rodents (http://www. 
vectorlabs.com/catalog.aspx?prodID=1715). For the detection of nuclei DAPI (Roche, 
Mannheim, Germany) 1 :5,000 diluted was used. For the detection of mouse PECAM-1, 
a rat anti-mouse PECAM-1 antibody (BO Biosciences, Breda, The Netherlands) 1 :50 
diluted was used, followed by incubation with either an Alexa Fluor 594 goat anti-rat 
antibody or an Alexa Fluor 488 goat anti-rat antibody (Invitrogen Life Technologies) 
1 :500 diluted. For the detection of human PECAM-1, a mouse anti-human PECAM-1 
antibody (Dako) was used, followed by incubation with an Alexa Fluor 594 goat anti­
mouse antibody (Invitrogen Life Technologies). For the detection of mouse pigR a 
goat anti-mouse pIGR antibody (R & D Systems, Abingdon, United Kingdom) was 
used, followed by incubation with an Alexa Fluor 488 donkey anti-goat antibody 
(Invitrogen Life Technologies) .  For the detection of human pigR a goat anti-human 
pigR antibody (R & D Systems, Abingdon, United Kingdom) was used, followed by 
incubation with an Alexa Fluor 488 donkey anti-goat antibody. For the detection of 
a-tubulin, a mouse anti-human a-tubulin (Sigma Aldrich) 1 :200 diluted was used, 
followed by incubation with an Alexa Fluor 594 goat anti-mouse antibody (Invitrogen 
Life Technologies) 1 :500 diluted. As isotype controls for the primary antibodies 
mouse IgG (Innovative Research, Plymouth, United States), rat anti-human CD4 
(AbD Serotec, Martinsried, Germany) and a goat IgG (Santa Cruz Biotechnology, 





Human PECAM-1, plgR and a-tubulin were detected by Western blotting with 
the same antibodies that were also used for immunofluorescence staining. Anti­
PECAM-1 and anti-plgR antibodies were diluted 1:200, while the anti-a-tubulin 
antibody was 1:1000 diluted. For detection of p53, a mouse anti-p53 antibody 
(Abeam, Cambridge, United Kingdom) 1:1000 diluted was used. Incubation with 
primary antibodies was followed by incubation with secondary antibodies IRDye 
800 CW goat anti-mouse (LiCor Biosciences, Bad Homburg, Germany) for PECAM-1 
and p53 detection, donkey anti-goat (LiCor Biosciences) for plgR detection, or IRDye 
700 CW goat anti-mouse (LiCor Biosciences) for a-tubulin detection. All secondary 
antibodies were 1 :5000 diluted. 
Immunofluorescent detection 
For immunofluorescent staining of brain, sections of 5µm thin were cut with 
a cryostat, placed on microscope glass slides and dried under a fan for at least 30 
minutes. Sections were fixed with acetone for 10 minutes and dried for 5 minutes. 
For immunofluorescent staining of HBMEC (Table 1), after 1 hour incubation with S. 
pneumoniae, cells were fixed with paraformaldehyde (Sigma Aldrich) 4% and washed 
2 times with PBS prior to starting the staining procedure. 
For the detection of PECAM-1 and S. pneumoniae in brain tissue (Table 1), 
the slides were first incubated with a mixture of anti-PECAM-1 and anti-capsule 
serotype 4 antibodies for 1 hour at room temperature (RT). Slides were then washed 
in PBS 3 times for 5 minutes. Subsequently, the slides were incubated with a mixture 
of Alexa Fluor 594 goat anti-rat and Alexa Fluor 488 goat anti-rabbit for 1 hour at 
room temperature (RT) in the dark. After washing with PBS 3 times for 5 minutes, 
the slides were incubated with DAPI (Roche, Mannheim, Germany) for 10 minutes 
at RT in the dark. 
For the detection of PECAM-1, plgR and S. pneumoniae in brain tissue (Table 1), the 
slides were first incubated with a mixture of anti-PECAM-1 and anti-plgR antibodies 
for 1 hour at room temperature (RT). Slides were then washed in PBS 3 times for 5 
minutes. Subsequently, the slides were incubated with a mixture of the appropriate 
secondary antibodies for 1 hour at RT in the dark. After washing with PBS 3 times for 
5 minutes, the slides were incubated with anti-capsule serotype 4 antibody labeled 
with Alexa Fluor 350, and then washed again 3 times with PBS for 5 minutes. 
For the detection of PECAM-1 and S. pneumoniae in HBMEC (Table 1 ), HBMEC 
were first incubated with mixture of anti-PECAM-1 antibody and anti-pneumococcal 
antiserum at RT for 1 hour. After washing 2 times with PBS, cells were incubated 
with mixture of Alexa Fluor 594 goat anti-mouse and Alexa Fluor 488 goat anti-rabbit 
antibodies for 1 hour at RT in the dark. Cells were then washed again 2 times with 
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PBS prior to incubation with DAPI for 10 minutes at RT in the dark. 
For the detection of PECAM-1, pigR and S. pneumoniae in HBMEC and HUVEC 
(Table 1), cells were first incubated with a mixture of anti-PECAM-1 and anti-pigR 
antibodies at RT for 1 hour. After washing 2 times with PBS, cells were incubated 
with a mixture of appropriate secondary antibodies for 1 hour at RT in the dark. Cells 
were then washed again 2 times with PBS prior incubation with anti-pneumococcal 
antiserum labeled with Alexa Fluor 350, then washed again 2 times with PBS for 
5 minutes. Citifluor solution (Science Services, Munich, Germany) was added to 
each tissue section/glass disk after which the coverslip was applied. The slides were 
analyzed with a Leica DM5500B microscope and images were recorded with a Leica 
DFC 360 FX camera. Additionally, a Leica SP2 AOBS confocal microscope was used. 
Image processing 
All the images recorded with the Leica DM5500B fluorescence microscope were 
processed with ImageJ (25). The TIFF images obtained with the 350nm (blue), 488nm 
(green) and 594nm (red) wavelength filters were merged using the Color-Merge 
Channels function. As a minor digital manipulation, background correction using 
the Brightness & Contrast command of Image} was applied to reduce the background 
only when the background was across the image. In all images subjected to this minor 
adjustment, the background subtraction was applied to all parts of the image. The 
LEI z-stacks obtained with the Leica SP2 AOBS confocal microscope were merged 
with Imaris (Bitplane Scientific Software). No digital adjustment was performed on 
these images. 
Bacterial quantification and co-localization analysis using Image] 
The surface covered by bacteria was measured using the Threshold function of 
Image} (25), by determining the area occupied by the 488 nm bacterial signal and the 
white pixels of the bacteria co-localizing with receptors. The percentage of bacteria 
co-localized with receptors compared to the total bacterial signal was calculated by 
dividing the surface area of white bacteria by the surface area of the green bacteria 
in each image. The images representing the bacterial and PECAM-1 signals were 
analyzed with the Image} (25) application Co-localization analysis. White pixels were 
automatically generated on the areas of the bacterial signal co-localized with the 
PECAM-1 signal. 
Physical interaction of S. pneumoniae with PECAM-1 protein 
Lysis buffer consisted of 50 mM tris-HCl (Promega, Mannheim, Germany) 
pH 7.4, 150 mM NaCl, 1% triton lO0X, 1% sodium deoxycholate, 0.1% SDS (all 
from Sigma Aldrich), 1 mM EDTA (Merck Millipore, Billerica, United States), and 
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protease inhibitors 1 X (Roche, Mannheim, Germany). 250 µI of lysis buffer was 
added to confluent monolayers of HBMEC or HUVEC grown in small T25 flasks 
(TPP, Trasadingen, Switzerland) . After 1 minute incubation at RT, monolayers were 
scraped with a cell scraper (Nalge Nunc International, Rochester, United States), 
harvested, and centrifuged at 20,600 rpm for 15 minutes at 4°C. The supernatant 
fraction was used for further analyses. As a quality control, the lysates were separated 
by SOS-PAGE and proteins were visualized by coomassie brilliant blue staining. 
A solution of approximately 106 CPU of unencapsulated S. pneumoniae TIGR4 was 
prepared in sterile PBS. 50 µI of HBMEC or HUVEC lysate was added to 50 µI of 
the bacterial solution and the mixture was incubated at 4°C with gentle agitation 
for 1 hour. The mixture of cell lysate and bacteria was then centrifuged at 20,600 
rpm for 20 minutes at 4°C. The supernatant was removed and the bacterial pellet 
washed 2 times with 100 µI PBS. After washing, the pellet was resuspended in 100 
µI of a mixture of anti-pneumococcal antiserum and anti-PECAM-1 antibody in PBS, 
followed by incubation at 4°C for 1 hour. After washing in PBS, the bacterial pellet 
was resuspended in a mixture of Alexa Fluor 488 goat anti-rabbit and Alexa Fluor 
594 goat antip10use antibodies in PBS. As a negative control mouse anti-human 
a-tubulin antibody was used. Incubation with anti-a-tubulin antibody was followed 
by incubation with Alexa Fluor 488 goat anti-mouse antibody. The bacterial pellet 
was finally resuspended in 100 µI of distilled water. A 5 µI drop was pipetted onto a 
microscope glass slide, and Citifluor solution (Science Services, Munich, Germany) 
was added to the slide after which a coverslip was applied. The slide was then 
analyzed with a Leica DM5500B fluorescence microscope and images were recorded 
with a Leica DFC 360 FX camera. 
Pneumococcal adherence to endothelial cells 
HBMEC and HUVEC were grown in 12-well plates (TPP) at 37°C with 5% CO2 
until confluency. Prior seeding HUVEC, each well was coated with gelatin for 
45 minutes. When immunofluorescent staining was performed after the adherence 
assay, cells were grown on glass disks placed inside each well. For adherence of 
HUVEC on glass, disks were coated with gelatin for 45 minutes. After removal of 
the gelatin, disks were incubated with 0.5% glutaraldehyde (Sigma Aldrich) for 45 
minutes. Disks were then washed 2 times with PBS and 2 times with HUVEC culture 
medium. After washing 2 times with PBS, anti PECAM-1 antibody diluted in RPMI 
was added to each well to a final concentration of 50 µg/ml and cells were incubated 
for 1 hour at 37°C with 5% CO2• As control we used HBMEC and HUVEC treated 
with mouse IgG (Innovative Research, Plymouth, United States) at 50 µg/ml or just 
RPMI. After washing the cells with sterile PBS, 900 µI cell culture medium was added 
to each well and 100 µI of approximately 106 CPU of unencapsulated TIGR4 was 
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added. After 1 hour incubation at 37°C at 5% CO2 cells were treated with a 50/50 mix 
of 1 % saponin (Sigma Aldrich) and trypsin-EDTA (0.05%-0.02%) (Gibco) and lysed. 
CFU were determined by plating serial dilutions of lysed cells on blood agar plates. 
The ratio of adherent bacteria was calculated by dividing the adherent bacteria by the 
total amount of bacteria in the well (adherent + not adherent bacteria). 
Detection of PECAM-1 protein in HBMEC and HUVEC lysates 
Proteins of the cell lysates were separated by SDS-PAGE using NuPAGE gels 
(Invitrogen), and then blotted (75 min, 100 mA per gel) onto a nitrocellulose membrane 
(Protran®, Schleicher & Schuell, Bath, United Kingdom). Antibody detection was 
performed with IRDye 800 CW IgG secondary antibodies (LiCor Biosciences, Bad 
Homburg, Germany), in accordance with the IgG isotype of the primary antibodies, 
and 700 CW goat anti-mouse for a-tubulin detection (see Antibodies and lectin), 
in combination with the Odyssey Infrared Imaging System (LiCor Biosciences). 
Fluorescence was recorded at 700 and 800 nm. 
Protein-protein interaction studies 
Approximately 5µg of anti-PECAM-1, anti-pigR antibody or mouse IgG were 
incubated with 15µ1 of Protein A/G Plus-Agarose beads (Santa Cruz Biotechnology) 
at 4"C for 1 hour under gentle agitation. Subsequently, to remove unbound antibody, 
the antibody-coated beads were centrifuged at 6,700g for 30 seconds at 4°C and 
washed with 500µ1 of the lysis buffer used to make cell lysates. This procedure 
was repeated 3 times, and afterwards the pellet was resuspended in 50µ1 of lysis 
buffer. Aliquots of cell lysates (-200µg protein) were incubated with 10µ1 of Protein 
A/G Plus-Agarose beads (Santa Cruz Biotechnology) at 4"C for 1 hour under gentle 
agitation. After centrifugation at 6,700 rpm for 30 seconds at 4 ·c, the cell lysates were 
mixed with antibody-coated beads and the total mix was incubated at 4°C for 1 hour 
under gentle agitation. Samples were then centrifuged at 8000 rpm for 30 seconds 
at 4°C and the pellets were washed with 500µ1 of lysis buffer. This procedure was 
repeated 3 times. Lastly, the pellets were resuspended in 50µ1 of lysis buffer and 
boiled at 95°C for 5 minutes. Proteins in the different samples were separated on 
NuPAGE gels (Invitrogen}, and then blotted (see above Western blotting procedure). 
Statistical analysis 
The independent student t-test of SPSS Statistics 20 (IBM) was used for the 
statistical analysis of the bacterial-endothelial adhesion assay results. The comparison 
between ratio of adherent bacteria in HBMEC/HUVEC cells treated with receptor 
antibodies and HBMEC/HUVEC cells treated with isotype IgG or RPMI without 
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Table 1 . lmmunofluorescent detection scheme 
Detection of J•t 2nd 3rd 4th 
PECAM-l and 
S. pneumoniae Anti PECAM-1 Anti capsule Alexa Fluor goat DAPI 
in brain tissue, antibody serotype 4 anti rabbit 488 
HBMEC and antibody 1 :5000 
HUVEC Dilution 1 :50 Dilution 1 :500 
Dilution 1 :50 
Detection of J•t 2nd 3rd 
PECAM-1 and S. 
pneumoniae in lung Anti PECAM-1 Anti capsule DAPI 
tissue antibody serotype 4 
antibody Dilution 1 :5000 
Dilution 1 :50 
Dilution 1 :50 
Detection of J•t 2nd 3rd 
PECAM-1, plgR 
and S. pneumoniae Mixture anti Mixture of Alexa Anti capsule 
in brain tissue, PECAM-1 and anti Fluor 594 donkey serotype 4 
HBMEC and plgR antibodies anti mouse and antibody labeled 
HUVEC Alexa Fluor 488 with Alexa Fluor 
Dilution of each 
antibody 1:50 
donkey anti goat 350 (Zenon Kit) 
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Despite the introduction of antimicrobial agents and vaccines, bacterial 
meningitis still remains a life-threating disease with high morbidity and mortality 
worldwide. The Gram-positive bacterium Streptococcus pneumoniae is the main 
causative agent of this disease (1). Bacterial meningitis is an inflammation of 
the meninges, the layers covering and protecting the brain and spinal cords. The 
inflammation is caused by bacteria, which enter the Central Nervous System (CNS) 
and spread in the brain. The blood-brain barrier is a specialized vasculature system, 
which separates the brain from the circulating blood and, as such, it has critical 
functions in both the protection and nutrient supply of the brain (2, 3). Endothelial 
cells form the layer that lines the interior surface of the blood vessels (4). To invade 
the brain from the blood, meningeal pathogens must first face the blood-brain 
barrier endothelium and develop strategies to pass this barrier. Transcytosis has been 
proposed as a mechanism employed by the bacteria for adhesion to, invasion into 
and translocation across human cell barriers (6, 12). The aim of the PhD research 
described in this thesis was to investigate where and how the interactions between 
S. pneumoniae and the blood-brain barrier take place during the events preceding the 
development of meningitis. 
S. pneumoniae is able to adhere to brain endothelial cells (5-8) but, when the present 
studies were started, the interactions between S. pneumoniae and brain endothelial 
cells had not been investigated in vivo. It was therefore first investigated whether S. 
pneumoniae adheres to the vascular endothelium in vivo, and whether pneurnococci 
have preferential sites of adhesion to the blood-brain barrier endothelium in vivo. 
The results documented in Chapter 2 show that S. pneumoniae indeed adheres to 
the blood-brain barrier endothelium in a murine in vivo model. Specifically, blood­
borne pneumococci adhered to the microvascular endothelium of the subarachnoid 
space, cerebral cortex and the septum, though the spatiotemporal distribution of S. 
pneumoniae over these sites differed. Notably, the choroid plexus had previously been 
proposed to be the area where the main bacterial invasion of the CNS occurs during 
bacterial meningitis (9, 10, 11). However, we observed pneumococci in the choroid 
plexus only during the later stages of pneumococcal infection. Although leukocyte 
influx in the brain during the entire course of infection was minimal, microglia and 
astrocytes were activated early on, already after 1 hour post infection, indicating that 
the local immune system in the brain was activated directly upon the presence of 
pneumococci in the blood. Signs of astrogliosis and microglial activation became 
even more prominent over the time course of infection. This implies that the local 
immune system of the brain immediately sensed the bacterial presence in the blood 
and/or bacterial adhesion to the endothelial cells, and was activated during the entire 
time course of pneumococcal infection. 
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Endothelial and epithelial cells express certain receptors on the plasma 
membrane to which bacteria can bind (6, 12). After investigating the spatiotemporal 
interactions of blood-borne S. pneumoniae to the brain microvascular endothelium, 
the role of specific receptors in S. pneumoniae adhesion to endothelial cells was 
investigated. The platelet-activating factor receptor (PAFR) is a G-protein coupled 
receptor of the platelet-activating factor (PAF), a mediator in diverse pathological 
processes, such as allergy, asthma, septic shock, arterial thrombosis, and inflammation 
(13, 14). S. pneumoniae has been proposed to adhere to PAFR and this adhesion 
may facilitate the passage of bacteria through endothelial cells leading to invasive 
disease (5, 6, 7). However, the current literature is characterized by conflicting data 
concerning the role of PAFR in invasive pneumococcal disease (IPD). Therefore, the 
current literature on PAFR interactions with S. pneumoniae and other pathogens was 
analyzed, summarized and discussed in Chapter 3. This included studies concerning 
genetic variations in the human PAFR related to clinical features of IPD. The in vitro 
and most of the in vivo experiments described in the papers discussed in Chapter 3 
indicated that PAFR is involved in the development of IPD. However, no unequivocal 
evidence that S. pneumoniae binds to PAFR in vivo was so far documented in the 
literature. 
In Chapter 4, evidence is provided that a direct interaction between PAFR 
and S. pneumoniae is not likely to occur. Immunofluorescent analysis of brain tissue 
from intravenously infected mice showed that S. pneumoniae does not co-localize 
with PAFR. This was corroborated by immunofluorescent detection of S. pneumoniae 
and PAFR in Human Brain Microvascular Endothelial Cells (HBMEC) and Human 
Umbilical Vein Endothelial Cells (HUVEC) incubated with pneumococci, which 
showed almost no co-localization between bacteria and the PAFR receptor. Thus, 
it was proposed that, although PAFR is involved in the adhesion of S. pneumoniae 
to endothelial cells, a direct binding of pneumococci to PAFR is unlikely. This is in 
line with published studies, which showed that when PAFR is genetically deleted or 
chemically inhibited, S. pneumoniae is still able to adhere to human cells in vitro and 
cause invasive infections in vivo. Importantly, this implies that pneumococci have the 
capability to bind to alternative receptors (5, 6, 7). 
The poly immunoglobulin receptor (pigR) mediates the transport of 
immunoglobulins across mucosa} epithelium (15, 16) and is known to be involved 
in pneumococcal adhesion to the epithelium of the human nasopharynx (12). 
However, it had not been investigated yet whether pigR also plays a role in S. 
pneumoniae adhesion to the brain vascular endothelium in vivo. This was therefore 
assessed by immunofluorescent analysis of brain tissue of intravenously infected 
mice. Importantly, the results presented in Chapter 4 show that most pneumococci 
are co-localized with pigR. The co-localization of bacteria and pigR was observed 
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also in HBMEC and HUVEC after incubation with pneumococci. Furthermore, by 
incubating pneumococci with HBMEC and HUVEC lysates, it was shown that S. 
pneumoniae can directly bind to pigR. The combined results therefore suggest that 
plgR could be a direct adhesion receptor for S. pneumoniae on the blood-brain barrier 
endothelium. 
In the present PhD research, attention was also focused on a third receptor 
molecule expressed on the cell membrane of brain vascular endothelial cells and its 
possible involvement in S. pneumoniae adhesion, namely the platelet endothelial cell 
adhesion molecule (PECAM-1). PECAM-1 is one of the major adhesion molecules 
expressed by endothelial cells and it has a crucial role in neuroinflammation and 
subsequent blood-brain barrier disruption (17, 18). Very recently, PECAM-1 was 
implicated in gastrointestinal infection caused by Salmonella typhimurium. Chapter 
5 describes a study conducted to investigate whether PECAM-1 could potentially be 
a receptor for S pneumoniae adhesion to the endothelium of the blood-brain barrier. 
Immunofluorescent analysis performed on brain tissue from intravenously infected 
mice showed that most pneumococci did indeed co-localize with PECAM-1. A similar 
co-localization was observed in vitro in HBMEC and HUVEC cells upon incubation 
with pneumococci. Blocking of PECAM-1 with a specific antibody in HBMEC and 
HUVEC cells led to a significant reduction of bacterial adhesion, indicating that 
PECAM-1 is functionally involved in S. pneumoniae adhesion to human endothelial 
cells. Using the same biochemical approach that was used to demonstrate the S. 
pneumoniae-pigR association (Chapter 4), it was then shown that S. pneumoniae can 
directly bind the PECAM-1 expressed by HBMEC and HUVEC cells. Importantly, in a 
subsequent series of experiments, it was shown that PECAM-1 co-localizes with pigR 
and infecting pneumococci and, moreover, that both receptors can directly interact 
with each other as was evidenced by co-immunoprecipitation experiments. Taken 
together, these observations imply that S. pneumoniae binds to PECAM-1 and pigR 
on brain microvascular endothelial cells, which possibly (co-)facilitates its passage 
across the blood-brain barrier and invasion of the brain. 
In conclusion, the results obtained in this PhD research imply that S. pneumoniae 
can cross the brain vascular endothelium as a result of adhesion to the PECAM-1 
and pigR receptors, followed by translocation through or between endothelial 
cells without causing major disruptions of the vascular endothelium. However, the 
question whether the pneumococcus either uses an intracellular route, a paracellular 
route or both routes for translocation across the brain microvascular endothelium 
remains to be answered. Lastly, while direct interactions were shown between S. 
pneumonia, pigR and PECAM-1, no evidence for direct interactions of S. pneumoniae 
with PAFR was obtained. This suggests that PAFR is only indirectly involved in the 




Co-operation of PAFR, plgR and PECAM-1 during pneumococcal adhesion to endothelial 
cells: a new model 
From the studies presented in this thesis and previous publications by 
others, it remains unclear what the exact role of PAFR is in invasive pneumococcal 
disease (IPD). The involvement of PAFR in S. pneumoniae adhesion to endothelial 
cells might well be exerted through the binding of PAF or pneumococcal cell wall 
components to the receptor and the subsequent inflammatory consequences of its 
activation. Inflammation leads to an upregulation of receptors expressed on the 
plasma membrane of cells (19), and PECAM-1 and pigR may be among them. In 
the presence of more pigR and PECAM-1, S. pneumoniae has more sites to adhere 
to the endothelial cells. Like others we have shown that the blocking of PAFR with 
a specific antibody leads to a significant reduction of pneumococcal adhesion to 
endothelial cells in vitro. We therefore hypothesize that, due to PAFR blocking, the 
upregulation of pigR and PECAM-1 may be prohibited. Possibly, the presence of 
pneumococci may trigger the autocrine production of PAF, directly or indirectly, 
which activates PAFR leading to an upregulation of pigR and PECAM-1. This would 
increase pneumococcal adherence to pigR and PECAM-1 and, in tum, more adherent 
bacteria would increase the chances of bacterial invasion into the cells. Besides PAF, 
secreted pneumococcal components, such as pneumolysin and CbpA, could bind to 
PAFR and activate this receptor (20). Clearly this remains to be demonstrated, and 
an in-depth investigation of secreted and surface-attached pneumococcal proteins, 
including proteomics and structural analyses, will be required to identify any 
protein(s) of S. pneumoniae that could be recognized and bound by PAFR. Once these 
as yet hypothetical proteins are identified, mutant S. pneumoniae strains lacking these 
proteins can be created to verify their possible roles in PAFR binding. The absence 
of such pneumococcal proteins would prevent PAFR activation and thus PECAM-1 
and pigR upregulation. The direct consequence would be that these S. pneumoniae 
mutants have a reduced ability to adhere to endothelial cells than the respective 
parental wild-type bacteria. In particular, the expression of pigR and PECAM-1 
in cells incubated with pneumococci lacking the hypothetical proteins and wild­
type pneumococci should be quantified to validate whether the expression of these 
two receptors is indeed not upregulated when the PAP-binding site is blocked. A 
parallel approach would be to use/develop specific antibodies directed against the 
PAF-binding site of PAFR. By treating endothelial cells with such antibodies in vitro, 
PAFR activation should be blocked and, consequently, the upregulation of pigR and 
PECAM-1 as well. The expected outcome would be that pneumococci adhere less 
to antibody-treated cells than to cells that were not treated with the antibody. If so, 
PECAM-1 and pigR would not be upregulated when PAFR is not activated. 
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The present studies have shown that, if pigR and PECAM-1 are blocked, the 
pneumococcal adhesion to endothelial cells is reduced. Bacteria cannot adhere to 
pigR and PECAM-1 upon their blocking by the respective antibodies, but PAFR 
activation may still be possible and could thus lead to upregulation of PECAM-1 
and pigR expression. Pneumococci could next adhere to pigR and PECAM-1, which 
would be increasingly expressed after PAFR activation. Using an experimental set up 
that allows a precise analysis of the sequence of events, we should be able to dissect 
this presumed co-operation of PAFR, pigR and PECAM-1 in pneumococcal adhesion 
to endothelial cells. It would furthermore be interesting to determine whether more 
bacterial adhesion leads to more invasion into and transmigration over endothelial 
cells, which could be studied in vitro using cell culture assays. Invasion into cells can 
be investigated by adding antibiotics into cell culture medium after cells have been 
incubated with bacteria. In this way all extracellular bacteria, including adherent 
bacteria, would be killed while only the intracellular bacteria survive. Transmigration 
can be studied in vitro using transwells, which are often applied in cell culture assays 
to study the migration of molecules from the apical to the basolateral side of confluent 
cell layers. 
In order to prevent the onset of meningitis and other invasive diseases upon 
pneumococcal bacteremia, the main goal would be to completely inhibit adhesion 
of pneumococci to endothelial cells. Clearly, if pneumococci cannot adhere to 
endothelial cells, bacterial invasion will most likely be prevented. In Chapter 5 data 
are provided, which suggest that PECAM-1 and pigR may form a double receptor on 
the plasma membrane of endothelial cells. To determine whether these two receptors 
do indeed form a double receptor, further interaction and structural analyses are 
needed that would also serve to pinpoint the relevant interfaces for protein-protein 
interactions. It would be important to complement crystallographic studies with other 
experimental and computational approaches (21). Current methods for comparative 
modeling allow the accurate construction of three-dimensional models for proteins 
of unknown structure, and binding site predictors can be used to propose binding 
regions (22) . Intriguingly, it is well conceivable that the putative double receptor 
composed of PECAM-1 and pigR could have a double function. Thus, it might 
exercise an immunoglobulin transfer function, the main physiological role of pigR 
and, at the same time, regulate endothelial cell-cell connections, known as one of the 
main functions of PECAM-1. 
Blockade of S. pneumoniae receptors: a new horizon for the prevention of pneumococcal 
meningitis 
Knowledge of the mechanisms by which the pneumococcus interacts with the 
blood-brain barrier before invading the brain is fundamental in order to develop 
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therapeutic strategies to avoid the adhesion of S. pneumoniae to the blood-brain 
barrier and, thus, the invasion of the pathogen into the CNS. The results presented 
in this thesis provide a better understanding of the events preceding pneumococcal 
meningitis and, in particular, of S. pneumoniae receptor-mediated adhesion to the 
blood-brain barrier endothelium. Specifically, it is shown that in mice intravenously 
infected with S. pneumoniae, the bacteria adhere to the blood-brain barrier as early 
as 1 hour post challenge, and that the amount of bacteria in the brain increases over 
the time of infection. Nevertheless, the influx of leukocytes into the brain remained 
low, even at 14 hours after challenge. Despite the low presence of leukocytes in the 
brain, clinical symptoms of the infected mice, astrogliosis and microglial activation 
were observed already at 1 hour post challenge, and a significant increase of pro­
inflammatory cytokines in the brain at 14 hours post challenge compared to mock 
conditions, were all signs of a possible progression to meningitis (8). The bacteremia­
derived meningitis model was used in this PhD research to investigate the events 
preceding meningitis. To study meningitis itself, intracisternal administration 
of bacteria was previously used to induce meningitis in vivo. Using this model, 
neutrophil influx in the brain was detected only at 30 hours after challenge (23), 
indicating that white blood cells can be detected in the brain only at the late stages 
of the disease. A high count of white blood cells in the cerebrospinal fluid (CSF) is 
often used as a clinical test for the diagnosis of meningitis (24). Moreover, classic 
symptoms of meningitis, such as rash, neck stiffness, photophobia, severe headache 
and impaired consciousness develop late (24). While these symptoms represent the 
classical picture of suspected meningitis, the disease may be already at an advanced 
stage in patients displaying them. Thus, it is not really surprising that at this stage 
the risks of brain damage is considerable even in case the infection is successfully 
fought with antibiotics (25). World Health Organization (WHO) data indicate that, 
even if the disease is diagnosed early and adequate treatment is started immediately, 
5% to 10% of the patients will die, typically within 24 to 48 hours after occurrence 
of the first symptoms. When left untreated, up to 50% of the patients may die. In 
case of recovery, brain damage, hearing loss or a learning disability appears in 10% 
to 20% of the survivors. It is therefore crucial to start interventions before bacteria 
have invaded the brain in order to optimize the survival chances of patients and 
to prevent permanent damage. Treatment with antibiotics is a common method to 
cure meningitis, but bacteria can develop resistance to antibiotics quickly. Routine 
vaccination against pneumococcal infections with the pneumococcal conjugate 
vaccine (PVC), which is active against seven common serotypes of this pathogen, has 
significantly reduced the incidence of pneumococcal meningitis (26, 27). Notably, 
in this thesis, the roles of PAFR, plgR and PECAM-1 in S. pneumoniae adhesion to 
the vascular endothelium of the blood-brain barrier are described. Hence, a possible 
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approach complementary to vaccines and antibiotics for curing or preventing 
pneumococcal meningitis could be the development of therapies that interfere with 
these receptors. This could for example be achieved with monoclonal antibodies 
blocking PAFR, plgR and PECAM-1, which would limit the adhesion of pneumococci 
to the blood-brain barrier. 
Bacteremia is the presence of bacteria in the blood stream, and it is shown in 
this thesis that pneumococci in the blood can reach and adhere to the blood-brain 
barrier after which they possibly invade the brain. A major cause of bacteremia is 
pneumonia, which can occur when an infection of the lungs grows out of control (28, 
29, 30). Patients with bacteremia and pneumonia can be considered at "high-risk" for 
progression towards brain infection and, for this reason, it could be valuable for them 
to receive innovative treatments that block pneumococcal receptors. This would 
prevent the bacteria from adhering to the blood-brain barrier and invading the brain. 
Such a treatment would even be of relevance for patients who are hospitalized with 
meningitis as it would still reduce the numbers of bacteria adhering to the blood­
brain barrier and, in combination with antibiotic therapy, both the blood-borne 
bacteria and the bacteria that have already reached the brain could be eliminated. 
To evaluate the validity of such a new therapeutic strategy in mice, the best 
approach would be to intravenously inject the bacteria then proceed with the 
systemic administration of the blocking antibodies and observe whether the systemic 
administration of blocking antibodies leads to less severe disease symptoms. The 
use of mice lacking the receptors could be used as an alternative approach, but the 
receptors cannot be genetically deleted in humans, while receptor-specific antibodies 
could be administered as therapeutic agents. Importantly, it has been reported that 
the absence of PAFR is not lethal in mice, which can grow and live as well as wild­
type mice (31). In PAFR-1• mice modifications of known angiogenic factors, such as 
VEGF, have not been observed, but a sustained rise of the chemokines CXCL2 and 
CCL2 has been detected, which may compensate for the absence of an important 
molecule in maintaining immunological surveillance (32). These findings indicate 
that the absence of PAFR in mice is compatible with a healthy life, although it has 
to be noted that this was observed under controlled conditions. This is a crucial 
issue, because the blocking of this receptor should prevent pneumococcal infection 
without causing lethal or dangerous side effects in patients. Mice lacking plgR 
were of normal size and fertility as well, but displayed increased IgG levels in their 
sera, suggesting a triggering of systemic immunity (33, 34). These findings indicate 
that the absence of plgR is not lethal either, but at the same time it seems that the 
absence of plgR is sensed as a potential danger by systemic immunity. PECAM-1 
is expressed not only by endothelial cells, but also by platelets, neutrophils and 
macrophages, and its signaling pathways might mediate resistance to apoptosis 
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and promote cell survival (17). Absence of PECAM-1 may therefore lead to several 
cellular dysfunctions. Interestingly, Duncan et al. showed that PECAM-1 is neither 
required for embryogenesis, fetal maturation, nor fertility in mice and, furthermore, 
PECAM-1 expression on platelets is not essential for platelet-platelet aggregation 
(35) . PECAM-1 1 animals develop normally and do not show any signs of an abnormal 
physiology under normal baseline conditions. However, as the animals age they 
can develop an autoimmune lupus-like syndrome and, when stressed, a variety 
of abnormal responses have also been noticed. In particular, PECAM-1 ·1• animals 
exhibited a prolonged bleeding time (36). Thus, although in certain circumstances 
the absence of the PAFR, pigR or PECAM-1 receptors did not cause serious problems 
in mice, dysfunctions and abnormalities due to a lack of these receptors cannot be 
excluded. Thus, while the blocking of these pneumococcal receptors could provide 
protection against meningitis, it will be crucial to develop strategies to avoid possible 
dysfunctions caused by their blocking before this approach can be implemented in 
the clinic. A possible way would be to first determine the site of each receptor to 
which bacteria bind, and then to investigate how to block this specific site in order to 
preclude pneumococcal adhesion without altering the physiological functions of the 
respective receptors. It has been shown that computational methods can accurately 
predict peptide binding sites on protein surfaces (37) and, by using these informatics 
tools, the pneumococcal binding sites of PAFR, plgR and PECAM-1 can in principle 
be predicted. Through site-directed mutagenesis, these binding sites of the receptors 
can be deleted and, in this way, various mutant versions of the respective receptors 
can be generated. Then with expression vectors, cell lines can be transfected in order 
to generate cells expressing the mutated versions of the receptors. For example, COS-7 
cells have been previously used for transfection with PAFR-expressing vectors and can 
be used also for PECAM-1 expression (7, 38), while transfection with pigR-expressing 
vectors has been reported in MDCK and Calu-3 cells (39, 40, 41). The receptor sites 
involved in the binding to the bacteria can thus be found by evaluating the adhesive 
behavior of S. pneumoniae to the cells expressing the different versions of the mutated 
receptors. When these binding sites are no longer present, bacterial adhesion should 
be significantly decreased. Genetically modified mice expressing the receptors 
lacking the binding sites for S. pneumoniae should then be generated to evaluate 
whether the deletion of the binding sites alters the normal physiological functions of 
the respective receptors. Based on the literature data described above, mutated PAFR 
is not likely to cause serious dysfunctions. However, mutated pigR may interfere 
with the normal transport of immunoglobulins across cells. It has been shown that 
treatment with phorbol myristyl acetate (PMA) activates isozymes of protein kinase 
C (PKC), a downstream protein in the signaling cascade of pigR (42). This activation 
stimulates not only pigR transcytosis, but more generally the pathway of a variety of 
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molecules in the transcytotic pathways (42). Thus, treahnent with PMA can stimulate 
cells to use other transcytotic systems and their receptors, in case immunoglobulin 
transfer mediated by pigR is altered. In this way transport of immunoglobulins can 
be maintained as well through other transcytotic ways. Regarding the vascular role 
of PECAM-1, it is important to bear in mind that the PECAM-1 protein is present in 
the junctions between endothelial cells in order to avoid problems, such as long-term 
bleeding, which could be dangerous for patients. However, in principle, it should 
be possible to develop monoclonal antibodies blocking the pneumococcal binding 
site of the PECAM-1 receptor. These could be administered systemically in mice 
prior to an intravenous challenge with S. pneumoniae to determine whether treahnent 
with these specific antibodies reduces the progression towards meningitis. Mice 
expressing the mutated receptors can also be generated but, clearly, genetic deletion of 
receptor genes in humans is not an option, while systemic administration of blocking 
antibodies has a realistic potential to become a new therapeutic approach for the 
prevention and cure of meningitis. While the blocking of pigR and PECAM-1 showed 
only a partial reduction of pneumococcal adherence to endothelial cells, the blocking 
of the PAFR, pigR and PECAM-1 receptors at the same time could be a potential 
way to completely preclude the adhesion of S. pneumoniae to the blood-brain barrier 
endothelium and, therefore, prevent completely the pneumococcal invasion into the 
brain. This, however, remains to be assessed experimentally. Clearly, an important 
advantage of conceivable therapies based on monoclonal antibodies against PAFR, 
plgR and PECAM-1 would be that these antibodies need to be administered only 
as long as pneumococci are detectable in the blood. Once these have been fought 
successfully with regular antibiotics, the antibody therapy can be stopped, which 
will reduce possible unwanted side effects to a minimum. 
In conclusion, by knowing the pathways by which S. pneumoniae adheres to 
endothelial cells it may become possible to interfere with these mechanisms and to 
develop innovative strategies for preventing and curing pneumococcal meningitis. 
This is an important objective, because pneumococcal meningitis is still a very serious 
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Ondanks de introductie van antimicrobacteriele middelen en vaccinaties blijft 
bacteriele meningitis nog steeds een wereldwijd levensbedreigende ziekte met een 
hoge morbiditeit en mortaliteit. De Gram-positieve bacterie Streptococcus pneumoniae 
is de hoofdveroorzaker van deze ziekte (1). Bacteriele meningitis is een ontsteking 
van de hersenvliezen, de lagen die de hersenen en het ruggenmerg bedekken en 
beschermen. De ontsteking wordt veroorzaakt door bacterien die het centrale 
zenuwstelsel binnendringen en zich vervolgens verspreiden naar de hersenen. De 
bloed-hersenbarriere is een specifiek vasculair systeem, dat de hersenen scheidt 
van de bloedsomloop en deze barriere heeft belangrijke functies op het gebied van 
de bescherming van de hersenen en de voedselvoorziening naar het brein (2,3). 
De bloed-hersenenbarriere bestaat uit een laag endotheelcellen welke zich aan de 
binnenkant van bloedvaten bevindt (4). Om de hersenen binnen te dringen, moeten 
de ziekteverwekkers van het hersenvlies dus eerst door deze bloed-hersenbarriere. 
Om hier doorheen te dringen hebben de pathogenen verschillende strategieen 
ontwikkeld. Het doel van dit promotieonderzoek was te onderzoeken waar en hoe 
interacties tussen S. pneumoniae en de bloed-hersenbarriere plaatsvinden voordat 
deze wordt doorbroken en het hersenvlies ontstoken raakt. 
Het is bekend dat S. pneumoniae (de pneumokok) zich kan hechten aan 
endotheelcellen van de bloedvaten van de hersenen (5-8), maar een daadwerkelijke 
interactie tussen S. pneumoniae en de endotheelcellen van de hersenen is nirnmer 
in een levend organisme (in vivo) aangetoond. Derhalve hebben wij onderzocht of 
S. pneumoniae door de bloed-hersenbarriere binnendringt door zich te hechten aan 
het vasculaire endotheel en of de pneumokok voorkeuren heeft voor bepaalde 
bindingsplaatsen gevormd door zogenaarnde adhesiernoleculen aan de bloed­
hersenbarriere. Hoofdstuk een bevat een kort overzicht van wat er bekend is over 
bovengenoemde processen en wat heeft gediend als startpunt voor het experirnentele 
onderzoek. 
Het tweede hoofdstuk laat zien dat S. pneumoniae zich inderdaad hecht aan 
het endotheel van de bloed-hersenbarriere. Daamaast hebben wij in dit hoofdstuk 
la ten zien dat sommige bacterien niet met het endotheel van de bloed-hersenbarriere 
co-lokaliseren, wat impliceert dat zij deze barriere zijn overgestoken. Derhalve lijkt 
het hechten aan het micro-vasculaire endotheel de manier waarop S. pneumoniae de 
bloed-hersenbarriere passeert. Dit proces vindt plaats in zowel de subarachno'idale 
ruimte, de hersenschors als het septum. De huidige wetenschappelijke consensus 
gaat ervan uit, dat de choroid plexus de plek is waar de belangrijkste bacteriele 
invasie plaatsvindt die de bacteriele meningitis veroorzaakt (9, 10, 11). We hebben 
echter alleen in latere stadia van een pneumokokkeninfectie de pneumokokken in 
de choroid plexus aan kunnen tonen. Gedurende het hele verloop van de infectie 
namen de leukocyten in de hersenen slechts minimaal toe, terwijl de rnicroglia en 
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astrocyten in de hersenen al binnen een uur na infectie actief werden. Dit toont aan dat 
de hersenen de mogelijkheid bezitten om een lokale immuunreactie te ontwikkelen 
tegen een bacteriele infectie. 
Bovenstaand onderzoek gaf aanleiding om de moleculaire mechanismen te 
onderzoeken die dit proces van bacteriele hechting aan de bloedvaten vormgeven. 
Het lijkt er op, dat de bacterien het mechanisme van transcytose gebruiken om zich 
eerst te hechten aan het endotheel, vervolgens binnen te dringen en zich uiteindelijk te 
verspreiden door menselijke cellen (6, 12). De specifieke receptoren op de membranen 
van de endotheelcellen die betrokken kunnen zijn bij invasieve pneumokokkenziekte 
(IPZ) omvatten onder andere de zogenoemde Platelet Activating Factor (Bloedplaatjes 
Activerende Factor) Receptor PAFR. PAFR is een G-prote'ine gekoppelde receptor van 
PAF, dat een intermediair is bij verschillende pathologische processen zoals allergie, 
astma, septische shock, arteriele trombose en ontstekingen (13, 14). Er wordt gedacht 
dat PAFR betrokken is bij het hechten van S. pneumoniae aan menselijke endotheelcellen, 
waardoor deze receptor de passage van bacterien door de endotheelcellen faciliteert, 
met een invasieve ziekte tot gevolg (5, 6, 7). Ondanks veel eerder onderzoek zijn er 
echter geen eenduidige data betreffende de exacte rol van PAFR in IPZ voorhanden. 
In hoofdstuk 3 hebben wij derhalve de bestaande literatuur over de 
wisselwerkingen tussen S. pneumoniae en andere ziekteverwekkers geanalyseerd. 
Tevens zijn wij ingegaan op onderzoeken naar menselijke genetische varianten van 
PAFR met betrekking tot IPZ. De eerdere onderzoeken in cellen en levende organismen 
hebben la ten zien, dat PAFR hoogstwaarschijnlijk betrokken is bij de ontwikkeling van 
IPZ. Er is echter geen hard bewijs geleverd, dat S. pneumoniae in deze organismen ook 
echt bindt aan PAFR. Wanneer PAFR genetisch verwijderd of chemisch veranderd 
wordt, is S. pneumoniae namelijk nog steeds in staat om te binden aan menselijke 
cellen. Dit impliceert dat pneumokokken de mogelijkheid hebben zich te hechten aan 
alternatieve receptoren. 
In hoofdstuk 4 bewijzen wij dat directie interactie tussen PAFR en S. pneumoniae 
niet waarschijnlijk is. Een blokkade van de PAFR leidt weliswaar tot een significante 
afname van binding van pneumokokken aan bloed-hersenbarrierecellen in 
weefselkweek, daarentegen laten immunofluorescentie analyses van hersenweefsel 
van intraveneus ge'infecteerde muizen zien, dat S. pneumoniae niet co-lokaliseert met 
PAFR in de bloedvaten. Dit hebben we bevestigd metbehulpvan immunofluorescentie­
analyses in menselijke bloedvatenendotheelcellen die waren ge'incubeerd met 
pneumokokken. Concluderend denken wij dat, hoewel PAFR zeker betrokken zal 
zijn bij binding van S. pneumoniae aan endotheelcellen, een directe associatie van 
pneumokokken met PAFR niet waarschijnlijk is. 
De zogenoemde poly immunoglobuline receptor (pigR) regelt het transport van 
immunoglobuline door mucosale epitheelcellen (15, 16) en het is bekend dat deze 
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receptor ook betrokken is bij de binding van pneumokokken aan het epitheel van de 
menselijke nasopharynx (12). Omdat onbekend was of pigR ook een rol speelt bij de 
binding van S. pneumoniae in vivo, hebben wij eveneens de rol van pigR in de binding 
van S. pneumoniae aan endotheelcellen van de bloed-hersenbarriere onderzocht. 
Immunofluorescentie-analyses van hersenweefsel van intraveneus ge'infecteerde 
muizen laten zien, <lat S. pneumoniae co-lokaliseert met pigR. Co-lokalisatie tussen 
bacterien en pigR is tevens vastgesteld bij bloedvatendotheelcellen in kweekvaatjes. 
Tevens vonden wij biochemisch bewijs <lat S. pneumoniae zich kan hechten aan pigR. 
Een combinatie van beide resultaten laat duidelijk zien <lat pigR wellicht een rol 
speelt als directe receptor voor de binding van S. pneumoniae aan het endotheel van 
de bloed-hersenbarriere. 
In dit proefschrift hebben wij als laatste aandacht besteed aan PECAM-1. 
PECAM-1 is een van de belangrijkste adhesiemoleculen in bloedvatendotheelcellen 
en het is bekend dat deze receptor een cruciale rol inneemt bij neuro-ontstekingen en 
daaropvolgende verstoringen van de bloed-hersenbarriere (17, 18). Hoofdstuk 5 gaat 
in op de rol van PECAM-1 in S. pneumoniae gemedieerde meningitis pathogenese. 
In het bijzonder is onderzocht of PECAM-1 een receptor voor de hechting van S. 
pneumoniae aan het endotheel van de bloed-hersenbarriere is. Immunofluorescentie­
analyses van hersenweefsel van intraveneus ge·infecteerde muizen laten zien, <lat de 
meeste S. pneumoniae cellen co-lokaliseren met PECAM-1. Eenzelfde co-lokalisatie 
hebben wij in vitro in met pneumokokken ge'incubeerde endotheelcellen aangetoond. 
Een blokkade van PECAM-1 in deze endotheelcellen zorgde voor een significante 
afname van bacteriele binding. Dit wijst erop dat PECAM-1 functioneel betrokken is 
bij binding van S. pneumoniae aan menselijke endotheelcellen. Tenslotte hebben wij 
biochemisch bewijs geleverd dat S. pneumoniae kan binden aan PECAM-1. 
Resumerend hebben we laten zien wat de rol van PAFR, pigR en PECAM-1 
is in de binding van S. pneumoniae aan endotheelcellen, in weefselkweek en in een 
muizenmodel van meningitis. PAFR speelt waarschijnlijk een indirect rol in dit 
proces, terwijl de pneumokok met zowel pigR als PECAM-1 een directe interactie 
aangaat. Of deze kennis kan worden vertaald naar therapeutische mogelijkheden om 
het ontstaan respectievelijk de verdere ontwikkeling van meningitis te blokkeren zal 
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